# Axcelead > Drug Discovery Partners --- ## Pages - [Bioinformatics](https://axcelead-us.com/bioinformatics/): Axcelead High Throughput Screening services are designed to help you create truly novel, original drugs rapidly with our integrated platform. Whether you're in the pharmaceutical, biotechnology, or academic sector, our comprehensive screening solutions can help you achieve your scientific goals more efficiently. - [Omics](https://axcelead-us.com/omics/): Axcelead High Throughput Screening services are designed to help you create truly novel, original drugs rapidly with our integrated platform. Whether you're in the pharmaceutical, biotechnology, or academic sector, our comprehensive screening solutions can help you achieve your scientific goals more efficiently. - [Topics](https://axcelead-us.com/topics/): News Topics 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 - [News Releases](https://axcelead-us.com/news-releases/): News News Releases 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 - [Chemistry](https://axcelead-us.com/chemistry/): Axcelead Chemistry services are designed to help you create the medicines of the future. Whether you're in the pharmaceutical, biotechnology, or academic sector, our comprehensive chemistry solutions can help you achieve your scientific goals more efficiently. - [Small Molecules](https://axcelead-us.com/small-molecules/): Axcelead is your partner in Targeted Protein Degradation Drug Discovery! Axcelead has comprehensive capabilities in Targeted Protein Degradation Drug Discovery drug discovery at the preclinical stages and a proven track record. Whether you are in the pharmaceutical, biotechnology, or academic sector, our comprehensive solutions can help you achieve your scientific goals more efficiently. - [Targeted Protein Degraders](https://axcelead-us.com/targeted-protein-degraders/): Axcelead is your partner in Targeted Protein Degradation Drug Discovery! Axcelead has comprehensive capabilities in Targeted Protein Degradation Drug Discovery drug discovery at the preclinical stages and a proven track record. Whether you are in the pharmaceutical, biotechnology, or academic sector, our comprehensive solutions can help you achieve your scientific goals more efficiently. - [RNA-Targeted Small Molecules](https://axcelead-us.com/rna-targeted-small-molecules/): Axcelead is your partner in RNA-Targeted Drug Discovery! Axcelead has comprehensive capabilities in integrated RNA-targeted small molecule drug discovery at the preclinical stages. Whether you are in the pharmaceutical, biotechnology, or academic sector, our comprehensive solutions can help you achieve your scientific goals more efficiently. - [Peptide](https://axcelead-us.com/peptide/): Axcelead is your partner in Peptide Drug Discovery! Axcelead peptide drug discovery services are designed to accelerate your peptide drug project with our comprehensive platform. Whether you are in the pharmaceutical, biotechnology, or academic sector, our comprehensive solutions can help you achieve your scientific goals more efficiently. - [Oligonucleotide](https://axcelead-us.com/oligonucleotide/): Axcelead is your partner in Oligonucleotide Drug Discovery! Axcelead oligonucleotide drug discovery services are designed to accelerate your oligonucleotide drug project with our comprehensive platform. Whether you are in the pharmaceutical, biotechnology, or academic sector, our comprehensive solutions can help you achieve your scientific goals more efficiently. - [High Throughput Screening](https://axcelead-us.com/high-throughput-screening/): Axcelead High Throughput Screening services are designed to help you create truly novel, original drugs rapidly with our integrated platform. Whether you're in the pharmaceutical, biotechnology, or academic sector, our comprehensive screening solutions can help you achieve your scientific goals more efficiently. - [Cardiovascular / Metabolic disease](https://axcelead-us.com/therapeutic-areas/cardiovascular-metabolic-disease/): Therapeutic Areas Cardiovascular / Metabolic Disease At Axcelead, we have extensive experience and know-how in the preclinical development of new... - [Thank you inquiry](https://axcelead-us.com/thank-you-inquiry/): Contact Us For questions and consultations about our business and services, please use the form below. Thank you for your... - [Previous Conferences](https://axcelead-us.com/events/previous-conferences/): Welcome to view the conferences that Axcelead Drug Discovery Partners, Inc. has attended. - [IND-Enabling Projects](https://axcelead-us.com/integrated-drug-discovery/ind-enabling-projects/): Unleash your research potential with Axcelead's IND-Enabling Projects, saving significant time and resources. Any newly generated IP is owned by our customers. - [IND-enabling](https://axcelead-us.com/integrated-drug-discovery/ind-enabling/): Axcelead offers refined IND enabling services to accelerate your drug discovery process. Our experienced and collaborative team supports your IND enabling projects with professional expertise and state-of-the-art facilities, delivering timely and cost-effective results. - [Technology Platforms](https://axcelead-us.com/technology-platforms/): - [Neuroscience](https://axcelead-us.com/therapeutic-areas/neuroscience/): Therapeutic Areas Advancing Neuroscience Research We understand that developing drugs for neuroscience indications can be challenging. We utilize an integrated... - [Immunology](https://axcelead-us.com/therapeutic-areas/immunology/): Therapeutic Areas Advancing Immunology Research We can design and carry out the most appropriate in vitro and/or in vivo studies... - [Oncology](https://axcelead-us.com/therapeutic-areas/oncology/): Therapeutic Areas Advancing Oncology Research We have a long and proven track record in the development of small molecules for... - [Therapeutic Areas](https://axcelead-us.com/therapeutic-areas/): - [Future Conferences](https://axcelead-us.com/events/conferences/): Welcome to view the conferences that Axcelead Drug Discovery Partners, Inc. will be attending. - [Events](https://axcelead-us.com/events/): - [Previous Seminars](https://axcelead-us.com/events/previous-seminars/): Welcome to view the seminars that Axcelead Drug Discovery Partners, Inc. has held. - [Future Seminars](https://axcelead-us.com/events/seminars/): Welcome to view the seminars that Axcelead Drug Discovery Partners, Inc. will be holding. - [Candidate Selection](https://axcelead-us.com/integrated-drug-discovery/candidate-selection/): Axcelead offers refined candidate selection services to accelerate your drug discovery process. Our experienced and collaborative team supports your candidate selection projects with professional expertise and state-of-the-art facilities, delivering timely and cost-effective results. - [Lead Generation / Optimization](https://axcelead-us.com/integrated-drug-discovery/lead-generation-optimization/): Axcelead offers refined lead generation and optimization services to accelerate your drug discovery process. Our experienced and collaborative team supports your lead generation and optimization projects with professional expertise, state-of-the-art facilities, and a large compound library/database originating from the pharmaceutical industry, delivering timely and cost-effective results. - [Hit Identification / Characterization](https://axcelead-us.com/integrated-drug-discovery/hit-identification-characterization/): Axcelead offers refined hit identification and characterization services to accelerate your drug discovery process. Our experienced and collaborative team supports your hit identification and characterization projects with professional expertise, state-of-the-art facilities, and a large compound library/database originating from the pharmaceutical industry, delivering timely and cost-effective results. - [Integrated Drug Discovery](https://axcelead-us.com/integrated-drug-discovery/): Axcelead offers integrated drug discovery and development solutions to clients worldwide, including academia, biotechnology, and pharmaceutical companies. Our experienced team works closely with you at every step of your drug discovery project, from target identification, hit identification and characterization, lead generation and optimization, and candidate selection to IND enabling and beyond. - [Target Identification / Validation](https://axcelead-us.com/integrated-drug-discovery/target-identification-validation/): Axcelead offers refined target identification and validation services to accelerate your drug discovery process. Our experienced and collaborative team supports your target identification and validation projects with professional expertise, state-of-the-art facilities, and a large compound library/database originating from the pharmaceutical industry, delivering timely and cost-effective results. - [Contact Us](https://axcelead-us.com/contact-us/): Contact Us For questions and consultations about our business and services, please use the form below. PGlmcmFtZSBzcmM9Imh0dHBzOi8vZ28uYXhjZWxlYWQuY29tL2wvOTk2MjYxLzIwMjItMTAtMDgvMndrZyIgd2lkdGg9IjEwMCUiIGhlaWdodD0iMTU1MCIgdHlwZT0idGV4dC9odG1sIiBmcmFtZWJvcmRlcj0iMCIgYWxsb3dUcmFuc3BhcmVuY3k9InRydWUiIHN0eWxlPSJib3JkZXI6IDAiPjwvaWZyYW1lPg== Contact Us Please... - [Resources](https://axcelead-us.com/resources/): - [Brochures](https://axcelead-us.com/resources/brochures/): Company Introduction 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 Integrated Drug Discovery 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 Therapeutic Areas 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 Technology Platforms 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 Therapeutic Modalities 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 - [Publications](https://axcelead-us.com/resources/publications/): Publications 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 - [Presentations](https://axcelead-us.com/resources/presentations/): Presentations PHNjcmlwdD4Kc2V0VGltZW91dChmdW5jdGlvbigpIHsKICBqUXVlcnkoZG9jdW1lbnQpLnJlYWR5KGZ1bmN0aW9uKCQpIHsgCgkkKCIuZnVzaW9uLXZlcnRpY2FsLW1lbnUtd2lkZ2V0IHVsIGxpIikuZWFjaChmdW5jdGlvbigpewoJCWxpbmtBbm51YWwgPSAkKCJhIiwgJCh0aGlzKSk7IAogICAgICAgIG9yaWdpbmFsSHJlZiA9ICQobGlua0FubnVhbCkuYXR0cigiaHJlZiIpOwogICAgICAgICQobGlua0FubnVhbCkuYXR0cigiaHJlZiIsIG9yaWdpbmFsSHJlZiArICI/Y2F0PTE4Iik7IC8vIFByZXNlbnRhdGlvbiBjYXRlZ29yeQogICAgfSk7CiAgfSk7Cn0sIDgwMCk7Cjwvc2NyaXB0Pg== - [Videos](https://axcelead-us.com/resources/videos/): Targeted Protein Degradation 1 Minute Guide for HTS Platform Global Webinar Hot Topics Screening Capabilities 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 - [Posters](https://axcelead-us.com/resources/posters/): Posters PHNjcmlwdD4Kc2V0VGltZW91dChmdW5jdGlvbigpIHsKICBqUXVlcnkoZG9jdW1lbnQpLnJlYWR5KGZ1bmN0aW9uKCQpIHsgCgkkKCIuZnVzaW9uLXZlcnRpY2FsLW1lbnUtd2lkZ2V0IHVsIGxpIikuZWFjaChmdW5jdGlvbigpewoJCWxpbmtBbm51YWwgPSAkKCJhIiwgJCh0aGlzKSk7IAogICAgICAgIG9yaWdpbmFsSHJlZiA9ICQobGlua0FubnVhbCkuYXR0cigiaHJlZiIpOwogICAgICAgICQobGlua0FubnVhbCkuYXR0cigiaHJlZiIsIG9yaWdpbmFsSHJlZiArICI/Y2F0PTE5Iik7IC8vIFByZXNlbnRhdGlvbiBjYXRlZ29yeQogICAgfSk7CiAgfSk7Cn0sIDUwMCk7Cjwvc2NyaXB0Pg== - [News](https://axcelead-us.com/news/): News Latest News and Press Releases 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 - [Test Page with Mega Menu](https://axcelead-us.com/test-page-with-mega-menu/): The Future of Drug Discovery is Here. Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt... - [Cookie Policy](https://axcelead-us.com/cookie-policy/): Policies Cookie Policy2021/05/27 About Cookies Cookies are data stored directly on your computer. They are used to gather information such... - [Privacy Policy: Personal Information Protection Policy](https://axcelead-us.com/privacy-policy-personal-information-protection-policy/): Policies Privacy Policy: Personal Information Protection Policy １． Policy Axcelead Drug Discovery Partners Inc. (the “Company”), in order to appropriately... - [About Us](https://axcelead-us.com/about-us/): About Us We are pioneering the future of drug discovery. https://axcelead-us. com/wp-content/uploads/2023/12/whoweare-topimage2. jpg Who We Are Axcelead is your trusted... - [Home](https://axcelead-us.com/): Axcelead accelerates the discovery and development of high-value therapeutic candidates for the preclinical stage leading to human clinical trials. - [Privacy Policy](https://axcelead-us.com/privacy-policy/): Policies Privacy Policy Axcelead Group has established a basic policy for the handling of personal information, and will comply with... --- --- ## Posts - [LOTTE BIOLOGICS, Axcelead Drug Discovery Partners, Inc., and Kanaph Therapeutics Inc. Sign 3-Way MOU to Develop ADC Toolbox](https://axcelead-us.com/news/sign-3-way-mou-to-develop-adc-toolbox/): - Exploring expansion of ADC services through synergy in ADC modality business via trilateral agreement - Aims to enhance ADC... - [Presentation on Prediction Model for Brain Concentration-Time Profiles of Compounds by Dr. Handa (Digital Unit) at the Structure-Activity Forum 2025](https://axcelead-us.com/topics/the-structure-activity-forum-2025/): Dr. Handa from the Digital Unit will present a prediction model for brain concentration–time profiles of compounds at the Structure–Activity... - [BIO International Convention 2025](https://axcelead-us.com/future-conferences/bio-international-convention-2025/): Boston, MA - [Results of joint research with Luxna Biotec, Inc published in "Nucleic Acid Therapeutics"](https://www.liebertpub.com/doi/10.1089/nat.2024.0047#new_tab): Nucleic Acid Therapeutics - [The results of joint research with Luxna Biotec, Inc published in "Nucleic Acid Therapeutics"](https://axcelead-us.com/news/the-results-of-joint-research-with-luxna-biotec-inc-published-in-nucleic-acid-therapeutics/): Hepatotoxicity Reduction Profiles of Antisense Oligonucleotides Containing Amido-Bridged Nucleic Acid and 2′-O,4′-C-Spirocyclopropylene Bridged Nucleic Acid Publication Amide-bridged nucleic acid (AmNA)... - [EASL Congress 2025](https://axcelead-us.com/previous-conferences/easl-congress-2025/): Amsterdam, the Netherlands - [ECO2025 (32nd European Congress on Obesity)](https://axcelead-us.com/previous-conferences/eco2025/): Malaga, Spain - [BIO KOREA 2025](https://axcelead-us.com/previous-conferences/bio-korea-2025/): COEX, Seoul, Korea - [Skeletal muscle and cardiac function in B10-mdx mice​](https://axcelead-us.com/posters/skeletal-muscle-and-cardiac-function-in-b10-mdx-mice/): APPW 2025 in Japan Download - [Drug Discovery Services for Liver Desease](https://axcelead-us.com/brochures/drug-discovery-service-for-liver-desease/): Download - [Research Article Co-Authored on Ferroptosis MoA Analysis Published in Communications Biology](https://axcelead-us.com/news/research-article-co-authored-on-ferroptosis-moa-analysis-published-in-communications-biology/): Protein covariation networks for elucidating ferroptosis inducer mechanisms and potential synergistic drug targets Publication Mechanism of action (MoA) analysis of... - [Protein covariation networks for elucidating ferroptosis inducer mechanisms and potential synergistic drug targets](https://www.nature.com/articles/s42003-025-07886-3#new_tab): Communications Biology - [Drug Discovery Chemistry 2025](https://axcelead-us.com/previous-conferences/drug-discovery-chemistry-2025/): San Diego, CA - [Covalent Drug Discovery](https://axcelead-us.com/brochures/covalent-drug-discovery/): Download - [Chemistry Capabilities](https://axcelead-us.com/brochures/chemistry-capabilities/): Download - [BIO-Europe Spring 2025](https://axcelead-us.com/previous-conferences/bio-europe-spring-2025/): Milan, Italy - [Global Life Science Partnering ＆Investor Conference 2025](https://axcelead-us.com/previous-conferences/global-life-science-partnering-%ef%bc%86investor-conference-2025/): San Diego, CA - [Discovery of mRNA G-quadruplex binders through high-throughtput Affinity Selection Mass Spectrometry screening and comprehensive hit profiling](https://axcelead-us.com/posters/discovery-of-mrna-g-quadruplex-binders-through-high-throughtput-affinity-selection-mass-spectrometry-screening-and-comprehensive-hit-profiling/): SLAS 2025 in San Diego Download - [Accelerate Targeted Protein Degradation Drug Discovery with Axcelead's Integrated Platform, DegLead](https://axcelead-us.com/previous-seminars/accelerate-targeted-protein-degradation-drug-discovery-with-axceleads-integrated-platform-deglead/): Join Axcelead webinar to learn more about the latest technologies and insights in drug discovery and development! - [Axcelead DDP Enters into Drug Discovery Service Agreement with Astellas for Targeted Protein Degraders](https://axcelead-us.com/news/20241226-e-newsrelease/): December 26, 2024 - Axcelead Drug Discovery Partners, Inc. (HQ: Fujisawa, Kanagawa, Japan; “Axcelead DDP”) announced today that it has... - [SLAS2025 International Conference & Exhibition](https://axcelead-us.com/previous-conferences/slas2025-international-conference-exhibition/): San Diego, CA - [Phosphorylation Dynamics and Kinase Interaction in mRNA Transcription-Associated Kinases: Autophosphorylation of CDK12 and its Modulation by CDK7 and CDK9](https://www.jstage.jst.go.jp/article/bpbreports/7/5/7_170/_article#new_tab): BPB Reports - [AASLD The Liver Meeting 2024](https://axcelead-us.com/previous-conferences/the-liver-meeting-tlm-2024/): San Diego, CA - [Identify Promising Novel Leads: Axcelead's integrated HTS platform powered by computational chemistry and AI/ML](https://axcelead-us.com/previous-seminars/axceleads-integrated-hts-platform-powered-by-computational-chemistry-and-ai-ml/): Join Axcelead webinar to learn more about the latest technologies and insights in drug discovery and development! - [Research results of a mouse model of chronic kidney disease (AXCC mice) generated in Axcelead DDP has been published in the American Journal of Pathology as a co-authored article.](https://axcelead-us.com/news/research-results-of-a-mouse-model-of-chronic-kidney-disease-axcc-mice-generated-in-axcelead-ddp-has-been-published-in-the-american-journal-of-pathology-as-a-co-authored-article/): A novel deep learning approach for analyzing glomerular basement membrane lesions in a mouse model of X-linked Alport syndrome Publication... - [A novel deep learning approach for analyzing glomerular basement membrane lesions in a mouse model of X-linked Alport syndrome](https://ajp.amjpathol.org/article/S0002-9440(24)00368-7/fulltext#new_tab): American Journal of Pathology - [Pharmacology Capabilities](https://axcelead-us.com/brochures/pharmacology-capabilities/): Download - [Xenogenic Engraftment of Human-Induced Pluripotent Stem Cell–Derived Pancreatic Islet Cells in an Immunosuppressive Diabetic Göttingen Mini-Pig Model](https://journals.sagepub.com/doi/10.1177/09636897241288932#new_tab): Cell Transplantation - [A Co-authored Paper regarding Immunocompromised type 1 Diabetic Mini-pigs was Published in the Cell Transplantation](https://axcelead-us.com/news/a-co-authored-paper-regarding-immunocompromised-type-1-diabetic-mini-pigs-was-published-in-the-cell-transplantation/): Xenogenic Engraftment of Human Induced Pluripotent Stem Cell–Derived Pancreatic Islet Cells in an Immunosuppressive Diabetic Göttingen Mini-pig Model Publication Transplantation... - [BIO-Europe 2024](https://axcelead-us.com/previous-conferences/bio-europe-2024/): Stockholm, Sweden - [Axcelead Drug Discovery Partners Enters into Master Service Agreement for Drug Discovery Projects with Acadia Pharmaceuticals](https://axcelead-us.com/news/axcelead-drug-discovery-partners-enters-into-master-service-agreement-for-drug-discovery-projects-with-acadia-pharmaceuticals/): September 10, 2024 - Axcelead Drug Discovery Partners, Inc. (HQ: Fujisawa, Kanagawa, Japan; hereinafter referred to as “Axcelead DDP”) announces... - [Axcelead DDP and Lilly Enter into A Research and Collaboration Agreement](https://axcelead-us.com/news/axcelead-ddp-and-lilly-enter-into-research-and-collaboration-agreement/): September 5, 2024 – Axcelead Drug Discovery Partners, Inc. (HQ: Fujisawa, Kanagawa, Japan; “Axcelead DDP”) announced today that it has... - [Drug Discovery Services for Neuroscience](https://axcelead-us.com/brochures/drug-discovery-services-for-neuroscience/): Download - [Neuroscience 2024](https://axcelead-us.com/previous-conferences/neuroscience-2024/): Chicago, IL - [Unique distribution of antisense oligonucleotidesin the brain by the intrathecal administration](https://axcelead-us.com/posters/unique-distribution-of-antisense-oligonucleotidesin-the-brain-by-the-intrathecal-administration/): The 9th Annual Meeting of the Nucleic Acid Therapeutics Society of Japan Download - [Axcelead Kinase Inhibitor Discovery Platform: Identification of Selective Inhibitors for 123 Kinases](https://axcelead-us.com/presentations/axcelead-kinase-inhibitor-discovery-platform-identification-of-selective-inhibitors-for-123-kinases/): Discovery on Target 2023 Sponsored Presentation Download - [Immunology Capabilities](https://axcelead-us.com/brochures/immunology-capabilities/): Download - [Cardiovascular/Metabolic Disease Capabilities](https://axcelead-us.com/brochures/cardiovascular-metabolic-disease-capabilities/): Download - [Innovative RNA-targeting Small Molecules](https://axcelead-us.com/brochures/innovative-rna-targeting-small-molecules/): Download - [In-silico Technologies for Medicinal Chemistry](https://axcelead-us.com/brochures/in-silico-technologies-for-medicinal-chemistry/): Download - [Axcelead DDP has become a certified provider of Single Cell Gene Expression Solution, from 10x Genomics](https://axcelead-us.com/news/axcelead-ddp-has-become-a-certified-provider-of-single-cell-gene-expression-solution-from-10x-genomics/): We’re delighted to announce that Axcelead Drug Discovery Partners, Inc. (“Axcelead DDP”) has received official certification from 10x Genomics as... - [Drug Discovery Services for Oncology](https://axcelead-us.com/brochures/drug-discovery-services-for-oncology/): Download - [Achieved the First Milestone in Drug Discovery Support to Otsuka Pharmaceutical](https://axcelead-us.com/news/achieved-the-first-milestone-in-drug-discovery-support-to-otsuka-pharmaceutical/): May 27, 2024 – Axcelead Drug Discovery Partners, Inc. (HQ: Fujisawa-city, Kanagawa; “Axcelead DDP”) announces that the first milestone has... - [BIO International Convention 2024](https://axcelead-us.com/previous-conferences/bio-international-convention-2024/): San Diego, CA - [Identification and removal of unexpected proliferative off target cells emerging after iPSC derived pancreatic islet cell implantation](https://www.pnas.org/doi/10.1073/pnas.2320883121#new_tab): Proceedings of the National Academy of Sciences - [Change of Representative Director](https://axcelead-us.com/news/change-of-representative-director/): Kanagawa, Japan, April 1, 2024 --- Axcelead Drug Discovery Partners, Inc (hereafter Axcelead DDP) announced that the following change in... - [AACR ANNUAL MEETING 2024](https://axcelead-us.com/previous-conferences/aacr-annual-meeting-2024/): San Diego, CA - [Characterization of membrane protein using mass spectrometry-based technologies — affinity selection-mass spectrometry (AS-MS)](https://axcelead-us.com/posters/characterization-of-membrane-protein-using-mass-spectrometry-based-technologies-affinity-selection-mass-spectrometry-as-ms/): SLAS 2024 in Boston Download - [Global Life Science Partnering ＆Investor Conference](https://axcelead-us.com/previous-conferences/global-life-science-partnering-%ef%bc%86investor-conference/): San Diego, CA - [Accelerate and achieve an optimal IND for your project～Smart-IND®～](https://axcelead-us.com/previous-seminars/accelerate-and-achieve-an-optimall-ind-for-your-project/): A webinar co-hosted by Axcelead Drug Discovery Partners (ADDP), SEKISUI MEDICAL, and KRCC. The webinar is for Korean scientists. After... - [Axcelead DDP's English Version of Official Website Renewed](https://axcelead-us.com/news/axcelead-ddps-english-version-of-official-website-renewed/): We are pleased to announce the renewal of Axcelead DDP's English version of the official website. The entire site has... - [Axcelead Drug Discovery Partners and Acadia Pharmaceuticals Launch 2nd Drug Discovery Project in Neuroscience](https://axcelead-us.com/news/axcelead-drug-discovery-partners-and-acadia-pharmaceuticals-launch-2nd-drug-discovery-project-in-neuroscience/): December 25, 2023 – Axcelead Drug Discovery Partners, Inc. (HQ: Fujisawa, Kanagawa, Japan; hereinafter referred to as “Axcelead DDP”) announces... - [Lineage tracing of T cell differentiation from T-iPSC by 2D feeder-free culture and 3D organoid culture](https://www.frontiersin.org/articles/10.3389/fimmu.2023.1303713/full#new_tab): Frontiers in Immunology - [How to proceed GLP toxicity study without cynomolgus monkeys](https://axcelead-us.com/previous-seminars/how-to-proceed-glp-toxicity-study-without-cynomolgus-monkeys-2/): High-throughput screening (HTS) is the key methodology to identify hit and lead compouds for drug discovery. The innovative technologies for... - [Rapid Discovery! Accelerate drug discovery from hit id to clinic](https://axcelead-us.com/previous-seminars/rapid-discovery-accelerate-drug-discovery-from-hit-id-to-clinic-2/): Mounting competitive pressure is forcing the biopharma industry to look at new ways to shorten the time scale for all... - [Driving innovative drug discovery through integrated high-throughput screening platform](https://axcelead-us.com/previous-seminars/driving-innovative-drug-discovery-through-integrated-high-throughput-screening-platform-2/): High-throughput screening (HTS) is the key methodology to identify hit and lead compouds for drug discovery. The innovative technologies for... - [In-Vivo Science and Axcelead DDP Entered into Cooperative Agreement for Drug Discovery Services Using Disease Model Animals](https://axcelead-us.com/news/in-vivo-science-and-axcelead-ddp-entered-into-cooperative-agreement-for-drug-discovery-services-using-disease-model-animals/): In-Vivo Science, Inc. (Headquarters: Meguro-ku, Tokyo; Branch Office: Kawasaki City, Kanagawa Prefecture; President: Koji Yoshimura; hereinafter “In-Vivo Science”) and Axcelead... - [SLAS2024 International Conference & Exhibition](https://axcelead-us.com/previous-conferences/name-of-conference-here/): Boston, MA - [Axcelead Company Introduction](https://axcelead-us.com/brochures/axcelead-company-introduction/): Download - [Target-based Drug Discovery](https://axcelead-us.com/brochures/target-based-drug-discovery/): Download - [Integrated Phenotypic Drug Discovery](https://axcelead-us.com/brochures/integrated-phenotypic-drug-discovery/): Download - [HTS Overview](https://axcelead-us.com/brochures/hts-overview/): Download - [High-Throughput Affinity Selection Mass Spectrometry](https://axcelead-us.com/brochures/ht-asms/): Download - [Lead Generation and Optimization](https://axcelead-us.com/brochures/lead-generation-and-optimization/): Download - [Targeted Protein Degrader Integrated Solutions](https://axcelead-us.com/brochures/targeted-protein-degrader-integrated-solutions/): Download - [Smart-IND--IND Enabling Package Service](https://axcelead-us.com/brochures/smart-ind-ind-enadling-package-service/): Download - [Tumorigenicity Testing Services for Regenerative Medicine Products](https://axcelead-us.com/brochures/tumorigenicity-testing-services-for-regenerative-medicine-products/): Download - [Cardiac QT Risk Assessment Using a Human iPS-cardiomyocytes](https://axcelead-us.com/brochures/cardiac-qt-risk-assessment-using-a-human-ips-cardiomyocytes/): Download - [Compound Screening Service using iPSC-derived Cells](https://axcelead-us.com/brochures/compound-screening-service-using-ipsc-derived-cells/): Download - [Mini Kinase Panel 46](https://axcelead-us.com/brochures/mini-kinase-panel-46/): Download - [Discovery On Target 2023](https://axcelead-us.com/previous-conferences/discovery-on-target-2023/): Sheraton Boston - [Strategies to determine the target human metabolites using Radiolabeled compounds - Example from nonclinical to clinical](https://axcelead-us.com/presentations/strategies-to-determine-the-target-human-metabolites-using-radiolabeled-compounds-example-from-nonclinical-to-clinical/): The 34th Workshop of the Korean Society of Non-clinical study Download - [Case study: Human relevancy and mode of action of toxic findings observed in GLP toxicity studies](https://axcelead-us.com/presentations/case-study-human-relevancy-and-mode-of-action-of-toxic-findings-observed-in-glp-toxicity-studies/): The 44th Annual Meeting of the Japanese Society of Toxicology Download - [New approach: Tailor-made immunosuppressed pig/monkey models for regenerative medicine](https://axcelead-us.com/presentations/new-approach-tailor-made-immunosuppressed-pig-monkey-models-for-regenerative-medicine/): CiRA 2019 International Symposium Download - [Echocardiographic evaluation of cardiotoxicity in mice treated with doxorubicin, an anticancer drug](https://axcelead-us.com/presentations/echocardiographic-evaluation-of-cardiotoxicity-in-mice-treated-with-doxorubicin-an-anticancer-drug/): The 48th Annual Meeting of the Japanese Society of Toxicology Download - [Rapid and efficient synthesis of deuterated cyclobutane derivatives using continuous photo flow chemistry](https://axcelead-us.com/posters/rapid-and-efficient-synthesis-of-deuterated-cyclobutane-derivatives-using-continuous-photo-flow-chemistry/): The 138th Annual Meeting of the Pharmaceutical Society of Japan Download - [Phenotypic screening with TREM2 knockout iCell® Microgria](https://axcelead-us.com/posters/phenotypic-screening-with-trem2-knockout-icell-microgria/): The 13th conference on biomolecular screenology Download - [Immunohistochemistry and in situ hybridization for Heat shock protein from mice treated with single administration of carbon tetrachloride](https://axcelead-us.com/posters/immunohistochemistry-and-in-situ-hybridization-for-heat-shock-protein-from-mice-treated-with-single-administration-of-carbon-tetrachloride/): The 39th Annual Meeting of the Japanese Society of Toxicologic Pathology Download - [Acetyl-CoA carboxylase 1 and 2 inhibition ameliorates hepatic fibrosis and steatosis in a murine model of nonalcoholic steatohepatitis](https://axcelead-us.com/posters/acetyl-coa-carboxylase-1-and-2-inhibition-ameliorates-hepatic-fibrosis-and-steatosis-in-a-murine-model-of-nonalcoholic-steatohepatitis/): The 92nd Annual Meeting of the Japanese Pharmacological Society Download - [Characterization of mesoridazine transport in human cerebral microvessel endothelial cells, hCMEC/D 3](https://axcelead-us.com/posters/characterization-of-mesoridazine-transport-in-human-cerebral-microvessel-endothelial-cells-hcmec-d-3/): 33rd JSSX Annual Meeting and 22nd MDO Download - [Characterization of metoclopramide transport in human cerebral microvessel endothelial cells, hCMEC/D 3](https://axcelead-us.com/posters/characterization-of-metoclopramide-transport-in-human-cerebral-microvessel-endothelial-cells-hcmec-d-3/): 34th JSSX Annual Meeting Download - [Comparison between administration routes in brain distribution and drug efficacy of ASO (ICV vs IT)](https://axcelead-us.com/posters/comparison-between-administration-routes-in-brain-distribution-and-drug-efficacy-of-aso-icv-vs-it/): The 8th Annual Meeting of the Nucleic Acid Therapeutics Society of Japan Download - [Discovery of Selective Inhibitors for 123 Protein Kinases Utilizing Internal Kinase Panel Dataset](https://axcelead-us.com/posters/discovery-of-selective-inhibitors-for-123-protein-kinases-utilizing-internal-kinase-panel-dataset/): Discovery On Target 2023 in Boston Download - [Establishment of intranasal administration method to conscious rats](https://axcelead-us.com/posters/establishment-of-intranasal-administration-method-to-conscious-rats/): 33rd Annual Meeting The Academy of Pharmaceutical Science and Technology Download - [Discovery of a B-Cell Lymphoma 6 Protein-Protein Interaction Inhibitor by a Biophysics-driven Fragment-based Approach](https://axcelead-us.com/posters/discovery-of-a-b-cell-lymphoma-6-protein-protein-interaction-inhibitor-by-a-biophysics-driven-fragment-based-approach/): Fragment-Based Drug Discovery Down Under Conference 2019 Download - [Effect of PassPort System on compounds with low transdermal absorption in hairless rats](https://axcelead-us.com/posters/effect-of-passport-system-on-compounds-with-low-transdermal-absorption-in-hairless-rats/): The 35th Annual Meeting of The Academy of Pharmaceutical Science and Technology, Japan Download - [PXB-mice with new donor hepatocytes: Reproducible animal model for prediction of huma pharmacokinetic parameter](https://axcelead-us.com/posters/pxb-mice-with-new-donor-hepatocytes-reproducible-animal-model-for-prediction-of-huma-pharmacokinetic-parameter/): 33rd JSSX Annual Meeting and 22nd MDO Download - [Evaluation of the extrapolation about the off-target effects of antisense oligonucleotides from in vitro to human](https://axcelead-us.com/posters/evaluation-of-the-extrapolation-about-the-off-target-effects-of-antisense-oligonucleotides-from-in-vitro-to-human/): The 6th Annual Meeting of the Nucleic Acids Therapeutics Society of Japan Download - [PK/PD evaluation of antisense oligonucleotides in tissues and cells](https://axcelead-us.com/posters/pk-pd-evaluation-of-antisense-oligonucleotides-in-tissues-and-cells/): The 8th Annual Meeting of the Nucleic Acid Therapeutics Society of Japan Download - [Results of joint research with the University of Tokyo published in the international scientific journal “Nature Communications”](https://axcelead-us.com/news/results-of-joint-research-with-the-university-of-tokyo-published-in-the-international-scientific-journal-nature-communications/): Axcelead Drug Discovery Partners Inc. (Headquarters: Fujisawa City, Kanagawa Prefecture; President & CEO: Nobuhiko Yamada; hereinafter “Axcelead DDP”) announces that... - [Intestinal Atp8b1 dysfunction causes hepatic choline deficiency and steatohepatitis](https://www.nature.com/articles/s41467-023-42424-x#new_tab): Nature Communications - [FRONTEO and Axcelead DDP Sign Master Collaboration Agreement for AI Drug Discovery Support Partnership](https://axcelead-us.com/news/fronteo-and-axcelead-ddp-sign-master-collaboration-agreement-for-ai-drug-discovery-support-partnership/): FRONTEO Inc. (Headquarters: Minato-ku, Tokyo; President & CEO: Masahiro Morimoto; hereinafter “FRONTEO”) and Axcelead Drug Discovery Partners Inc. (Headquarters: Fujisawa... - [Identification of the first highly selective inhibitor of human lactate dehydrogenase B](https://doi.org/10.1038/s41598-021-00820-7#new_tab): Scientific Reports - [Lobular distribution of enhanced expression levels of heat shock proteins using in-situ hybridization in the mouse liver treated with a single administration of CCl4](https://www.jstage.jst.go.jp/article/tox/advpub/0/advpub_2023-0053/_article#new_tab): Journal of Toxicologic Pathology - [BIO-Europe: Meet us in Munich, Germany](https://axcelead-us.com/news/bio-europe-meet-us-in-munich-germany/): Axcelead will be exhibiting at upcoming BIO-Europe in Munich, Germany. Visit us at Booth #10 to learn how we can... - [Discovery On Target 2023: Meet us in Boston](https://axcelead-us.com/news/discovery-on-target-2023-meet-us-in-boston/): Axcelead will be exhibiting at upcoming Discovery On Target 2023 in Boston. Visit us at Booth #200 to learn how... - [Axcelead DDP’s Drug Discovery Support Business Honored with the 6th Japan Medical Research and Development Grand Prize](https://axcelead-us.com/news/axcelead-ddps-drug-discovery-support-business-honored-with-the-6th-japan-medical-research-and-development-grand-prize/): Axcelead Drug Discovery Partners Inc. (“Axcelead DDP”) is pleased to announce that it has been honored with the Startup Encouragement... - [Discussions Begin on Collaborative Genomic Drug Discovery Support Using the IQVIA Genome Wide Study Platform](https://axcelead-us.com/news/discussions-begin-on-collaborative-genomic-drug-discovery-support-using-the-iqvia-genome-wide-study-platform/): Axcelead Drug Discovery Partners Inc. (Headquarters: Fujisawa, Kanagawa; President and CEO: Nobuhiko Yamada; hereinafter, “Axcelead DDP”) and IQVIA Solutions Japan... - [BIO International Convention 2023: Meet us in Boston](https://axcelead-us.com/news/bio-international-convention-2023-meet-us-in-boston/): Axcelead will be exhibiting at upcoming BIO International Convention 2023 in Boston. Visit us at Japan Pavilion Booth #1353 to... - [Luncheon seminar at the 43rd Workshop of the Korean Society of Nonclinical Study](https://axcelead-us.com/news/luncheon-seminar-at-the-43rd-workshop-of-the-korean-society-of-nonclinical-study/): Join us for our luncheon seminar and visit us at booth #8 during the 43rd Workshop of the Korean Society... - [Discovery of a Novel Series of Potent, Selective, Orally Available, and Brain-Penetrable C1s Inhibitors for Modulation of the Complement Pathway](https://pubs.acs.org/doi/10.1021/acs.jmedchem.3c00348#new_tab): Journal of Medicinal Chemistry - [Interview with Ikeura, President and CEO of Axcelead, a holding company, was published in “PHARMA JAPAN”. 『Axcelead to Expand Overseas Biz, Shoots for 130 Billion Yen Sales and 5,000-Plus Researchers』](https://axcelead-us.com/news/interview-with-ikeura-president-and-ceo-of-axcelead-a-holding-company-was-published-in-pharma-japan-%e3%80%8eaxcelead-to-expand-overseas-biz-shoots-for-130-billion-yen-sales-and/): As a global CRDMO (Contract Research, Development and Manufacturing Organization), Axelead, a holding company, will be fully developing its overseas... - [Change of President & CEO](https://axcelead-us.com/news/change-of-president-ceo/): Kanagawa, Japan, April 13, 2023 — We announced that it has decided to make the following changes to its President... - [Multi-laboratory evaluation of immunoaffinity LC-MS-based glucagon-like peptide-1 assay](https://pubmed.ncbi.nlm.nih.gov/36961372/#new_tab): Bioanalysis - [Orizuru Therapeutics and Axcelead DDP Collaborate on Drug Discovery Support Services Regarding iPS Cells](https://axcelead-us.com/news/orizuru-therapeutics-and-axcelead-ddp-collaborate-on-drug-discovery-support-services-regarding-ips-cells/): Kyoto and Kanagawa, Japan, March 10, 2023 — Orizuru Therapeutics Inc. (“OZTx”) and Axcelead Drug Discovery Partners, Inc (“Axcelead DDP”)... - [Teijin and Axcelead to Establish Drug Discovery Research JV](https://axcelead-us.com/news/teijin-and-axcelead-to-establish-drug-discovery-research-jv/): Tokyo, Japan, February 20, 2023 — Teijin Limited and Axcelead, Inc. jointly announced today their basic agreement on a capital... - [Axcelead DDP Selected as Project Partner for Harvard Business School Immersive Field Course](https://axcelead-us.com/news/axcelead-ddp-selected-as-project-partner-for-harvard-business-school-immersive-field-course/): Axcelead Drug Discovery Partners Inc. (Head Office: Fujisawa, Kanagawa prefecture, CEO: Yoshinori Ikeura, “Axcelead DDP”) was selected as a Project... - [Consideration for the Validation of Clinical Laboratory Method in Non-Clinical Fields](https://www.future-science.com/doi/10.4155/bio-2022-0178#new_tab): Future Science - [Kaken Pharmaceutical and Axcelead DDP Begin Collaboration to Create Innovative New Drugs](https://axcelead-us.com/news/kaken-pharmaceutical-and-axcelead-ddp-begin-collaboration-to-create-innovative-new-drugs/): Kaken Pharmaceutical Co. , Ltd. (“Kaken”, Head Office: Bunkyo-ku, Tokyo; President and Representative Director, Hiroyuki Horiuchi) and Axcelead Drug Discovery... - [CDK8/19 inhibition plays an important role in pancreatic β-cell induction from human iPSCs](https://stemcellres.biomedcentral.com/articles/10.1186/s13287-022-03220-4#new_tab): Stem Cell Research & Therapy - [ThinkCyte and Axcelead DDP collaborate to advance novel phenotypic screening methods](https://axcelead-us.com/news/thinkcyte-and-axcelead-ddp-collaborate-to-advance-novel-phenotypic-screening-methods/): Tokyo and Fujisawa, Japan. December 27, 2022: ThinkCyte and Axcelead Drug Discovery Partners (DDP) announced a research partnership focused on... - [Axcelead Drug Discovery Partners, Inc. has become a certified provider of spatial transcriptomics technology, Visium, from 10x Genomics](https://axcelead-us.com/news/axcelead-drug-discovery-partners-inc-has-become-a-certified-provider-of-spatial-transcriptomics-technology-visium-from-10x-genomics/): We’re delighted to announce that we have received official certification from 10x Genomics as a Certified Service Provider (CSP) of... - [Axcelead DDP and Knowledge Palette Enter into a Collaborative Research Contract on Gene Expression Analysis Concerning Drug-Resistant Cancer](https://axcelead-us.com/news/axcelead-ddp-and-knowledge-palette-enter-into-a-collaborative-research-contract-on-gene-expression-analysis-concerning-drug-resistant-cancer/): Axcelead Drug Discovery Partners Inc. (headquarters: Fujisawa, Kanagawa; CEO: Yoshinori Ikeura) and Knowledge Palette, Inc. (headquarters: Kawasaki, Kanagawa; Co-Founders and... - [Dr. Hideo Fukui will chair the international symposium about new modalities at the American College of Toxicology 2022 annual meeting.](https://axcelead-us.com/news/dr-hideo-fukui-will-chair-the-international-symposium-about-new-modalities-at-the-american-college-of-toxicology-2022-annual-meeting/): The American College of Toxicology 2022 annual meeting will be held in Denver on November 13 to 16, and an... - [Axcelead Drug Discovery Partners and Acadia Pharmaceuticals Launch Drug Discovery Collaboration in Neuroscience](https://axcelead-us.com/news/axcelead-drug-discovery-partners-and-acadia-pharmaceuticals-launch-drug-discovery-collaboration-in-neuroscience/): October 5, 2022 – Axcelead Drug Discovery Partners Inc. (HQ: Fujisawa, Kanagawa, Japan; hereinafter referred to as “Axcelead DDP”) announces... - [Epigeneron and Axcelead DDP singed a master collaboration agreement on drug discovery research for novel drug targets](https://axcelead-us.com/news/epigeneron-and-axcelead-ddp-singed-a-master-collaboration-agreement-on-drug-discovery-research-for-novel-drug-targets/): Epigeneron Inc. , (Headquarters: Chuo-ku, Tokyo, President: Tetsuya Mishima, “Epigeneron”) and Axcelead Drug Discovery Partners, Inc. (Headquarters: Fujisawa City, Kanagawa... - [Perseus Proteomics and Axcelead DDP launch a collaboration for an antibody drug discovery support service](https://axcelead-us.com/news/perseus-proteomics-and-axcelead-ddp-launch-a-collaboration-for-an-antibody-drug-discovery-support-service/): Perseus Proteomics Inc. (Head office: Meguro, Tokyo; President & CEO: Takuya Yokokawa, “Perseus”) and Axcelead Drug Discovery Partners Inc. (Head... - [ARCALIS and Axcelead DDP Announce Collaboration to Provide Integrated Drug Discovery Support Service for mRNA Therapeutics](https://axcelead-us.com/news/arcalis-and-axcelead-ddp-announce-collaboration-to-provide-integrated-drug-discovery-support-service-for-mrna-therapeutics/): TOKYO, JAPAN, 20 JULY 2022: ARCALIS Inc. (Head office: Kashiwa, Chiba; President & CEO: Tomoyuki Fujisawa; “ARCALIS”) and Axcelead Drug... - [Construction and Functional Evaluation of a Three-Dimensional Blood–Brain Barrier Model Equipped With Human Induced Pluripotent Stem Cell-Derived Brain Microvascular Endothelial Cells](https://www.researchgate.net/publication/359885521_Construction_and_Functional_Evaluation_of_a_Three-Dimensional_Blood-Brain_Barrier_Model_Equipped_With_Human_Induced_Pluripotent_Stem_Cell-Derived_Brain_Microvascular_Endothelial_Cells#new_tab): Pharmaceutical Research - [Axcelead DDP and Knowledge Palette Entered into a Collaborative Research Contract for Establishment of a New Evaluation Platform Using Axcelead DDP’s Compound Libraries and Large-Scale Transcriptome Analysis Technologies](https://axcelead-us.com/news/axcelead-ddp-and-knowledge-palette-entered-into-a-collaborative-research-contract-for-establishment-of-a-new-evaluation-platform-using-axcelead-ddps-compound-libraries-and-large-scale-transcr/): Axcelead Drug Discovery Partners Inc. (headquarters: Fujisawa, Kanagawa; CEO: Yoshinori Ikeura; hereinafter referred to as “Axcelead DDP”) and Knowledge Palette,... - [Characterization and reduction of non-endocrine cells accompanying islet-like endocrine cells differentiated from human iPSC](https://www.nature.com/articles/s41598-022-08753-5#new_tab): Scientific Reports - [IP Generator, Axcelead, and Axcelead Drug Discovery Partners Signed a Comprehensive Business Alliance Agreement](https://axcelead-us.com/news/ip-generator-axcelead-and-axcelead-drug-discovery-partners-signed-a-comprehensive-business-alliance-agreement/): To Establish a Platform for the Efficient and High-quality Drug Discovery Aiming to Resolve Social Issues by Reducing Medical CostsOn... - [Hitachi and Axcelead DDP Launch Manufacturing Process Development Support Service for Cell Therapy and Gene Therapy](https://axcelead-us.com/news/hitachi-and-axcelead-ddp-launch-manufacturing-process-development-support-service-for-cell-therapy-and-gene-therapy/): Supporting optimization of product development and manufacturing with automation and quality assessment Tokyo, December 15, 2021 — Hitachi, Ltd. (TSE:6501,... - [Axcelead Drug Discovery Partners was rated as “Excellent” by Japan Agency for Medical Research and Development (AMED)* in a program for “Drug Discovery Seeds Development”](https://axcelead-us.com/news/axcelead-drug-discovery-partners-was-rated-as-excellent-by-japan-agency-for-medical-research-and-development-amed-in-a-program-for-drug-discovery-seeds-development/): Axcelead Drug Discovery Partners, Inc. (Axcelead DDP) has supported 24 research projects aiming at new drug development in an infrastructure... - [xFOREST Therapeutics, Axcelead DDP and Kyowa Kirin Initiated an Collaboration in RNA Structures Targeted Drug Discovering](https://axcelead-us.com/news/xforest-therapeutics-axcelead-ddp-and-kyowa-kirin-initiated-an-collaboration-in-rna-structures-targeted-drug-discovering/): Tokyo, Japan, October ##, 2021 — xFOREST Therapeutics Co. , Ltd. (Headquarter: Kamigyo-ku, Kyoto, Japan, President and CEO: Shunichi Kashida,... - [Axcelead DDP participates in “MONSTAR-SCREEN-2” of the 4th-stage industry-academia collaborative Cancer Genome Screening Project for Individualized Medicine in Japan “SCRUM-Japan”, as a joint research institute](https://axcelead-us.com/news/axcelead-ddp-participates-in-monstar-screen-2-of-the-4th-stage-industry-academia-collaborative-cancer-genome-screening-project-for-individualized-medicine-in-japan-scrum-jap/): We are pleased to announce that Axcelead Drug Discovery Partners Inc. , (Headquarters: Fujisawa, Kanagawa, JAPAN, CEO: Yoshinori Ikeura, hereinafter... - [Axcelead has entered into a comprehensive agreement including transfer of key drug discovery platforms with a major Japanese pharmaceutical company](https://axcelead-us.com/news/axcelead-has-entered-into-a-comprehensive-agreement-including-transfer-of-key-drug-discovery-platforms-with-a-major-japanese-pharmaceutical-company/): Axcelead Drug Discovery Partners Co. , Ltd. (Headquarters: Fujisawa, Kanagawa, President,　CEO: Yoshinori Ikeura; Axcelead) announces that the company has strengthened... - [Reliable identification of cardiac cunduction abnormalities in drug discovery using automated patch clamp II: Best practices for Nav1.5 peak current in a high throughput screening enviroment](https://linkinghub.elsevier.com/retrieve/pii/S1056871921001787#new_tab): Journal of Pharmacological and Toxicological Methods - [Identification of novel inhibitors of Keap1/Nrf2 by a promising method combining protein–protein interaction‑oriented library and machine learning](https://www.nature.com/articles/s41598-021-86616-1#new_tab): Scientific reports - [Cryo-EM structure of K+-bound hERG channel complexed with the blocker astemizole](https://doi.org/10.1016/j.str.2020.12.007#new_tab): Structure - [Axcelead’s response to the COVID-19 emergency declaration in January 2021](https://axcelead-us.com/news/axceleads-response-to-the-covid-19-emergency-declaration-in-january-2021/): On January 7, the Japanese government declared State of Emergency to prevent the spread of COVID-19 pandemic for the Tokyo... - [Evommune and Axcelead Drug Discovery Partners Launch A Collaboration On A PKCtheta Program To Kick-off Evommune’s Inflammation Pipeline](https://axcelead-us.com/news/evommune-and-axcelead-drug-discovery-partners-launch-a-collaboration-on-a-pkctheta-program-to-kick-off-evommunes-inflammation-pipeline/): Inhibition of PKCtheta as a therapeutic target has the potential to treat multiple inflammatory diseases Los Altos, California, USA and... - [Comprehensive Cardiac Safety Assessment using hiPS-cardiomyocytes (Consortium for Safety Assessment using Human iPS Cells: CSAHi)](https://www.eurekaselect.com/176144/article#new_tab): Current Pharmaceutical Biotechnology - [Bidirectional, non-necrotizing glomerular crescents are the critical pathology in X-linked Alport syndrome mouse model harboring nonsense mutation of human COL4A5](https://www.nature.com/articles/s41598-020-76068-4#new_tab): Scientific Reports - [Axcelead and Kyowa Kirin Started an Innovative Collaboration in Small-Molecule Drug Development](https://axcelead-us.com/news/axcelead-and-kyowa-kirin-started-an-innovative-collaboration-in-small-molecule-drug-development/): Tokyo, Japan, October 2, 2020 —Axcelead Drug Discovery Partners Inc. （Axcelead, President: Yoshinori Ikeura）and Kyowa Kirin Co. , Ltd. (Kyowa... - [Reliable identification of cardiac liability in drug discovery using automated patch clamp: Benchmarking best practices and calibration standards for improved proarrhythmic assessment](https://www.sciencedirect.com/science/article/abs/pii/S1056871920302136#new_tab): Journal of Pharmacological and Toxicological Methods - [Otsuka Pharmaceutical and Axcelead Drug Discovery Partners announce joint research in ​​CNS indications](https://axcelead-us.com/news/otsuka-pharmaceutical-and-axcelead-drug-discovery-partners-announce-joint-research-in-cns-indications/): June 29,2020- Otsuka Pharmaceutical Co. , Ltd. (Headquarters: Chiyoda-ku, Tokyo, President: Makoto Inoue; Otsuka Pharmaceutical) and Axcelead Drug Discovery Partners... - [Acetyl-CoA carboxylase 1 and 2 inhibition ameliorates steatosis and hepatic fibrosis in a MC4R knockout murine model of nonalcoholic steatohepatitis](https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0228212#new_tab): PLOS ONE - [PassPort Technologies and Axcelead Drug Discovery Partners](https://axcelead-us.com/news/passport-technologies-and-axcelead-drug-discovery-partners/): Enter a comprehensive collaborative partnership in the field of drug discovery service using PassPort System, a new active transdermal drug... - [Fujifilm and Axcelead Drug Discovery Partners begin collaborating to advance drug discovery solutions using iPSCs](https://axcelead-us.com/news/fujifilm-and-axcelead-drug-discovery-partners-begin-collaborating-to-advance-drug-discovery-solutions-using-ipscs/): To enhance the Process of Research and Development of Drug Candidates Tokyo/Kanagawa, July 10, 2019 ―FUJIFILM Corporation (President: Kenji Sukeno;... - [Transfer of All Axcelead Shares to Whiz Partners DDG Fund Completed](https://axcelead-us.com/news/transfer-of-all-axcelead-shares-to-whiz-partners-ddg-fund-completed/): April 1, 2019 – Whiz Partners Inc. (hereinafter, “Whiz”), headquartered in Minato Ward, Tokyo, announced that it has completed an... - [Axcelead Drug Discovery Partners and ERS Genomics Enter into CRISPR/Cas9 License Agreement](https://axcelead-us.com/news/axcelead-drug-discovery-partners-and-ers-genomics-enter-into-crispr-cas9-license-agreement/): Fujisawa, Japan and Dublin, Ireland, October 4, 2018 – Axcelead Drug Discovery Partners, Inc. (hereinafter referred to as “Axcelead”) and... - [Announcement on starting preparation to become a company independent from Takeda](https://axcelead-us.com/news/announcement-on-starting-preparation-to-become-a-company-independent-from-takeda/): We are pleased to announce that Axcelead Drug Discovery Partners Inc. (“Axcelead”) preparation to become a company independent from Takeda... - [Announcement of Start of Business Partnership between Axcelead and LAP&P for Modeling and Simulation of Drug Discovery](https://axcelead-us.com/news/announcement-of-start-of-business-partnership-between-axcelead-and-lapp-for-modeling-and-simulation-of-drug-discovery/): We are pleased to announce that Axcelead Drug Discovery Partners, Inc. (Yoshinori Ikeura, President; Headquarters: Fujisawa-shi, Kanagawa, Japan; hereinafter referred... --- # # Detailed Content ## Pages ### Bioinformatics > Axcelead High Throughput Screening services are designed to help you create truly novel, original drugs rapidly with our integrated platform. Whether you're in the pharmaceutical, biotechnology, or academic sector, our comprehensive screening solutions can help you achieve your scientific goals more efficiently. - Published: 2025-06-09 - Modified: 2025-06-09 - URL: https://axcelead-us.com/bioinformatics/ Technology Platforms Bioinformatics Bioinformatics Solutions to Accelerate Drug Discovery Turning Omics Data into Actionable Insights Our bioinformatics solutions help accelerate drug discovery by turning complex omics and genomics data into clear actionable insights. From early-stage research to mechanistic exploration, we empower your decision-making with interactive, intuitive data visualizations. Our platform enables you to: Identify and prioritize therapeutic targets Understand mechanisms of action (MoA), including both on- and off-target effects Discover and validate biomarkers for more precise patient stratification Repurpose drugs and expand therapeutic indications Make data-driven decisions on across diverse therapeutic modalities, including small molecules, biologics, and advanced therapies https://axcelead-us. com/wp-content/uploads/2025/06/bioinformatics-image2. 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https://axcelead-us. com/wp-content/uploads/2025/06/bioinformatics-overcoming. webpOvercoming Challenges in Drug Discovery While the demand for omics analysis is growing rapidly, interpreting complex and partially understood biological mechanisms remains the bottleneck for advancing translational research. Our bioinformatics framework is designed to address the following challenges: Difficulty linking genomic variants to functional disease mechanisms Lack of context-specific target prioritization Unclear MoA for phenotypic screening hits Sparse, noisy, or incomplete biomarker data Poor translatability of preclinical findings Mechanism and quality control challenges in cell therapy products 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https://axcelead-us. com/wp-content/uploads/2025/06/bioinformatics-keyfeatures. webp Omics Based Hypothesis Generation Capability to analyze diverse omics datasets, such as transcriptomics, proteomics, and metabolomics, with robust workflows tailored to each modality. Data interpretation is guided by advanced methods including pathway analysis, network modeling, co-expression analysis (e. g. , WGCNA), and machine learning enabling hypothesis generation relevant to disease mechanisms and therapeutic targets. Large Language Models Large language models trained on biomedical literature are applied to... --- ### Omics > Axcelead High Throughput Screening services are designed to help you create truly novel, original drugs rapidly with our integrated platform. Whether you're in the pharmaceutical, biotechnology, or academic sector, our comprehensive screening solutions can help you achieve your scientific goals more efficiently. - Published: 2025-05-21 - Modified: 2025-05-29 - URL: https://axcelead-us.com/omics/ Technology Platforms Omics Multiple Omics Platform for Precision Drug Discovery Driving Translational Research and Innovation in Drug Discovery Our advanced omics technologies provide a comprehensive view of biological systems, linking genes as blueprints, proteins as the building blocks of cells, and metabolites as indicators of phenotypic changes and cellular morphology. This approach helps overcome key challenges in drug discovery by: Uncovering hidden disease mechanisms Decoding mechanisms of action (MoA) Identifying dynamic biomarkers for better outcomes Stratifying patient subtypes for precision medicine Supporting hypothesis-driven and data-driven compound evaluation https://axcelead-us. com/wp-content/uploads/2025/05/omics-img1. 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https://axcelead-us. com/wp-content/uploads/2025/05/omics-img2. jpg Overcoming Challenges in Drug Discovery Our omics platform is designed to solve the following critical obstacles in drug discovery by integrating high-resolution, cross-platform omics data, which accelerates drug discovery and development: Bridging gaps in disease pathophysiology Closing the gap between preclinical efficacy and human outcomes Identifying MoA for new compounds in complex disease models Early detection of off-target toxicological effects Finding relevant biomarkers for dynamic treatment monitoring Identifying patient subgroups with diverse responses Our Key Capabilities Project-tailored omics services categorized by platform with end-to-end support: study design, sample prep, data acquisition, bioinformatics and hypothesis generation. Somatic Mutation Custom Panel Single-cell RNA-seq Single-nucleus RNA-seq Spatial Transcriptomics Bulk RNA-seq Global Proteomics Post-Translational Modifications Proteomics Chemical Proteomics Proteogenomics Non-targeted metabolomics/lipidomics Wide-target metabolomics/lipidomics Focused Metabolite Panels Metabolic Flux Analysis Extracellular Vehicles Analysis Technology Features Ultra-low input: detects somatic variants from just 10 ng gDNA Targeted enrichment: PCR focus on >1,000 disease loci for deep (2,000×) coverage High throughput: 30 samples in 12... --- ### Topics - Published: 2025-05-21 - Modified: 2025-05-21 - URL: https://axcelead-us.com/topics/ News Topics 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 --- ### News Releases - Published: 2025-05-21 - Modified: 2025-05-21 - URL: https://axcelead-us.com/news-releases/ News News Releases 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 --- ### Chemistry > Axcelead Chemistry services are designed to help you create the medicines of the future. Whether you're in the pharmaceutical, biotechnology, or academic sector, our comprehensive chemistry solutions can help you achieve your scientific goals more efficiently. - Published: 2024-12-13 - Modified: 2024-12-13 - URL: https://axcelead-us.com/chemistry/ Technology Platforms Chemistry Chemistry Accelerates Drug Discovery Success Axcelead leverages our expertise and technologies of rational drug design and synthetic chemistry to create the medicines of the future https://axcelead-us. com/wp-content/uploads/2024/11/drugdiscovery-chemistry-img. png While it takes a very long time to generate candidate compounds in success at a typical CRO, we accelerate drug discovery in one-stop service with a wealth of experience, technologies and expertise based on a spin-off from pharmaceutical company. We offer full chemistry support in drug discovery across small molecule, peptide and oligonucleotide modality from hit to candidate generation. We provide you innovative and flexible chemistry solutions to the challenges and problems you face by our expertise and technologies. 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 Our Full Capabilities in Chemistry Chemistry is at the core of what we do. Our proprietary capabilities offer a wide range of high quality and cost-effective services, aimed at designing the best molecules across a diverse array of assay technologies. Learn more about our full capabilities and how we can partner together. Medicinal Chemistry Computational Chemistry Synthetic Chemistry Analytical Chemistry Medicinal Chemistry “All-in-one” medicinal chemistry with rational design system, advanced synthetic chemistry, and analytical chemistry Extensive experienced scientists with track records leading drug discovery team Experiences in a wide range of therapeutic areas and target classes High-speed and high-quality Design-Make-Test-Analysis (DMTA) cycle close tie-up with Axcelead’s biology, pharmacology, pharmacokinetics, and safety functions Main Services - Hit Expansion - Lead Generation - Lead Optimization https://axcelead-us. com/wp-content/uploads/2024/08/medicinal-img. png Computational Chemistry Computational chemistry systems - SBDD systems - LBDD systems - Knowledge... --- ### Small Molecules > Axcelead is your partner in Targeted Protein Degradation Drug Discovery! Axcelead has comprehensive capabilities in Targeted Protein Degradation Drug Discovery drug discovery at the preclinical stages and a proven track record. Whether you are in the pharmaceutical, biotechnology, or academic sector, our comprehensive solutions can help you achieve your scientific goals more efficiently. - Published: 2024-12-13 - Modified: 2024-12-13 - URL: https://axcelead-us.com/small-molecules/ Therapeutic Modalities Small Molecules Small Molecule Drugs: The Cornerstone of Future Pharmaceutical Innovation Small molecule drugs have been the dominant form in pharmaceuticals to date, and even as modalities diversify in the future, they are expected to continue to comprise the majority of newly approved drugs. This is because they are economical for medical use and convenient for patients. In other words, small molecule drugs are less expensive to produce compared to others and can be administered in flexible ways such as orally, sublingually, or by injection, which is patient friendly. Furthermore, in the field of central nervous system diseases, small molecules with the potential to penetrate the brain are a modality that should be further developed. Therefore, the discovery of small molecule drugs will continue to play an important role in the future. Streamlining Drug Discovery with Integrated Expertise Axcelead offers a comprehensive platform that enables one-stop drug discovery for small molecule drugs, effectively addressing key challenges from target identification to IND. Through its integrated drug discovery approach, Axcelead leverages expertise across chemistry, biology, pharmacology, DMPK, and safety, working in synergy to advance projects efficiently. This streamlined process ensures drug discovery can be completed in the shortest possible time. https://axcelead-us. com/wp-content/uploads/2024/12/streaming-image2. 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://axcelead-us. com/wp-content/uploads/2024/12/accellerating-image2. png Accelerating Innovation with Data and AI Technologies Axcelead provides access to data from approximately 1,000 projects across multiple therapeutic areas, including 180+ projects with curated, ready-to-go compounds and assays known as IND-Enabling Projects. By utilizing these resources, Axcelead quickly and efficiently advances drug discovery projects... --- ### Targeted Protein Degraders > Axcelead is your partner in Targeted Protein Degradation Drug Discovery! Axcelead has comprehensive capabilities in Targeted Protein Degradation Drug Discovery drug discovery at the preclinical stages and a proven track record. Whether you are in the pharmaceutical, biotechnology, or academic sector, our comprehensive solutions can help you achieve your scientific goals more efficiently. - Published: 2024-11-14 - Modified: 2024-12-20 - URL: https://axcelead-us.com/targeted-protein-degraders/ Therapeutic Modalities Targeted Protein Degradation Axcelead Holistic Solution for Targeted Protein Degradation (TPD) Drug Discovery Axcelead has comprehensive capabilities in TPD drug discovery at the preclinical stages and a proven track record. No matter what stage your project is in, Axcelead will offer a tailored solution for you, whether you need support for part or all of it. Targeted Protein Degradation Targeted Protein Degradation (TPD) has emerged as a promising new therapeutic modality in drug discovery. Unlike traditional approaches that focus on inhibiting protein functions, TPD utilizes the ubiquitin-proteasome system to target specific proteins for degradation. In other words, it leverages the cell's natural protein degradation machinery to selectively eliminate disease-causing proteins. The Targeted Protein Degradation (TPD) offers many advantages, including: A broad target range, including previously undruggable targets More profound efficacy through the removal of the target protein Lower clinical doses due to its catalytic mechanism Improved safety through tissue or cell selective degradation Oral administration https://axcelead-us. com/wp-content/uploads/2024/10/tpd-advantages. 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https://axcelead-us. com/wp-content/uploads/2024/10/tpd-function. jpg TPD can be primarily classified into bifunctional degraders, such as PROTAC®, and monomeric degraders, including molecular glue degraders and monovalent degraders. Each type has its advantages and disadvantages. Bifunctional degraders can be designed rationally in initial discovery stage. On the other hand, the molecular complexity poses challenges of molecule optimization, synthesis, purification, ADME and so on. Regarding the discovery of monomeric degraders, in some cases, selectivity and identification of degradation mechanism are challenges. Another common hurdle of TPD is the need for a highly specialized and diverse assay... --- ### RNA-Targeted Small Molecules > Axcelead is your partner in RNA-Targeted Drug Discovery! Axcelead has comprehensive capabilities in integrated RNA-targeted small molecule drug discovery at the preclinical stages. Whether you are in the pharmaceutical, biotechnology, or academic sector, our comprehensive solutions can help you achieve your scientific goals more efficiently. - Published: 2024-11-14 - Modified: 2024-12-18 - URL: https://axcelead-us.com/rna-targeted-small-molecules/ Therapeutic Modalities RNA-Targeted Small Molecules Axcelead Holistic Solution for RNA-targeted Small Molecule Axcelead has comprehensive capabilities in integrated RNA-targeted small molecule drug discovery at the preclinical stages. No matter what stage your project is in, Axcelead will offer a tailored solution for you, whether you need support for part or all of it. RNA-targeted Small Molecules RNA-targeted small molecules represent a novel approach in drug discovery that involves the design of compounds to interact specifically with RNA molecules within cells. Unlike traditional drug discovery methods that primarily focus on targeting proteins, RNA-targeted small molecules aim to modulate RNA-derived function, which plays crucial roles in various cellular processes and disease mechanisms. The RNA-targeted small molecules platform offers many advantages, including: Broad Target Space: RNA molecules represent a vast and diverse set of potential drug targets, offering opportunities to address diseases with unmet medical needs. Drugging Undruggable Targets: RNA-targeted small molecules can target RNA structures or sequences that are traditionally considered challenging to drug with other modalities. Oral administration: Systemic exposure including central nervous system by oral administration https://axcelead-us. com/wp-content/uploads/2024/10/rna-advantages. 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https://axcelead-us. com/wp-content/uploads/2024/10/rna-challenges. jpgIn contrast, it also faces challenges: Discovery of “real promising” hits: Insufficiency of RNA-focused compound library and gap between cell-free and cellular assay remain significant challenges. Specificity: Ensuring specificity and minimizing off-target effects is crucial to the development of safe and effective RNA-targeted small molecule therapeutics. Optimization: Structure-based drug design is generally difficult due to the flexibility of RNA structures. Axcelead Platform Solves Your RNA-targeted Small Molecule Challenges Special RNA-focused... --- ### Peptide > Axcelead is your partner in Peptide Drug Discovery! Axcelead peptide drug discovery services are designed to accelerate your peptide drug project with our comprehensive platform. Whether you are in the pharmaceutical, biotechnology, or academic sector, our comprehensive solutions can help you achieve your scientific goals more efficiently. - Published: 2024-08-08 - Modified: 2024-12-03 - URL: https://axcelead-us.com/peptide/ Therapeutic Modalities Peptide Our Approach to Overcoming Challenges in Peptide Drug Discovery 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 A Comprehensive One-Stop Solution for All Your Peptide Drug Discovery Challenges! Axcelead has intelligent platform technologies to create peptide therapeutics with optimized profiles suitable for clinical development. These technologies help address challenges in peptide drug discovery, including basic sequence, in vitro activity, in vitro stability, in vivo duration and oral absorption. https://axcelead-us. com/wp-content/uploads/2024/08/unmatched-capabilities. jpg Peptide Design Axcelead creates appropriate peptide sequences with its unique strategies and technologies. 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 Sequence and scaffold designs Sequence designs to improve pharmacological activity Sequence designs to improve DMPK https://axcelead-us. com/wp-content/uploads/2024/08/peptide-design. png Structural analysis Cocrystal structure analysis Single-crystal structure analysis NMR analysis https://axcelead-us. com/wp-content/uploads/2024/08/peptide-structural-analysis. png In silico analysis Identification of hot spots and design proposal Binding model analysis and evaluation Scaffold design using structure hopping technology https://axcelead-us. com/wp-content/uploads/2024/08/peptide-acode. png A-code: In silico drug discovery technology created by Axcelead Peptide Synthesis Axcelead has extensive experience in all peptide-related modalities, including multi-cyclic peptides and peptide drug conjugates, to meet your needs. Synthesis technology Multi-sample parallel synthesis High-quality bulk synthesis (e. g. for in vivo test) Precise and high-speed purification https://axcelead-us. com/wp-content/uploads/2024/08/peptide-synthesis. jpg Modalities Short-chain peptides and long-chain peptides Cyclic peptides(e. g. bicyclic, tricyclic) Modified peptides Peptide conjugates Peptide prodrugs Nonpeptide polyamide https://axcelead-us. com/wp-content/uploads/2024/08/peptide-modalities. jpg Peptide Evaluation Axcelead offers comprehensive evaluation services to peptides from multiple perspectives. Pharmacokinetic and physicochemical property Membrane permeability study (PAMPA/Caco-2/MDR1) Physicochemical property test (solubility/EPSA/LogD) Plasma stability study Metabolic stability study Pharmacokinetic study Pharmacology study Covers a wide range of therapeutics areas... --- ### Oligonucleotide > Axcelead is your partner in Oligonucleotide Drug Discovery! Axcelead oligonucleotide drug discovery services are designed to accelerate your oligonucleotide drug project with our comprehensive platform. Whether you are in the pharmaceutical, biotechnology, or academic sector, our comprehensive solutions can help you achieve your scientific goals more efficiently. - Published: 2024-07-17 - Modified: 2025-06-03 - URL: https://axcelead-us.com/oligonucleotide/ Therapeutic Modalities Oligonucleotide Your Partner in Oligonucleotide Drug Discovery Safety and delivery are the main challenges associated with discovering and developing complex oligonucleotides therapies. Axcelead offers a comprehensive platform that excels in repeating both in vivo and in vitro evaluations in the short term and proposing optimal solutions to help our partners overcome these challenges. Accelerate your oligonucleotide drug discovery and development process with Axcelead https://axcelead-us. com/wp-content/uploads/2024/07/strength-diagram-new. pngPHN0eWxlPgouc3RyZW5ndGgtd2hpdGV3cmFwIHsKICBoZWlnaHQ6IDI3MHB4Owp9Ci5ub3JtYWwtd2VpZ2h0IHsKIAlmb250LXdlaWdodDogNDAwIWltcG9ydGFudDsgCn0KQG1lZGlhIG9ubHkgc2NyZWVuIGFuZCAobWF4LXdpZHRoOiA2MDBweCl7CiAgLnN0cmVuZ3RoLXdoaXRld3JhcCB7CiAgICBoZWlnaHQ6IGF1dG87CiAgfQogIH0KPC9zdHlsZT4= We have a proven track record and unmatched capabilities Sequence Design The efficient optimization of antisense oligonucleotide (ASO) sequences for target mRNAs. Sequence selection combined with off-target analysis to reduce toxicity risk Ability of avoiding characteristic sequences with safety and toxicity concerns Selection of sequences that are less prone to aggregation and self-association by considering the secondary structures Optimization of modified nucleic acid units and modification patterns through excellent balance between activity and safety https://axcelead-us. com/wp-content/uploads/2024/07/sequence-diagram. png PK Analysis & Distribution Evaluation Insufficient drug efficacy can sometimes be attributed to poor delivery to cells within the target tissue. At Axcelead, we employ advanced techniques to investigate this issue. Through quantitative analysis and visualization utilizing IHC (immunohistochemistry) and ISH (in situ hybridization), we thoroughly evaluate the distribution of oligonucleotides at the cellular level. This approach allows us to gain valuable insights into drug delivery mechanisms and optimize treatment strategies for enhanced therapeutic outcomes. Quantitative analysis Based on our extensive experience, we select the most suitable methods, such as LC-MS/MS and Hybridization ELISA, and promptly report the results. In addition, we can analyze ligand-conjugated... --- ### High Throughput Screening > Axcelead High Throughput Screening services are designed to help you create truly novel, original drugs rapidly with our integrated platform. Whether you're in the pharmaceutical, biotechnology, or academic sector, our comprehensive screening solutions can help you achieve your scientific goals more efficiently. - Published: 2024-07-17 - Modified: 2024-12-18 - URL: https://axcelead-us.com/high-throughput-screening/ Technology Platforms High Throughput Screening We Can Help You Create Truly Novel, Original Drugs Our integrated High Throughput Screening (HTS) platform, including a pharma-origin library of 1. 2+ million compounds, assay development capabilities, and a track record of over 700 projects, helps you rapidly identify your hit compounds. We help you identify original and proprietary hits through our 1. 2+ million compound library, which originates from a pharmaceutical company and includes 60% internally synthesized compounds We can design an efficient hit identification process and prioritize hits by leveraging our accumulated proprietary data Our faster, pharma-standard HTS can significantly contribute to reduce drug discovery timeline https://axcelead-us. com/wp-content/uploads/2024/07/hts-image. 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 Our Full Capabilities in HTS We have a lot to offer with screening services aimed at identifying new chemical matter. Our team provides high-quality and cost-effective screening services covering a wide range of assay technologies. Track Record and Experimental Data Assay Development Compound Libraries Hit Expansion and Hit-to-lead Track Record and Experimental Data 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 Over 90% Hit Ratio of Screening Experimental data for 989 individual targets are available Over 700 track records of HTS projects Assay Development We regularly invest in the best assays and platform technologies to support our customers’ needs in screening activities. Offers efficient material preparation and assay development services that enable swift transition to LG/LO stages Achieved over 480 track records of assay development, over 80% developed at Axcelead Typical assay menu examples Enzyme - Luminescence, Absorbance, Coupling, Fluorescence, TR-FRET, AlphaScreen - Label-free assay (Rapidfire-MS) - ELISA - Radiometric... --- ### Cardiovascular / Metabolic disease - Published: 2024-05-08 - Modified: 2024-12-11 - URL: https://axcelead-us.com/therapeutic-areas/cardiovascular-metabolic-disease/ Therapeutic Areas Cardiovascular / Metabolic Disease At Axcelead, we have extensive experience and know-how in the preclinical development of new therapies for cardiovascular and metabolic diseases. We support our partners advance programs from discovery through target identification/validation, lead generation/optimization, with various in vitro and in vivo disease models. https://axcelead-us. com/wp-content/uploads/2024/05/cardiovascular-img1. jpghttps://axcelead-us. com/wp-content/uploads/2023/12/green-background. jpgPHN0eWxlPgouZ3JlZW4tZmlsbGVyIGltZyB7CiAgICBtYXgtaGVpZ2h0OiAzNTBweCAhaW1wb3J0YW50OwogICAgaGVpZ2h0OiAyNTBweCAhIEltcG9ydGFudDsKICAgIHdpZHRoOiA5MDBweCAhaW1wb3J0YW50OwogICAgb2JqZWN0LWZpdDogY292ZXI7Cn0KLmNhcmRpb3Zhc2N1bGFyLWltZyB7CiAgbWF4LXdpZHRoOiA4MCUhaW1wb3J0YW50Owp9CgpAbWVkaWEgb25seSBzY3JlZW4gYW5kIChtYXgtd2lkdGg6IDUwMHB4KXsgCiAgLmNhcmRpb3Zhc2N1bGFyLWltZyB7CiAgbWF4LXdpZHRoOiAxMDAlIWltcG9ydGFudDsKfQp9Cjwvc3R5bGU+ Select the best molecule by leveraging our proven animal models that engage the target Cardiovascular and metabolic diseases are complicated diseases involving various organs, and drug discovery requires deep expertise. At Axcelead, our team has abundant experience in drug discovery for heart failure, kidney diseases, obesity, MASH, etc. We will take your projects to the clinic by performing the same clinical assessments with a diverse evaluation like energy expenditure, fat composition, and more. --- ### Thank you inquiry - Published: 2024-01-04 - Modified: 2024-01-04 - URL: https://axcelead-us.com/thank-you-inquiry/ Contact Us For questions and consultations about our business and services, please use the form below. Thank you for your inquiry. Our team will contact you within 3-4 working days. --- ### Previous Conferences > Welcome to view the conferences that Axcelead Drug Discovery Partners, Inc. has attended. - Published: 2023-12-19 - Modified: 2024-05-24 - URL: https://axcelead-us.com/events/previous-conferences/ Events Conferences PHN0eWxlPgouZnVzaW9uLWJ1dHRvbi5idXR0b24tZmxhdC5jb25mZXJlbmNlLWxlYXJubW9yZTpob3ZlciB7CiAgICBiYWNrZ3JvdW5kOiB0cmFuc3BhcmVudCFpbXBvcnRhbnQ7CiAgY29sb3I6ICMwMDAhaW1wb3J0YW50OwogIGJvcmRlci1ib3R0b206IDNweCBzb2xpZCB2YXIoLS1tYWluZ3JlZW4pOwp9Ci5mdXNpb24tYnV0dG9uLmJ1dHRvbi1mbGF0LmNvbmZlcmVuY2UtbGVhcm5tb3JlOmhvdmVyIHNwYW57CiAgICBiYWNrZ3JvdW5kOiB0cmFuc3BhcmVudCFpbXBvcnRhbnQ7CiAgY29sb3I6IHZhcigtLW1haW5ncmVlbikhaW1wb3J0YW50Owp9Cjwvc3R5bGU+ --- ### IND-Enabling Projects > Unleash your research potential with Axcelead's IND-Enabling Projects, saving significant time and resources. Any newly generated IP is owned by our customers. - Published: 2023-12-13 - Modified: 2024-12-13 - URL: https://axcelead-us.com/integrated-drug-discovery/ind-enabling-projects/ Integrated Drug Discovery Offering End-to-End Solutions IND-Enabling Projects Axcelead acquired multiple projects from Takeda through its spin-out in 2017 in multiple therapeutic areas including Oncology, Inflammation and Immunology, Cardiovascular/Metabolic Disease and Neuroscience. These exciting projects are available for co-creation of drug candidates with our customers. The IND-Enabling Projects provide an opportunity for newly generated IP, which is owned by our customers. To help you advance an IND-Enabling Projects, Axcelead drug discovery services are capable of advancing projects to IND filing and beyond. https://axcelead-us. com/wp-content/uploads/2023/12/home-hiddenvalue. jpg Currently, we have 180+ small molecule and peptide projects against the select below high-value therapeutic targets: ERBB4 inhibitor IAP antagonist MAPK14 inhibitor HCN4 inhibitor If you are interested in learning more, please reach out directly to our business development department. Contact Us Click here for service details. --- ### IND-enabling > Axcelead offers refined IND enabling services to accelerate your drug discovery process. Our experienced and collaborative team supports your IND enabling projects with professional expertise and state-of-the-art facilities, delivering timely and cost-effective results. - Published: 2023-12-13 - Modified: 2024-06-17 - URL: https://axcelead-us.com/integrated-drug-discovery/ind-enabling/ Integrated Drug Discovery Offering End-to-End Solutions IND Enabling Smart-IND Our proprietary process is designed to accelerate the development project time of your drug from candidate selection to IND filing, reduce R&D costs and achieve an IND in under 12 months. Smart-IND is a one-stop shop with Axcelead – we will create the optimal strategy to achieve a successful IND and manage the entire project with our partner CRO and CDMO processes. This reduces your operational burden for an IND, enabling you to focus on the patient-focused aspects of a first-in-human program. https://axcelead-us. com/wp-content/uploads/2023/12/home-ind-enabling. jpg Key benefits to working with us on a SMART-IND: Achievement of an optimal IND based on the project goal and target product profile Fully support by project manager as a single contact Non-GMP bulk preparation with route scouting Implementation of the best package plan according to various modalities Appropriate animal selection including KI/KO animals for on-target tox evaluation Smooth transition to clinical development through modeling, simulation, PK/PD assays and analyses --- ### Technology Platforms - Published: 2023-12-13 - Modified: 2023-12-13 - URL: https://axcelead-us.com/technology-platforms/ --- ### Neuroscience - Published: 2023-12-13 - Modified: 2024-10-22 - URL: https://axcelead-us.com/therapeutic-areas/neuroscience/ Therapeutic Areas Advancing Neuroscience Research We understand that developing drugs for neuroscience indications can be challenging. We utilize an integrated drug discovery service package to provide appropriate solutions to solve common issues in this field of research. https://axcelead-us. com/wp-content/uploads/2023/12/CNS-1-2. jpghttps://axcelead-us. com/wp-content/uploads/2023/12/green-background. jpghttps://axcelead-us. com/wp-content/uploads/2023/12/CNS-2. jpg Axcelead focuses on targeting biological pathways associated with drivers of neurological disease. When you partner with us, we will validate the scientific hypothesis of hitting a particular target based on the change of gene and protein expression using iPSC, patient-derived CSF, plasma and brain cells. Further, we will evaluate the potential of your compound using various measures of brain function and efficacy with behavioral tests specific to the development of neuroscience drugs. Neuroscience Brochure PGRpdiBjbGFzcz0iZG93bmxvYWQtcGRmLXdyYXAiPjxpbWcgc3JjPSIvd3AtY29udGVudC91cGxvYWRzLzIwMjMvMTEvaWNvbi1kb3dsb2FkLnBuZyIgYWx0PSIiIHdpZHRoPSI2MCIgaGVpZ2h0PSI2MyIgLz4gPGEgY2xhc3M9ImRvd25sb2FkLWxpbmsiIGhyZWY9Imh0dHBzOi8vYXhjZWxlYWQtdXMuY29tL3dwLWNvbnRlbnQvdXBsb2Fkcy8yMDI0LzA4L0RydWctRGlzY292ZXJ5LVNlcnZpY2VzLWZvci1OZXVyb3NjaWVuY2UtYXQtQXhjZWxlYWQucGRmIiB0YXJnZXQ9Il9ibGFuayIgcmVsPSJub29wZW5lciI+RG93bmxvYWQ8L2E+PC9kaXY+ --- ### Immunology - Published: 2023-12-13 - Modified: 2024-01-05 - URL: https://axcelead-us.com/therapeutic-areas/immunology/ Therapeutic Areas Advancing Immunology Research We can design and carry out the most appropriate in vitro and/or in vivo studies to advance your project for inflammation and immunological diseases. https://axcelead-us. com/wp-content/uploads/2023/12/immunology-1. jpghttps://axcelead-us. com/wp-content/uploads/2023/12/green-background. jpghttps://axcelead-us. com/wp-content/uploads/2023/12/immunology-2. jpg Axcelead's capabilities translate into unmatched product designs. Our proprietary process focuses on obtaining the right immune and inflammatory reactions in cells from multiple species in our preclinical models, obtaining efficacy in our preclinical models and creating a novel MOA at our facility utilizing human tissue and blood samples. --- ### Oncology - Published: 2023-12-13 - Modified: 2024-05-27 - URL: https://axcelead-us.com/therapeutic-areas/oncology/ Therapeutic Areas Advancing Oncology Research We have a long and proven track record in the development of small molecules for oncology. We help our partners advance cancer programs from discovery through target identification/validation, hit identification/characterization, lead generation/optimization, IND filing and then NDA filing. https://axcelead-us. com/wp-content/uploads/2023/12/therapeuticcs-img1. jpghttps://axcelead-us. com/wp-content/uploads/2023/12/green-background. jpghttps://axcelead-us. com/wp-content/uploads/2023/12/therapeuticcs-img2. jpg Axcelead focuses on biology and following the data. We harness our wealth of expertise in target identification/validations, in vitro cell based assays, in vivo studies and translational research to achieve compounds with optimal profiles to perform well in the preclinical, clinical and real-world settings. And given our success in this area, we are leveraging these learnings and expanding into immuno-oncology to create drugs that affect the cancer tumor microenvironment and host immunity. Oncology Brochure PGRpdiBjbGFzcz0iZG93bmxvYWQtcGRmLXdyYXAiPjxpbWcgc3JjPSIvd3AtY29udGVudC91cGxvYWRzLzIwMjMvMTEvaWNvbi1kb3dsb2FkLnBuZyIgYWx0PSIiIHdpZHRoPSI2MCIgaGVpZ2h0PSI2MyIgLz4gPGEgY2xhc3M9ImRvd25sb2FkLWxpbmsiIGhyZWY9Imh0dHBzOi8vYXhjZWxlYWQtdXMuY29tL3dwLWNvbnRlbnQvdXBsb2Fkcy8yMDI0LzAzL0RydWctRGlzY292ZXJ5LWZvci1PbmNvbG9neV9PTkMwMDAxRV8yMDI0MDMucGRmIiB0YXJnZXQ9Il9ibGFuayIgcmVsPSJub29wZW5lciI+RG93bmxvYWQ8L2E+PC9kaXY+ --- ### Therapeutic Areas - Published: 2023-12-13 - Modified: 2024-12-11 - URL: https://axcelead-us.com/therapeutic-areas/ --- ### Future Conferences > Welcome to view the conferences that Axcelead Drug Discovery Partners, Inc. will be attending. - Published: 2023-12-09 - Modified: 2024-05-24 - URL: https://axcelead-us.com/events/conferences/ Events Conferences PHN0eWxlPgouZnVzaW9uLWJ1dHRvbi5idXR0b24tZmxhdC5jb25mZXJlbmNlLWxlYXJubW9yZTpob3ZlciB7CiAgICBiYWNrZ3JvdW5kOiB0cmFuc3BhcmVudCFpbXBvcnRhbnQ7CiAgY29sb3I6ICMwMDAhaW1wb3J0YW50OwogIGJvcmRlci1ib3R0b206IDNweCBzb2xpZCB2YXIoLS1tYWluZ3JlZW4pOwp9Ci5mdXNpb24tYnV0dG9uLmJ1dHRvbi1mbGF0LmNvbmZlcmVuY2UtbGVhcm5tb3JlOmhvdmVyIHNwYW57CiAgICBiYWNrZ3JvdW5kOiB0cmFuc3BhcmVudCFpbXBvcnRhbnQ7CiAgY29sb3I6IHZhcigtLW1haW5ncmVlbikhaW1wb3J0YW50Owp9Cjwvc3R5bGU+ --- ### Events - Published: 2023-12-09 - Modified: 2023-12-09 - URL: https://axcelead-us.com/events/ --- ### Previous Seminars > Welcome to view the seminars that Axcelead Drug Discovery Partners, Inc. has held. - Published: 2023-12-09 - Modified: 2024-05-24 - URL: https://axcelead-us.com/events/previous-seminars/ Events Seminars --- ### Future Seminars > Welcome to view the seminars that Axcelead Drug Discovery Partners, Inc. will be holding. - Published: 2023-12-09 - Modified: 2024-05-24 - URL: https://axcelead-us.com/events/seminars/ Events Seminars --- ### Candidate Selection > Axcelead offers refined candidate selection services to accelerate your drug discovery process. Our experienced and collaborative team supports your candidate selection projects with professional expertise and state-of-the-art facilities, delivering timely and cost-effective results. - Published: 2023-12-09 - Modified: 2024-06-17 - URL: https://axcelead-us.com/integrated-drug-discovery/candidate-selection/ Integrated Drug Discovery Offering End-to-End Solutions Candidate Selection Candidate Selection is vital in drug discovery as in which, the optimized compounds are evaluated whether they are feasible for IND application filing and clinical studies. The candidate compound is selected and proposed based on the results of human effective dose prediction and safety assessment. Axcelead offers you one-stop and high-quality candidate selection by our accumulated experience. https://axcelead-us. com/wp-content/uploads/2023/12/home-candidate-select. jpg PK/PD/E analysis TK/TD analysis Modelling & Simulation Human PK & Effective concentrations & Effective doses prediction Drug-drug interaction risk assessment In vitro and in vivo exploratory safety studies --- ### Lead Generation / Optimization > Axcelead offers refined lead generation and optimization services to accelerate your drug discovery process. Our experienced and collaborative team supports your lead generation and optimization projects with professional expertise, state-of-the-art facilities, and a large compound library/database originating from the pharmaceutical industry, delivering timely and cost-effective results. - Published: 2023-12-09 - Modified: 2024-12-18 - URL: https://axcelead-us.com/integrated-drug-discovery/lead-generation-optimization/ Integrated Drug Discovery Offering End-to-End Solutions Lead Generation / Optimization Axcelead has all must-have functions for efficient lead generation and optimization in one place, covering medicinal and analytical chemistries as well as in vitro and in vivo biology including DMPK and safety evaluation. Furthermore, Axcelead also uses proprietary in silico systems with AI and high throughput synthesis technology to guide rational drug design and compound delivery. Axcelead has done more than 50 projects with many companies for 5 years and contributed to 7 candidates and 1 IND. https://axcelead-us. com/wp-content/uploads/2023/12/smart-ind-image. jpg Assets - Compound Libraries (1. 2+ M compounds)　 - Scientific data (except client’s data) inherited from pharma Drug discovery PJ - >50 PJs experiences for 5 years - Hidden Value Projects (>150 PJs) Design platform - Self-developing in-silico systems “A-CODE” with LBDD, SBDD - Cheminformatics and AI Synthesis platform - High throughput parallel synthesis - Chiral synthesis, flow chemistry, photo chemistry　 - Route scouting and scale-up synthesis - Purification, analysis, structure determination　 - Peptide synthesis Evaluation platform in one place - Screening / Virtual screening - Biology　 - DMPK & Safety --- ### Hit Identification / Characterization > Axcelead offers refined hit identification and characterization services to accelerate your drug discovery process. Our experienced and collaborative team supports your hit identification and characterization projects with professional expertise, state-of-the-art facilities, and a large compound library/database originating from the pharmaceutical industry, delivering timely and cost-effective results. - Published: 2023-12-09 - Modified: 2025-02-07 - URL: https://axcelead-us.com/integrated-drug-discovery/hit-identification-characterization/ Integrated Drug Discovery Offering End-to-End Solutions Hit Identification / Characterization Axcelead will design a robust HTS strategy, starting from assay development through hit characterization, based on 700+ HTS experiences. Using carefully curated library sets from 1. 2+ million compounds inherited from a pharmaceutical company, we have achieved a success hit identification rate of 90+%. We also focus on advancing hit compounds to development candidates efficiently. Annotation information from our database, medicinal chemist reviews, and high-throughput ADME tests can be utilized for hit prioritization. Through evaluating similar compounds from our compound library and utilizing high-throughput synthesis platform, we will prioritize the best hit chemotypes ensuring quality Lead Generation start. https://axcelead-us. com/wp-content/uploads/2023/12/home-smart-hts. jpg Compound Libraries Virtual Screening Target-Based High-Throughput Screening (HTS) - Biochemical & Mass Spectrometry-Based Assay - Cellular Assay - Affinity Selection Mass Spectrometry (ASMS)　 - Thermal Shift Assay (TSA)　 - Fragment Based Drug Discovery (FBDD) Phenotypic Screening - Phenotypic Assay　 - iPSC　 - Target Deconvolution New Modalities - Targeted Protein Degradation　 - RNA Targeting Drug　 Hit Characterization - Hit Expansion & High-Throughput Synthesis - Structural Biology & Biophysics　 --- ### Integrated Drug Discovery > Axcelead offers integrated drug discovery and development solutions to clients worldwide, including academia, biotechnology, and pharmaceutical companies. Our experienced team works closely with you at every step of your drug discovery project, from target identification, hit identification and characterization, lead generation and optimization, and candidate selection to IND enabling and beyond. - Published: 2023-12-09 - Modified: 2024-06-17 - URL: https://axcelead-us.com/integrated-drug-discovery/ Integrated Drug Discovery Fully integrated drug discovery services from target discovery to IND enabling translational research. https://axcelead-us. com/wp-content/uploads/2024/01/idd-banner-indentification. png To accelerate and increase success rate of your drug discovery, Axcelead's experiences and collaborative team facilitates each stage of your drug discovery project with its professional expertise, state-of-the-art facilities, and pharma origin huge compounds library/database, delivering timely and cost-effective results. PHN0eWxlPgouaWRkLWltYWdlIGltZyB7CiAgaGVpZ2h0OiAxMDBweCFpbXBvcnRhbnQ7CiAgd2lkdGg6IGF1dG8haW1wb3J0YW50Owp9Cjwvc3R5bGU+https://axcelead-us. com/wp-content/uploads/2024/01/idd-tiv. png Target Identification / Validation https://axcelead-us. com/wp-content/uploads/2024/01/idd-hic. png Hit Identification / Characterization https://axcelead-us. com/wp-content/uploads/2024/01/idd-leadgeneration. png Lead Generation / Optimization https://axcelead-us. com/wp-content/uploads/2024/01/idd-candidate. png Candidate Selection https://axcelead-us. com/wp-content/uploads/2024/01/idd-ind. png IND Enabling --- ### Target Identification / Validation > Axcelead offers refined target identification and validation services to accelerate your drug discovery process. Our experienced and collaborative team supports your target identification and validation projects with professional expertise, state-of-the-art facilities, and a large compound library/database originating from the pharmaceutical industry, delivering timely and cost-effective results. - Published: 2023-12-09 - Modified: 2024-06-17 - URL: https://axcelead-us.com/integrated-drug-discovery/target-identification-validation/ Integrated Drug Discovery Offering End-to-End Solutions Target Identification / Validation Target Identification would have a significant impact in drug discovery research. Axcelead offers the platform to support the identification of novel drug target using human data driven transcriptomics and proteomics. Target validation of identified candidates is also performed in Axcelead using human samples and a variety of animal disease models. Target Identification Gene expression profiling - Bulk RNA-seq - Single cell RNA-seq - Single nuclear RNA-seq Spatial transcriptomics Proteomics Bioinformatics analysis Target Validation Research in relation to disease - Human samples Efficacy of tool compounds - Human iPS-derived cells - Various disease models Generation of KO/KI animals https://axcelead-us. com/wp-content/uploads/2023/12/smarttarget-image. jpg --- ### Contact Us - Published: 2023-12-04 - Modified: 2024-02-29 - URL: https://axcelead-us.com/contact-us/ Contact Us For questions and consultations about our business and services, please use the form below. PGlmcmFtZSBzcmM9Imh0dHBzOi8vZ28uYXhjZWxlYWQuY29tL2wvOTk2MjYxLzIwMjItMTAtMDgvMndrZyIgd2lkdGg9IjEwMCUiIGhlaWdodD0iMTU1MCIgdHlwZT0idGV4dC9odG1sIiBmcmFtZWJvcmRlcj0iMCIgYWxsb3dUcmFuc3BhcmVuY3k9InRydWUiIHN0eWxlPSJib3JkZXI6IDAiPjwvaWZyYW1lPg== Contact Us Please feel free to contact us. Please send your inquiry to intl_contact@axcelead. com if the contact form fails. Our e-mail replies are addressed to you personally. Please refrain from reprinting or secondary use of any part or all of the contents. https://axcelead. wpenginepowered. com/wp-content/uploads/2023/12/contactus-image. jpg --- ### Resources - Published: 2023-12-01 - Modified: 2023-12-01 - URL: https://axcelead-us.com/resources/ --- ### Brochures - Published: 2023-11-30 - Modified: 2024-06-07 - URL: https://axcelead-us.com/resources/brochures/ Company Introduction 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 Integrated Drug Discovery PHNjcmlwdD4Kc2V0SW50ZXJ2YWwoZnVuY3Rpb24oKSB7CiAgalF1ZXJ5KGRvY3VtZW50KS5yZWFkeShmdW5jdGlvbigkKSB7IAoJJCgnLm1ldGEtdGFncycpLmNvbnRlbnRzKCkuZmlsdGVyKGZ1bmN0aW9uKCkgewogICAgICAgIHJldHVybiB0aGlzLm5vZGVUeXBlID09PSAzOyAvLyBGaWx0ZXIgb3V0IHRleHQgbm9kZXMKICAgIH0pLnJlbW92ZSgpOwoKCSQoIi5wb3N0ZXJzLWJsb2cgYXJ0aWNsZSIpLmVhY2goZnVuY3Rpb24oKXsKCQltZXRhVGFnID0gJCgiLmZ1c2lvbi1zaW5nbGUtbGluZS1tZXRhIiwgJCh0aGlzKSk7CgkJcG9zdFRpdGxlID0gJCgiZGl2LmVudHJ5LXRpdGxlIiwgJCh0aGlzKSk7IAoKCQkkKG1ldGFUYWcpLmluc2VydEJlZm9yZSgkKHBvc3RUaXRsZSkpOwogICAgfSk7CiAgICAgCiAgfSk7Cn0sIDUwMCk7Cjwvc2NyaXB0Pgo8c3R5bGU+CmRpdi5lbnRyeS10aXRsZSBhIHsKICBjb2xvcjogIzAwMDsKfSAKZGl2LmVudHJ5LXRpdGxlIGE6aG92ZXIgewogIGNvbG9yOiB2YXIoLS1tYWlucmVkKSFpbXBvcnRhbnQ7Cn0gCi5mdXNpb24tc2luZ2xlLWxpbmUtbWV0YSB7CiAgICBtYXJnaW4tdG9wOiAwcHg7CiAgICBmb250LXNpemU6IDE2cHg7CiAgICBib3JkZXI6IG5vbmU7CiAgICB0ZXh0LXRyYW5zZm9ybTogdXBwZXJjYXNlOwogICAgbWFyZ2luLWJvdHRvbTogOHB4IWltcG9ydGFudDsKICAgIGZvbnQtd2VpZ2h0OiA1MDA7CiAgICBwb2ludGVyLWV2ZW50czogbm9uZTsKICAgY29sb3I6IHZhcigtLW1haW5ncmVlbik7Cn0KLmZ1c2lvbi1ibG9nLWxheW91dC1ncmlkIC5mdXNpb24tcG9zdC1jb250ZW50LWNvbnRhaW5lcnsKICAgIG1hcmdpbi10b3A6IDI1cHg7Cn0KLmZ1c2lvbi1ibG9nLWxheW91dC1ncmlkLmZ1c2lvbi1ibG9nLWVxdWFsLWhlaWdodHMgLmZ1c2lvbi1wb3N0LXdyYXBwZXIgewogICAgYm9yZGVyLWJvdHRvbTogMnB4IHNvbGlkIHZhcigtLW1haW5ncmF5KSFpbXBvcnRhbnQ7CiAgcGFkZGluZzogMzBweCAxMHB4IDAhaW1wb3J0YW50OwogIHBvc2l0aW9uOiByZWxhdGl2ZTsKfQoucG9zdGVycy1ibG9nIC5mdXNpb24tYmxvZy1sYXlvdXQtZ3JpZCAuZnVzaW9uLXBvc3QtZ3JpZCB7CiAgICBwYWRkaW5nOiAyMHB4OwogICAgbWluLWhlaWdodDogMjAwcHg7Cn0KYXJ0aWNsZSAuZG93bmxvYWQtcGRmLXdyYXAgewogICAgbWFyZ2luLXRvcDogMzBweDsKICBwb3NpdGlvbjogYWJzb2x1dGU7CiAgYm90dG9tOiAyMHB4Cn0KLmZ1c2lvbi1ib2R5IC5mdXNpb24tbG9hZC1tb3JlLWJ1dHRvbiB7CiAgICBmb250LXdlaWdodDogNjAwOwogICAgd2lkdGg6IGF1dG8haW1wb3J0YW50OwogICAgbWFyZ2luOiBhdXRvOwogICAgcGFkZGluZzogMHB4IDQwcHg7CiAgICBib3JkZXItcmFkaXVzOiA2cHg7CiAgICBiYWNrZ3JvdW5kOiAjNGJiMjM0IWltcG9ydGFudDsKICBtYXJnaW4tdG9wOiA2MHB4Owp9Ci5mdXNpb24tYm9keSAuZnVzaW9uLWxvYWQtbW9yZS1idXR0b246aG92ZXIgewogICAgYmFja2dyb3VuZDogI2FmMDA0MCFpbXBvcnRhbnQ7Cn0KQG1lZGlhIG9ubHkgc2NyZWVuIGFuZCAobWF4LXdpZHRoOiA4MDBweCl7CiAgLmZ1c2lvbi1ibG9nLWxheW91dC1ncmlkIC5mdXNpb24tcG9zdC1ncmlkIHsKICAgIHBhZGRpbmc6IDIwcHggMCFpbXBvcnRhbnQ7CiAgfQogIC5mdXNpb24tYmxvZy1sYXlvdXQtZ3JpZC5mdXNpb24tYmxvZy1lcXVhbC1oZWlnaHRzIC5mdXNpb24tcG9zdC13cmFwcGVyIHsKICAgIHBhZGRpbmc6IDBweCAwcHggMCFpbXBvcnRhbnQ7CiAgfQogICN3cmFwcGVyICNtYWluIC5mdXNpb24tYmxvZy1zaG9ydGNvZGUgLmVudHJ5LXRpdGxlLCAKICAuZnVzaW9uLWJsb2ctc2hvcnRjb2RlIC5lbnRyeS10aXRsZSB7CiAgICBmb250LXNpemU6IDE3cHghaW1wb3J0YW50OwogIH0KICAucG9zdGVycy1ibG9nIC5mdXNpb24tYmxvZy1sYXlvdXQtZ3JpZCAuZnVzaW9uLXBvc3QtZ3JpZCB7CiAgICBtaW4taGVpZ2h0OiAxNjBweDsKfQp9Cjwvc3R5bGU+ Therapeutic Areas 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 Technology Platforms 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 Therapeutic Modalities 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 --- ### Publications - Published: 2023-11-30 - Modified: 2023-12-16 - URL: https://axcelead-us.com/resources/publications/ Publications 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 --- ### Presentations - Published: 2023-11-30 - Modified: 2024-06-05 - URL: https://axcelead-us.com/resources/presentations/ Presentations PHNjcmlwdD4Kc2V0VGltZW91dChmdW5jdGlvbigpIHsKICBqUXVlcnkoZG9jdW1lbnQpLnJlYWR5KGZ1bmN0aW9uKCQpIHsgCgkkKCIuZnVzaW9uLXZlcnRpY2FsLW1lbnUtd2lkZ2V0IHVsIGxpIikuZWFjaChmdW5jdGlvbigpewoJCWxpbmtBbm51YWwgPSAkKCJhIiwgJCh0aGlzKSk7IAogICAgICAgIG9yaWdpbmFsSHJlZiA9ICQobGlua0FubnVhbCkuYXR0cigiaHJlZiIpOwogICAgICAgICQobGlua0FubnVhbCkuYXR0cigiaHJlZiIsIG9yaWdpbmFsSHJlZiArICI/Y2F0PTE4Iik7IC8vIFByZXNlbnRhdGlvbiBjYXRlZ29yeQogICAgfSk7CiAgfSk7Cn0sIDgwMCk7Cjwvc2NyaXB0Pg== --- ### Videos - Published: 2023-11-30 - Modified: 2024-02-27 - URL: https://axcelead-us.com/resources/videos/ Targeted Protein Degradation 1 Minute Guide for HTS Platform Global Webinar Hot Topics Screening Capabilities 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 --- ### Posters - Published: 2023-11-30 - Modified: 2023-12-21 - URL: https://axcelead-us.com/resources/posters/ Posters PHNjcmlwdD4Kc2V0VGltZW91dChmdW5jdGlvbigpIHsKICBqUXVlcnkoZG9jdW1lbnQpLnJlYWR5KGZ1bmN0aW9uKCQpIHsgCgkkKCIuZnVzaW9uLXZlcnRpY2FsLW1lbnUtd2lkZ2V0IHVsIGxpIikuZWFjaChmdW5jdGlvbigpewoJCWxpbmtBbm51YWwgPSAkKCJhIiwgJCh0aGlzKSk7IAogICAgICAgIG9yaWdpbmFsSHJlZiA9ICQobGlua0FubnVhbCkuYXR0cigiaHJlZiIpOwogICAgICAgICQobGlua0FubnVhbCkuYXR0cigiaHJlZiIsIG9yaWdpbmFsSHJlZiArICI/Y2F0PTE5Iik7IC8vIFByZXNlbnRhdGlvbiBjYXRlZ29yeQogICAgfSk7CiAgfSk7Cn0sIDUwMCk7Cjwvc2NyaXB0Pg== --- ### News - Published: 2023-11-30 - Modified: 2024-01-04 - URL: https://axcelead-us.com/news/ News Latest News and Press Releases 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 --- ### Test Page with Mega Menu - Published: 2023-11-29 - Modified: 2023-11-29 - URL: https://axcelead-us.com/test-page-with-mega-menu/ The Future of Drug Discovery is Here. Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Who We Are Duis irure dolor reprehenderit in voluptate velit esse cillum Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Quis ipsum suspendisse ultrices gravida. Risus commodo viverra maecenas accumsan lacus vel facilisis. Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Quis ipsum suspendisse. What We Do Duis irure dolor reprehenderit in voluptate velit esse cillum https://axcelead. wpenginepowered. com/wp-content/uploads/2023/11/post-img1. jpg High-Throughput Screening Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Learn More › https://axcelead. wpenginepowered. com/wp-content/uploads/2023/11/post-img2. jpg High-Throughput Screening Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Learn More › https://axcelead. wpenginepowered. com/wp-content/uploads/2023/11/post-img3. jpg High-Throughput Screening Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Learn More › Learn More Client Outcomes Duis irure dolor reprehenderit in voluptate velit esse cillum Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Quis ipsum suspendisse ultrices gravida. Risus commodo viverra maecenas accumsan lacus vel facilisis. Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore... --- ### Cookie Policy - Published: 2023-11-29 - Modified: 2024-01-04 - URL: https://axcelead-us.com/cookie-policy/ Policies Cookie Policy2021/05/27 About Cookies Cookies are data stored directly on your computer. They are used to gather information such as browser type, service time, pages accessed, language settings, and other traffic data. The main objective of using cookies is to allow websites to read cookies stored on users’ computers so that they can provide better service to repeat users. For more information on cookies, visit: www. allaboutcookies. org Intended Use of Cookies This website uses cookies with the consent of users to provide them with better experiences. Use of Google Analytics This website uses Google Analytics to provide a better experience for users. Google Analytics uses cookies to gather and analyze information about service usage and to report activities and trends. For Google’s privacy policy, see: https://www. google. com/policies/privacy/ Disabling Cookies If you do not wish your information to be collected using cookies, you can reject sending and receiving cookies by changing the browser settings. For details on cookie settings, refer to the help menu of your browser. Please note that if you disable cookies, not all the features of this website may be available. Inquiries If you have any questions or comments about this Policy, please contact: ADDP_Compliance@axcelead. com. Cookie Policy Updates This Cookie Policy may be updated from time to time. The Last Update legend at the top indicates the date the Policy was last revised. The revised Policy will be effective upon its publication on this website. --- ### Privacy Policy: Personal Information Protection Policy - Published: 2023-11-29 - Modified: 2023-12-16 - URL: https://axcelead-us.com/privacy-policy-personal-information-protection-policy/ Policies Privacy Policy: Personal Information Protection Policy １． Policy Axcelead Drug Discovery Partners Inc. (the “Company”), in order to appropriately protect personal information in light of the importance of protecting personal information, complies with the Act on the Protection of Personal Information (Act No. 57 of 2003, the “Act”) and other laws and regulations, as well as the guidelines of the Personal Information Protection Commission and other guidelines. In addition, the Company complies with this Policy and handle personal information in an appropriate and safe manner. As for the handling of specified personal information, please see “Basic Policy regarding the Proper Handling of Individual Numbers and Specified Personal Information”. ２． Acquisition and Use of Personal Information ⑴　Acquisition of personal information The Company acquires personal information within the scope of business conducted by the Company, for clearly defined purposes of use and by appropriate means. When the Company directly acquires personal information stipulated in a contract or other written documents (including electromagnetic records) from each person, the purpose of use shall be clearly stated in advance, and the information shall be acquired by lawful and fair means. ⑵　Use of personal information The Company will use personal information to the extent necessary for the purpose of use. Personal information will not be used for any purposes other than the stated purpose of use, without the consent of the person in concern. ３．Purpose of Use of Personal Information The Company will use personal information for the purpose of use listed below. If personal... --- ### About Us - Published: 2023-11-16 - Modified: 2025-05-22 - URL: https://axcelead-us.com/about-us/ About Us We are pioneering the future of drug discovery. https://axcelead-us. com/wp-content/uploads/2023/12/whoweare-topimage2. jpg Who We Are Axcelead is your trusted drug discovery and development partner. We were formed in 2017 as a Takeda spin-out with a singular vision in mind – to support healthcare innovation as the world’s most trusted drug discovery solutions provider. We bring our vision to life by harnessing our expertise and proven track record of success in small molecule, cell therapy and immune-oncology drug discovery to our partners to advance and improve their drug pipelines. Mission & Vision Mission To be the most trusted companion to all who endeavor to bring highly innovative medicine to the world. Vision Become the most sought-after solution provider of drug discovery to all corporate, start-up, academia, and public institutions Become the hub for drug discovery ecosystem that bridges foundational sciences to clinical developments https://axcelead-us. com/wp-content/uploads/2023/12/mission-img2. 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 Corporate Officer of Drug Discovery Solutions Business, Axcelead, Inc. / CEO, Axcelead Drug Discovery Partners, Inc. and Axcelead Tokyo West Partners, Inc. Former COO of Axcelead DDP 20 years of experience in Drug Discovery >5 years of experience in national university in Japan as an assistant professor >30 publications Board Director, Co-CEO and CTO, Axcelead, Inc. / Board Chairperson, Axcelead Drug Discovery Partners, Inc. Former Head of Shonan research center, Takeda Pharmaceutical Company Former Chairman of Japan Pharmaceutical Manufacturers Association R&D committee Former Board member of Japan Bioindustry Association RSC, Med. Chem. Comm. editorial board >30 years of experience in Drug discovery（>5 INDs) >15... --- ### Home > Axcelead accelerates the discovery and development of high-value therapeutic candidates for the preclinical stage leading to human clinical trials. - Published: 2023-11-14 - Modified: 2024-01-09 - URL: https://axcelead-us.com/ The Future of Drug Discovery is Here. Axcelead accelerates the discovery and development of high-value therapeutic candidates for the preclinical stage leading to human clinical trials. We leverage our proprietary end-to-end platform to enable our biotechnology and pharmaceutical partners to deliver benefits to patients around the world. https://axcelead-us. com/wp-content/uploads/2023/12/whoweare-img2. jpg Who We Are Axcelead is your trusted drug discovery and development partner. We were formed in 2017 as a Takeda spin-out with a singular vision in mind - to support healthcare innovation as the world’s most trusted drug discovery solutions provider. We bring our vision to life by harnessing our expertise and proven track record of success in small molecule, cell therapy and immune-oncology drug discovery to our partners to advance and improve their drug pipelines. What We Do Oncology, immunology, neuroscience drug discovery and so much more. At Axcelead, we are focused on accelerating the discovery and development of high-value drug classes through our end-to-end platform, enabling our biotechnology and pharmaceutical partners to deliver benefit to patients around the world. Client Outcomes We are your trusted partner. At Axcelead, we have an aggressive mission to become the most trusted drug development solutions provider to leading biotechnology and pharmaceutical companies. Our wealth of expertise and knowledge stems from our robust client base, with over 100 facilities including pharmaceutical companies, venture companies and academia utilizing its services. Our current partners in the US consist of cutting-edge companies developing new and proven drug candidates and modalities for oncology, immunology and neuroscience indications.... --- ### Privacy Policy - Published: 2023-11-06 - Modified: 2024-01-04 - URL: https://axcelead-us.com/privacy-policy/ Policies Privacy Policy Axcelead Group has established a basic policy for the handling of personal information, and will comply with this policy accurately and sincerely, and will work to manage and protect all personal information, etc. , including customers’ personal information, in a safer and more appropriate manner. Privacy Policy Cookie Policy Axcelead Drug Discovery Partners, Inc. 26-1, Muraoka-Higashi 2-chome, Fujisawa, Kanagawa 251-0012, Japan e-mail: ADDP_Compliance@axcelead. com --- --- --- ## Posts ### LOTTE BIOLOGICS, Axcelead Drug Discovery Partners, Inc., and Kanaph Therapeutics Inc. Sign 3-Way MOU to Develop ADC Toolbox - Published: 2025-06-17 - Modified: 2025-06-16 - URL: https://axcelead-us.com/news/sign-3-way-mou-to-develop-adc-toolbox/ - Categories: News, News Releases - Exploring expansion of ADC services through synergy in ADC modality business via trilateral agreement - Aims to enhance ADC capabilities through collaborative innovation with specialized partner LOTTE BIOLOGICS (President James Park), Axcelead Drug Discovery Partners, Inc. ( Representative Director and CEO, Kengo Okada, PhD. ), and Kanaph Therapeutics Inc. (CEO, Byoung Chul Lee, PhD) announced that they have signed a tripartite Memorandum of Understanding (MOU) to build an ADC Toolbox for the development of antibody-drug conjugates (ADCs). Through this agreement, the three companies will collaborate on the joint research and development of linker and payload technologies, which are key components in the development of next-generation ADC cancer therapies. Axcelead Drug Discovery Partners, Inc. , a world-class drug discovery platform Contract Research Organization (CRO) by inheriting the drug discovery platform from Takeda Pharmaceutical Company in Japan, plans to leverage a compound library comprising more than 1. 2 million compounds and more than 1,000 legacy projects, to generate novel payload candidates not yet applied to ADCs. Kanaph Therapeutics Inc. will focus on developing an innovative platform that addresses the limitations of existing linker and payload technologies in ADC development. The linker and payload technologies developed through this collaboration will be transferred to LOTTE BIOLOGICS, which will utilize them to further enhance the competitiveness of its ADC platform, including SoluFlex Link. LOTTE BIOLOGICS plans to offer an ADC Toolbox service, enabling clients to select and apply a variety of technologies tailored to their needs. This service is expected to reinforce the company’s... --- ### Presentation on Prediction Model for Brain Concentration-Time Profiles of Compounds by Dr. Handa (Digital Unit) at the Structure-Activity Forum 2025 - Published: 2025-06-10 - Modified: 2025-06-12 - URL: https://axcelead-us.com/topics/the-structure-activity-forum-2025/ - Categories: Topics Dr. Handa from the Digital Unit will present a prediction model for brain concentration–time profiles of compounds at the Structure–Activity Forum 2025, organized by the Structure–Activity Relationship Division, The Pharmaceutical Society of Japan, to be held online on June 20, 2025. If you are planning to attend the forum, we encourage you to join the presentation. Conference Name: Structure–Activity Forum 2025 Organized by: The Division of Structure–Activity Studies , The Pharmaceutical Society Japan Co-sponsored by: Chem-Bio Informatics Society (CBI Society), Japan Date & Time: Friday, June 20th, 10:40 - 11:20 am (JST) Location: Online Title: Advancing Practical Machine Learning Models in Drug Discovery Presenter: Koichi Handa Presentation Summary With recent advances in AI technology, the importance of predictive models that leverage large-scale, high-quality data has grown significantly in the field of drug discovery. Our company has developed predictive models capable of accurately estimating 23 pharmacokinetic and toxicity-related endpoints—such as solubility, membrane permeability, and toxicity—based on in vitro and in vivo data collected under standardized conditions. In particular, predicting brain penetration is critical for central nervous system (CNS) disorders, but conventional methods have limitations. To address this, we have developed a Deep two-compartment model that predicts brain concentration-time profiles. This model optimizes compartment parameters using actual measurement data, enabling more practical and reliable predictions. Through the continuous development and application of our AI platform, we aim to address these challenges. In this presentation, we will share insights gained from this ongoing work. Axcelead DDP's Soulution At Axcelead DDP, we are advancing... --- ### BIO International Convention 2025 - Published: 2025-05-21 - Modified: 2025-05-22 - URL: https://axcelead-us.com/future-conferences/bio-international-convention-2025/ - Categories: Future Conferences Boston, MA Conference Name: BIO International Convention 2025 Time: June 16-19, 2025 Location: Boston Convention & Exhibition Center Axcelead Drug Discovery Partner, Inc. and ARCALIS, Inc. , group companies of Axcelead, Inc. , will be attending BIO International Convention 2025 in Boston, MA, USA. Visit us at Booth #3278 to learn how we can empower your drug discovery. Let’s connect in the partneringOne system to discuss more details. Our team looks forward to meeting you there! https://axcelead-us. com/wp-content/uploads/2024/01/bio-yoshinori-3-297x300. jpg Yoshinori Ikeura, PhD Board Director, Co-CEO and CTO, Axcelead, Inc. / Board Chairperson, Axcelead Drug Discovery Partners, Inc. Former Head of Shonan research center, Takeda Pharmaceutical Company Former Chairman of Japan Pharmaceutical Manufacturers Association R&D committee Former Board member of Japan Bioindustry Association RSC, Med. Chem. Comm. editorial board >30 years of experience in Drug discovery（>5 IND) >15 publication, >15 patent https://axcelead-us. com/wp-content/uploads/2024/02/ii-san-1-297x300. png Masayuki Ii, PhD CSO, Axcelead Drug Discovery Partners, Inc. Former Head of inflammation DDU, Takeda Pharmaceutical Company >25 years of experience in drug discovery and development, lead of research in global development programs >20 publicastions, >40 patents https://axcelead-us. com/wp-content/uploads/2024/01/bio-aso-2-1-297x300. jpg Kazuyoshi Aso, PhD Head, Global Business Development, Axcelead Drug Discovery Partners, Inc. Former VP, Head of Chemistry, Axcelead DDP Former VP, Head of Medicinal Chemistry, Tri-I TDI >5 years of experience in global business development >30 years of experience in drug discovery research >30 publications, >20 patents https://axcelead-us. com/wp-content/uploads/2025/05/belinda-297x300. jpg Belinda Deng Global Business Development, Axcelead Drug Discovery Partners, Inc. >10 years of experience in B2B marketing at global... --- ### Results of joint research with Luxna Biotec, Inc published in "Nucleic Acid Therapeutics" - Published: 2025-04-25 - Modified: 2025-04-25 - URL: https://www.liebertpub.com/doi/10.1089/nat.2024.0047#new_tab - Categories: Publications Nucleic Acid Therapeutics --- ### The results of joint research with Luxna Biotec, Inc published in "Nucleic Acid Therapeutics" - Published: 2025-04-25 - Modified: 2025-05-21 - URL: https://axcelead-us.com/news/the-results-of-joint-research-with-luxna-biotec-inc-published-in-nucleic-acid-therapeutics/ - Categories: News, Topics Hepatotoxicity Reduction Profiles of Antisense Oligonucleotides Containing Amido-Bridged Nucleic Acid and 2′-O,4′-C-Spirocyclopropylene Bridged Nucleic Acid Publication Amide-bridged nucleic acid (AmNA) and 2′-O,4′-C-spirocyclopropylene-bridged nucleic acid (scpBNA) are bridged nucleic acid analogs with high complementary binding affinity and nuclease resistance. AmNA and scpBNA overcome the hepatotoxicity caused by phosphorothioate-modified gapmers, but the mechanism remains unclear. In this study, we found that antisense oligonucleotides (ASOs) combining AmNA, scpBNA, and phosphodiester (PO) linkages significantly reduced mouse hepatotoxicity. Histopathological findings of the liver observed in the LNA and AmNA-scpBNA groups were attenuated in the AmNA-scpBNA-PO group. Bioinformatics analysis suggested that the reduction in hepatotoxicity may involve the expression changes of mitochondrial-related genes, Atp5o and Sdhb. This study demonstrated that AmNA, scpBNA, and PO modifications could reduce hepatotoxicity and improve the potential of ASOs. This study is joint research with Luxna Biotech Co. , Ltd, and Axcelead DDP performed the pathological analysis and transcriptome analysis. We conducted immunohistochemical analysis using our proprietary anti-PS-ASO antibodies to evaluate the distribution of administered ASOs in liver tissue. In addition, transcriptomic analysis was performed to identify gene expression changes and investigate their potential association with ASO-induced hepatotoxicity. Furthermore, electron microscopy enabled the detection of ultrastructural alterations in tissues and cells triggered by ASO administration. Axcelead DDP Solution At Axcelead DDP, we accelerate nucleic acid drug discovery by providing solutions for the visualization and safety evaluation of nucleic acid therapeutics. We offer comprehensive support across all stages of nucleic acid drug discovery—from sequence design and delivery technologies to ADME, efficacy, and... --- ### EASL Congress 2025 - Published: 2025-04-24 - Modified: 2025-05-16 - URL: https://axcelead-us.com/previous-conferences/easl-congress-2025/ - Categories: Previous Conferences Amsterdam, the Netherlands Conference Name: EASL Congress 2025 Time: May 7-10, 2025 Location: Amsterdam, the Netherlands Axcelead will be attending EASL Congress 2025 in Amsterdam, the Netherlands. Visit us at Booth #BS22 to learn how we can empower you at each stage of liver disease drug discovery. Our scientist, Takumi Sugawara, will also be presenting a poster at the conference. We look forward to meeting you there! https://axcelead-us. com/wp-content/uploads/2025/04/EASL2025_HP掲載用. png Click here for our liver disease drug discovery services. Click here for our pharmacology capabiliteis. Poster Presentation Title: Identification of differences in therapeutic mechanisms between Resmetirom and Semaglutide on metabolic dysfunction-associated steatohepatitis treatment in western diet-fed melanocortin 4 receptor knockout mice Presenter: Takumi Sugawara Date&Time: Friday,May 9th. The presenter will be available during the morning and afternoon coffee breaks throughout the day. Poster Number: FRI-438 Abstract: The first MASH therapeutic drug, resmetirom, a THR-β agonist, was approved by the FDA, and semaglutide, a GLP-1 analog, also showed positive effects on MASH patients in a phase III clinical trial. This study simultaneously evaluated these drugs in western diet-fed MC4R-KO mice, which show substantial obesity and insulin resistance similar to that of a patient with MASH. Although both resmetirom and semaglutide improved liver injury and steatosis, there are differences on body composition change and energy expenditure based on their mechanisms. In addition to resmetirom, semaglutide might also be available on the market. As these drugs have different mechanisms of action, combination therapy with them may provide a more effective treatment for MASH. Axcelead DDP’s Solutions:... --- ### ECO2025 (32nd European Congress on Obesity) - Published: 2025-04-23 - Modified: 2025-05-16 - URL: https://axcelead-us.com/previous-conferences/eco2025/ - Categories: Previous Conferences Malaga, Spain Conference Name: ECO 2025 (32nd European Congress on Obesity) Time: May 11-14, 2025 Location: Malaga, Spain Axcelead will be attending ECO 2025 in Malaga, Spain. Our scientist, Kosuke Hitaka, will be presenting a poster at the conference. We look forward to meeting you there! Poster Presentation Title:Comparison of anti-obese effects on GLP-1 analogue peptides, Semaglutide, Tirzepatide and Retatrutide using MC4R deficient obesity model mice Presenter: Kosuke Hitaka Date&Time: May 13th, Tuesday, 18:00-18:45 Poster Number:PO4. 142 Abstract: In 2024, semaglutide, a GLP-1 agonist, was launched as a treatment for obesity, making headlines. In recent years, clinical trial results of Tirzepatide and Retatrutide have been reported, and their high anti-obesity effects are expected to improve the quality of life of patients with obesity. On the other hand, there are no reports of non-clinical studies evaluating the effects of these GLP-1 agonists simultaneously. Therefore, in this study, we simultaneously tested semaglutide, tirzepatide, and retatrutide in MC4R KO mice and compared their effects. As a result, it was confirmed that Tirzepatide showed a higher weight loss effect than Semaglutide. The results also suggest that while both GLP-1 agonists have a high anti-obesity effect, they also decrease muscle mass. This result may suggest that the muscle loss effect is a common effect of GLP-1 agonists. We hope that the results of this study will contribute to the development of drug discovery research in the anti-obesity field. Axcelead DDP’s Solutions: Well-known obesity models, such as Diet Induced Obesity (DIO) mice, db/db mice, and ob/ob mice, are... --- ### BIO KOREA 2025 - Published: 2025-04-21 - Modified: 2025-05-16 - URL: https://axcelead-us.com/previous-conferences/bio-korea-2025/ - Categories: Previous Conferences COEX, Seoul, Korea Conference Name: BIO KOREA 2025 Time: May 7-9, 2025 Location: COEX, SEOUL Axcelead is coming to BIO KOREA 2025! Join us at Booth #A22 at COEX, Seoul, to discover how Axcelead can accelerate and support your drug discovery journey—from hit finding to IND enabling. Our team, Yoshinori Ikeura and Takeshi Yamasaki, will be at the booth and participating in partnering meetings throughout the event. Whether you’re exploring new partnerships or looking for expert insights, we look forward to connecting with you in Seoul! https://axcelead-us. com/wp-content/uploads/2024/01/bio-yoshinori-3-297x300. jpg Yoshinori Ikeura, PhD Board Director, Co-CEO and CTO, Axcelead, Inc. /Board Chairperson, Axcelead Drug Discovery Partners, Inc. Former Head of Shonan research center, Takeda Pharmaceutical Company Former Chairman of Japan Pharmaceutical Manufacturers Association R&D committee Former Board member of Japan Bio industry Association RSC, Med. Chem. Comm. editorial board >30 years of experience in Drug discovery（>5 INDs) >15 publications, >15 patents https://axcelead-us. com/wp-content/uploads/2025/04/yamasaki-1-300x297. jpg Takeshi Yamasaki Global Business Development, Axcelead Drug Discovery Partners, Inc. Former Principal Scientist, Takeda Pharmacetical Company Principal Scientist, Tri-I TDI in NY (2014-2015) Former Medicinal Chemistry lead at Reborna biosciences Former Process Chemistry lead at EA pharma >20 years’ experience in Drug discovery, >5 patents --- ### Skeletal muscle and cardiac function in B10-mdx mice​ - Published: 2025-04-15 - Modified: 2025-04-16 - URL: https://axcelead-us.com/posters/skeletal-muscle-and-cardiac-function-in-b10-mdx-mice/ - Categories: Posters - Tags: Pathology APPW 2025 in Japan Download --- ### Drug Discovery Services for Liver Desease - Published: 2025-04-14 - Modified: 2025-04-14 - URL: https://axcelead-us.com/brochures/drug-discovery-service-for-liver-desease/ - Categories: Brochures - Tags: Therapeutic Areas Download --- ### Research Article Co-Authored on Ferroptosis MoA Analysis Published in Communications Biology - Published: 2025-04-08 - Modified: 2025-05-21 - URL: https://axcelead-us.com/news/research-article-co-authored-on-ferroptosis-moa-analysis-published-in-communications-biology/ - Categories: News, Topics Protein covariation networks for elucidating ferroptosis inducer mechanisms and potential synergistic drug targets Publication Mechanism of action (MoA) analysis of hit compounds identified through phenotypic screening is a crucial step in drug discovery and the elucidation of novel biological mechanisms. While various MoA analysis techniques have been developed, none can guarantee absolute success, highlighting the need for new approaches. In this study, we successfully elucidated the MoA of ferroptosis-inducing compounds, a form of regulated cell death, using the PLOM-CON analysis method (Protein Localization and Modification-based Covariation Network analysis method). This method captures changes in the "quantity, quality, and localization" of proteins induced by drug treatment via fluorescent antibody staining. These changes are then visualized as covariation networks based on their temporal coordination. Furthermore, the covariation network data obtained through this approach suggested novel combination therapy strategies. This study demonstrates that PLOM-CON analysis is a powerful tool for compound MoA analysis and has the potential to expand research in combination drug therapy. Axcelead DDP Solution In addition to our phenotypic screening services, Axcelead DDP offers mechanism of action (MoA) analysis services using fingerprinting and chemical proteomics. If you are considering a new phenotypic screening approach or facing challenges in identifying the MoA of your compounds, please feel free to contact us. We are here to support your drug discovery research. https://axcelead-us. com/wp-content/uploads/2025/04/ono_400_250. png Akito Ono Screening Business Unit After graduating from the Graduate School of Engineering at Osaka University, he joined Takeda Pharmaceutical Company Limited. In 2017, he joined Axcelead Drug... --- ### Protein covariation networks for elucidating ferroptosis inducer mechanisms and potential synergistic drug targets - Published: 2025-03-31 - Modified: 2025-04-01 - URL: https://www.nature.com/articles/s42003-025-07886-3#new_tab - Categories: Publications Communications Biology --- ### Drug Discovery Chemistry 2025 - Published: 2025-03-25 - Modified: 2025-05-16 - URL: https://axcelead-us.com/previous-conferences/drug-discovery-chemistry-2025/ - Categories: Previous Conferences San Diego, CA Conference Name: Drug Discovery Chemistry 2025 Time: April 14-17, 2025 Location: Hilton Bayfront, San Diego, California Axcelead will be attending Drug Discovery Chemistry 2025 at the Hilton Bayfront in San Diego, California. Visit us at Booth #316 to learn how we can empower you at every stage of your chemistry-driven drug discovery. Our scientist, Jun Chiba, will also be presenting a poster at the conference. We look forward to meeting you there! https://axcelead-us. com/wp-content/uploads/2025/03/DDC2025_Seamless-Hardwall2. jpg Our Full Capabilities in Chemistry Click here for our chemistry service. Click here for our covalent drug discovery integrated solutions. https://axcelead-us. com/wp-content/uploads/2025/03/Chiba-300x169. jpg Poster Presentation Title: Identification of covalent JNK inhibitor Presenter: Jun Chiba Date&Time: April 15, Tuesday: 10:00am - 2:00pm, 3:35 - 4:35pm April 16, Wednesday: 9:35 - 10:30am Poster Number: A02 Abstract: Covalent drugs like EGFR and BTK inhibitors have gained attention. We focused on c-Jun N-terminal kinase (JNK) and modified our reported JNK inhibitor. The compounds showed time-dependent JNK3 inhibition in presence of dithiothreitol, suggesting covalent binding. We evaluated this through Protein-MS, digested peptide analysis, and X-ray crystallography. This presentation will highlight our capabilities in covalent drug discovery. Axcelead DDP’s Solutions: Axcelead provides technologies at every stage of covalent drug discovery, including ligand design, screening, mechanistic understanding, and target protein identification. Axcelead's Covalent Drug Discovery Platform integrates specialized capabilities: Screening – Enzyme and cell-based assays, compound reactivity and time-dependency analysis, crystal structure analysis, and whole protein MS assays. Compound Library – A cysteine-focused covalent library (2,000 compounds), and an HTS library with... --- ### Covalent Drug Discovery - Published: 2025-03-11 - Modified: 2025-03-11 - URL: https://axcelead-us.com/brochures/covalent-drug-discovery/ - Categories: Brochures - Tags: Integrated Drug Discovery Download --- ### Chemistry Capabilities - Published: 2025-03-11 - Modified: 2025-03-11 - URL: https://axcelead-us.com/brochures/chemistry-capabilities/ - Categories: Brochures - Tags: Technology Platforms Download --- ### BIO-Europe Spring 2025 - Published: 2025-02-20 - Modified: 2025-05-16 - URL: https://axcelead-us.com/previous-conferences/bio-europe-spring-2025/ - Categories: Previous Conferences Milan, Italy Conference Name: BIO-Europe Spring 2025 Time: March 17-19, 2025 Location:Milan, Italy Axcelead will be attending BIO-Europe Spring 2025 in Milan, Italy. Visit us at Booth #19 to learn how we can empower your drug discovery. Let’s connect in the partneringOne system to discuss more details. Our team looks forward to meeting you there! https://axcelead-us. com/wp-content/uploads/2024/01/bio-yoshinori-3-297x300. jpg Yoshinori Ikeura, PhD Board Director, Co-CEO and CTO, Axcelead, Inc. /Board Chairperson, Axcelead Drug Discovery Partners, Inc. Former Head of Shonan research center, Takeda Pharmaceutical Company Former Chairman of Japan Pharmaceutical Manufacturers Association R&D committee Former Board member of Japan Bio industry Association RSC, Med. Chem. Comm. editorial board >30 years of experience in Drug discovery（>5 INDs) 16 publications, 17 patents https://axcelead-us. com/wp-content/uploads/2024/02/ii-san-1-297x300. png Masayuki Ii, PhD CSO, Axcelead Drug Discovery Partners, Inc. Former Head of inflammation DDU, Takeda Pharmaceutical Company 29 years of experience in Drug discovery, lead of reserach in global development program >20 publications, >40 patents https://axcelead-us. com/wp-content/uploads/2025/02/Murai-297x300. jpg Saomi Murai, PhD Director, Global Business Development, Axcelead Drug Discovery Partners, Inc Former Global Project lead of Oncology, Takeda Pharmaceutical Company 18 years of experience in Drug discovery 10 publications --- ### Global Life Science Partnering ＆Investor Conference 2025 - Published: 2025-02-12 - Modified: 2025-05-16 - URL: https://axcelead-us.com/previous-conferences/global-life-science-partnering-%ef%bc%86investor-conference-2025/ - Categories: Previous Conferences San Diego, CA Conference Name: Global Life Science Partnering & Investor Conference Time: February 25 - 27, 2025 Location: THE LODGE AT TORREY PINES | LA JOLLA, CALIFORNIA Axcelead will be attending Global Life Science Partnering & Investor Conference presented by Biocom California. Our team will be available onsite to discuss how we can improve your drug discovery. We look forward to meeting you there! https://axcelead-us. com/wp-content/uploads/2024/01/bio-yoshinori-3-297x300. jpg Yoshinori Ikeura, PhD Board Director, Co-CEO and CTO, Axcelead, Inc. /Board Chairperson, Axcelead Drug Discovery Partners, Inc. Former Head of Shonan research center, Takeda Pharmaceutical Company Former Chairman of Japan Pharmaceutical Manufacturers Association R&D committee Former Board member of Japan Bio industry Association RSC, Med. Chem. Comm. editorial board >30 years of experience in Drug discovery（>5 INDs) 16 publications, 17 patents https://axcelead-us. com/wp-content/uploads/2024/01/bio-aso-2-1-297x300. jpg Kazuyoshi Aso, PhD Head, Global Business Development, Axcelead Drug Discovery Partners, Inc. Former VP, Head of Chemistry, Axcelead DDP Former VP, Head of Medicinal Chemistry, Tri-I TDI >5 years of Business Development experience >30 years of drug discovery research experience 33 publications, 24 patents https://axcelead-us. com/wp-content/uploads/2025/02/Fujitani-1-297x300. png Yasushi Fujitani, PhD Senior Director, Science Strategy and Planning, Axcelead Drug Discovery Partners, Inc. >25 years of experience of Drug Discovery Research in Novartis and Takeda 5 years of experience in Medical Affairs in Takeda and Gilead >30 publications and 3 patents --- ### Discovery of mRNA G-quadruplex binders through high-throughtput Affinity Selection Mass Spectrometry screening and comprehensive hit profiling - Published: 2025-02-05 - Modified: 2025-02-05 - URL: https://axcelead-us.com/posters/discovery-of-mrna-g-quadruplex-binders-through-high-throughtput-affinity-selection-mass-spectrometry-screening-and-comprehensive-hit-profiling/ - Categories: Posters - Tags: Screening SLAS 2025 in San Diego Download --- ### Accelerate Targeted Protein Degradation Drug Discovery with Axcelead's Integrated Platform, DegLead > Join Axcelead webinar to learn more about the latest technologies and insights in drug discovery and development! - Published: 2025-01-15 - Modified: 2025-03-11 - URL: https://axcelead-us.com/previous-seminars/accelerate-targeted-protein-degradation-drug-discovery-with-axceleads-integrated-platform-deglead/ - Categories: Previous Seminars Join this webinar to find out how we can help accelerate your Targeted Protein Degradation Drug Discovery! In this webinar, we will introduce our "DegLead Platform™," an integrated TPD platform, and showcase how our strengths—including specialized chemistry, a comprehensive compound library, diverse assay systems, and advanced ADME solutions—can drive success in your TPD projects. Additionally, we will share application case studies and valuable insights. Webinar Overview : Targeted Protein Degradation (TPD), including bifunctional degraders and molecular glue degraders, represents a paradigm shift in small molecule drug discovery. However, challenges remain in successfully discovering new TPD drugs. For example, bifunctional degraders face issues such as unfavorable ADME and physicochemical properties due to their molecular complexity. Regarding molecular glue degraders, the discovery of promising compounds often relies heavily on serendipity. Axcelead, a pharma-originated integrated drug discovery solutions provider, established in 2017 as a spin-out from Takeda Pharmaceutical Company, has inherited drug discovery platforms from Takeda and Teijin Pharma. We have identified TPD as a key focus area and have developed proprietary integrated TPD solutions to address these challenges. In this webinar, we will introduce our "DegLead Platform™," an integrated TPD platform, and showcase how our strengths—including specialized chemistry, a comprehensive compound library, diverse assay systems, and advanced ADME solutions—can drive success in your TPD projects. Additionally, we will share application case studies and valuable insights. Speaker https://axcelead-us. com/wp-content/uploads/2025/01/Kamitani_san-2. jpg Hirotaka Kamitani Director, Science Strategy & Planning Joined Axcelead Drug Discovery Partners, Inc. in 2018 A scientist specializing in small molecule drug discovery with expertise in medicinal chemistry and next-generation small molecule modalities Well-versed in TPD and RNA-targeting small molecule drug discovery and leading development of the proprietary platforms A project leader for integrated drug discovery projects, experienced in a wide range of disease areas and target classes Host https://axcelead-us. com/wp-content/uploads/2025/01/Aso-san. jpg Kazuyoshi Aso, PhD Head of Global Business Development Former VP, Head of Chemistry, Axcelead DDP... --- ### Axcelead DDP Enters into Drug Discovery Service Agreement with Astellas for Targeted Protein Degraders - Published: 2024-12-26 - Modified: 2025-05-21 - URL: https://axcelead-us.com/news/20241226-e-newsrelease/ - Categories: News, News Releases December 26, 2024 - Axcelead Drug Discovery Partners, Inc. (HQ: Fujisawa, Kanagawa, Japan; “Axcelead DDP”) announced today that it has entered into a drug discovery service agreement with Astellas Pharma, Inc. (HQ: Chuo-Ku, Tokyo, Japan; “Astellas”) to explore new candidate compounds for targeted protein degraders. Axcelead DDP focuses on targeted protein degradation as the next generation of small-molecule drug discovery and provides an integrated service solution called DegLeadTM Platform to solve various challenges in targeted protein degrader discovery, including synthetic technologies for rapid generation of targeted protein degraders, compound libraries, diverse high-throughput screening systems and profiling assay systems. Under the agreement, Axcelead DDP will support Astellas’ targeted protein degrader discovery utilizing DegLeadTM Platform and contribute to the generation of breakthrough new drug candidate compounds. “We are pleased to conclude this agreement with Astellas based on their positive evaluation of our core technology – the integrated DegLeadTM Platform solution,” said Kengo Okada, PhD. , Representative Director and CEO of Axcelead DDP. “This agreement is evidence that our drug discovery solution for targeted protein degrader is a promising service that provides proprietary value to our clients. We continue to support our clients' drug discovery by continuously evolving our pharmaceutical company-derived drug discovery platform by incorporating cutting-edge technologies. ” About Axcelead DDP Axcelead DDP is Japan’s first drug discovery solution provider established in July 2017 by inheriting the drug discovery platform from Takeda Pharmaceutical. Screening, medicinal chemistry, pharmacology/biology, DMPK, and safety research functions are integrated into one center with a state-of-the-art research base... --- ### SLAS2025 International Conference & Exhibition - Published: 2024-12-13 - Modified: 2025-05-16 - URL: https://axcelead-us.com/previous-conferences/slas2025-international-conference-exhibition/ - Categories: Previous Conferences San Diego, CA Conference Name: SLAS2025 International Conference & Exhibition Time: January 25-29, 2025 Location: San Diego Convention Center, San Diego, California Axcelead will be attending SLAS2025 International Conference & Exhibition at San Diego Convention Center in San Diego, California. Visit us at Booth #3343 to learn how we can empower you to rapidly identify your hit compounds. Our scientist, Mitsuru Hirano, will also be presenting during the conference. Our team looks forward to meeting you there! Axcelead offers an integrated HTS platform that combines computational chemistry with AI/ML to maximize the efficiency and quality of hit identification. https://axcelead-us. com/wp-content/uploads/2024/12/SLAS2025_banner-for-web. pngOur Full Capabilities in HTS -Track Record and Experimental Data -Assay Development -Compound Libraries -Hit Expansion and Hit-to-lead Click here for service details. Click here for Axcelead HTS webinar video. https://axcelead-us. com/wp-content/uploads/2024/12/hirano. png Poster Presentation Title: Discovery of mRNA G-quadruplex binders through high-throughput Affinity Selection Mass Spectrometry screening and comprehensive hit profiling Presenter: Mitsuru Hirano Date & Time: 2:00 PM - 3:00 PM, Monday January 27, 2025 Poster Number: 1353-B --- ### Phosphorylation Dynamics and Kinase Interaction in mRNA Transcription-Associated Kinases: Autophosphorylation of CDK12 and its Modulation by CDK7 and CDK9 - Published: 2024-11-06 - Modified: 2024-11-10 - URL: https://www.jstage.jst.go.jp/article/bpbreports/7/5/7_170/_article#new_tab - Categories: Publications BPB Reports --- ### AASLD The Liver Meeting 2024 - Published: 2024-11-05 - Modified: 2025-05-16 - URL: https://axcelead-us.com/previous-conferences/the-liver-meeting-tlm-2024/ - Categories: Previous Conferences San Diego, CA Conference Name: AASLD The Liver Meeting 2024 Time: Friday, November 15, 7:00 am - Tuesday, November 19, 5:00 pm (EST) Location: San Diego, California Axcelead will be attending AASLD The Liver Meeting 2024 in San Diego, California. Our scientist will be onsite to give a poster presentation at Poster Assignment Number 2259. Poster Presentation: Poster Title: Comprehensive profiles of the microbiome and metabolome within the gut-liver axis in Western diet-fed MC4R knockout mice. (Abstract Poster) Presenter: Mitsuharu Matsumoto Date & Time: 11/16/2024, 8:00 am - 5:00 pm Poster Assignment Number: 2259 Session: Gut Liver Axis and Microbiome Axcelead DDP's Soulution We can provide MASH model mice by feeding MC4R KO mice with a high-fat diet, which mimic human MASH pathology with obesity and insulin resistance. Using these models and our metabolomics platform, we can measure and interpret a wide range of metabolites, including hydrophilic and lipid metabolites. Additionally, we offer specialized evaluation systems for specific molecules, such as persulfides, and microbiome analysis to support this research. Through these approaches, we support your research in identifying PD markers for MASH and obesity, and we offer unique and optimal solutions. Please feel free to contact us for research on MASH or other diseases. https://axcelead-us. com/wp-content/uploads/2024/11/mathumoto. jpg Mitsuharu Matsumoto Pharmacology Business Unit Contact Us --- ### Identify Promising Novel Leads: Axcelead's integrated HTS platform powered by computational chemistry and AI/ML > Join Axcelead webinar to learn more about the latest technologies and insights in drug discovery and development! - Published: 2024-10-31 - Modified: 2025-03-11 - URL: https://axcelead-us.com/previous-seminars/axceleads-integrated-hts-platform-powered-by-computational-chemistry-and-ai-ml/ - Categories: Previous Seminars Join this webinar to find out how we can help you identify promising novel leads! In this webinar, we will showcase our integrated HTS platform and share our successful track record. We will also highlight the latest advances powered by computational chemistry and AI/ML technologies. Webinar Overview : High Throughput Screening (HTS) is one of the most powerful tools in small molecule drug discovery for identifying promising novel leads. The success of HTS depends on the design of an appropriate screening flow, the development of robust assay systems, and the availability of a high-quality compound library. Axcelead, a drug discovery solution provider, established in 2017 as a spin-off from Takeda Pharmaceutical Company, inherited Takeda’s preclinical research functions, including HTS. With a proprietary library of over 1. 2 million compounds, 60% of which are originally synthesized, Axcelead excels in identifying high-quality hits. In this webinar, we will showcase our integrated HTS platform and share our successful track record. We will also highlight the latest advances powered by computational chemistry and AI/ML technologies. Speaker https://axcelead-us. com/wp-content/uploads/2024/10/hata_san. jpg Akito Hata Screening Business Unit Head / Digital Unit Head, Axcelead Drug Discovery Partners, Inc. A scientist in early stage drug discovery particularly in in vitro biology and high-throughput screening Joined Axcelead Drug Discovery Partners, Inc. in 2021 and contributed to the development of kinase inhibitor platform and targeted protein degradation platform Led Protein Science team since 2023 and took on responsibility of Screening Business Unit since January 2024 Previously worked as a research scientist at Takeda Pharmaceuticals, Inc. both in Japan and Boston, US. Experienced a wide variety of early stage small molecule drug discovery projects at Takeda Japan, and biologics projects for antibody and cell therapy at Takeda Boston Host https://axcelead-us. com/wp-content/uploads/2024/10/ii_san. jpg Masayuki Ii, PhD CSO, Axcelead... --- ### Research results of a mouse model of chronic kidney disease (AXCC mice) generated in Axcelead DDP has been published in the American Journal of Pathology as a co-authored article. - Published: 2024-10-31 - Modified: 2025-05-21 - URL: https://axcelead-us.com/news/research-results-of-a-mouse-model-of-chronic-kidney-disease-axcc-mice-generated-in-axcelead-ddp-has-been-published-in-the-american-journal-of-pathology-as-a-co-authored-article/ - Categories: News, Topics A novel deep learning approach for analyzing glomerular basement membrane lesions in a mouse model of X-linked Alport syndrome Publication The study shows that female AXCC mice carrying a nonsense mutation in the COL4A5 gene of human Alport syndrome that was generated in AxceleadDDP, exhibit a mosaic expression pattern of abnormal type IV collagen in the renal glomeruli, mimicking the pathology of female patients with Alport syndrome. The evaluations conducted at the University of Tsukuba, Showa University, and AxceleadDDP, respectively, demonstrated the usefulness of AI-based pathological image analysis techniques and valuable findings for prognostic prediction and early therapeutic intervention for Alport syndrome. Axcelead DDP Solution In this case, pathological image analysis using HALO (indica Labs) performed at AxceleadDDP deeply contributed to the research achievements as one of the key result. The value of the image analysis data is further enhanced by combining AI-based analysis tools with the knowledge and skills of pathology experts. The service could be used for evaluation of drug efficacy and toxicity, MOA analysis, and pharmacokinetic studies in various organs, tissues, and cells, and please contact us to discuss your solution. Related Resouces : University of Tsukuba Related Publication : AXCC mouse (Axcelead DDP-generated Col4a5 R471X-CKD model mouse) https://axcelead-us. com/wp-content/uploads/2024/10/kobayashi-300x169. jpg Ryosuke Kobayashi, DVM, PhD I possess expertise in areas including veterinary and toxicologic pathology, safety assessment, and spatial omics analysis. we have a proven track record of providing the solutions that drive drug discovery research of our customers. https://axcelead-us. com/wp-content/uploads/2024/10/hashikami_640_360-300x169. png Kentarou Hashikami, Master of Engineering... --- ### A novel deep learning approach for analyzing glomerular basement membrane lesions in a mouse model of X-linked Alport syndrome - Published: 2024-10-25 - Modified: 2024-11-10 - URL: https://ajp.amjpathol.org/article/S0002-9440(24)00368-7/fulltext#new_tab - Categories: Publications American Journal of Pathology --- ### Pharmacology Capabilities - Published: 2024-10-23 - Modified: 2025-06-16 - URL: https://axcelead-us.com/brochures/pharmacology-capabilities/ - Categories: Brochures - Tags: Technology Platforms Download --- ### Xenogenic Engraftment of Human-Induced Pluripotent Stem Cell–Derived Pancreatic Islet Cells in an Immunosuppressive Diabetic Göttingen Mini-Pig Model - Published: 2024-10-21 - Modified: 2024-10-24 - URL: https://journals.sagepub.com/doi/10.1177/09636897241288932#new_tab - Categories: Publications Cell Transplantation --- ### A Co-authored Paper regarding Immunocompromised type 1 Diabetic Mini-pigs was Published in the Cell Transplantation - Published: 2024-10-21 - Modified: 2025-05-21 - URL: https://axcelead-us.com/news/a-co-authored-paper-regarding-immunocompromised-type-1-diabetic-mini-pigs-was-published-in-the-cell-transplantation/ - Categories: News, Topics Xenogenic Engraftment of Human Induced Pluripotent Stem Cell–Derived Pancreatic Islet Cells in an Immunosuppressive Diabetic Göttingen Mini-pig Model Publication Transplantation of islet-like cells generated from human pluripotent stem cells such as ES cells and iPS cells is expected to be a promising treatment for type 1 diabetes mellitus. Human iPS cell-derived pancreatic islet cells (iPIC) were discovered in a joint research project (T-CiRA) between the Center for iPS Cell Research and Application (CiRA) of Kyoto University and Takeda Pharmaceutical Company Limited. In the development of cell therapy products, it is said to be desirable to evaluate their efficacy in large animals with closer in size to humans as a bridge to clinical trials. In this paper, we induced hyperglycemia by administering streptozotocin, a drug that destroys pancreatic beta cells, to mini-pigs that underwent thymectomy and splenectomy. Furthermore, by administering immunosuppressants, we generated immunocompromised type 1 diabetic mini pigs that can be transplanted with human cells. Five weeks after implantation, histological analysis of the implanted iPICs embedded in fibrin gel revealed numerous islet-like structures with insulin-positive cells. It was also found that human C-peptide, an index of insulin secretion, was secreted into the blood. These data support the observation that the iPICs engrafted well. Future evaluation of human cells in this immunocompromised pig model could accelerate and development of cell therapy products. In this study, Axcelead DDP was conducted the setting the target plasma levels of immunosuppressants from in vitro studies, the establishment of an immunocompromised diabetic pig model, and cell... --- ### BIO-Europe 2024 - Published: 2024-09-27 - Modified: 2025-05-16 - URL: https://axcelead-us.com/previous-conferences/bio-europe-2024/ - Categories: Previous Conferences Stockholm, Sweden Conference Name: BIO-Europe 2024 Time: November 4-6, 2024 Location:Stockholmsmässan, Stockholm, Sweden Axcelead Drug Discovery Partner, Inc. and ARCALIS, Inc. , group companies of Axcelead, Inc. , will be attending BIO-Europe 2024 in Stockholm, Sweden. Visit us at Booth #196 to learn how we can empower your drug discovery. Let’s connect in the partneringOne system to discuss more details. Our team looks forward to meeting you there! https://axcelead-us. com/wp-content/uploads/2024/01/bio-yoshinori-3-297x300. jpg Yoshinori Ikeura, PhD Board Director, Co-CEO and CTO, Axcelead, Inc. / Board Director, Chairperson, Axcelead Drug Discovery Partners, Inc. Former Head of Shonan research center, Takeda Pharmaceutical Company Former Chairman of Japan Pharmaceutical Manufacturers Association R&D committee Former Board member of Japan Bio industry Association RSC, Med. Chem. Comm. editorial board >30 years of experience in Drug discovery（>5 IND) >16 publication, >17 patent https://axcelead-us. com/wp-content/uploads/2024/02/ii-san-1-297x300. png Masayuki Ii, PhD CSO, Axcelead Drug Discovery Partners, Inc. Former Head of inflammation DDU, Takeda Pharmaceutical Company >29 years of experience in Drug discovery, lead of reserach in global development program >20 publications, >40 patents https://axcelead-us. com/wp-content/uploads/2024/01/bio-aso-2-1-297x300. jpg Kazuyoshi Aso, PhD Head, Global Business Development, Axcelead Drug Discovery Partners, Inc. Former VP, Head of Chemistry, Axcelead Drug Discovery Partners, Inc. Former VP, Head of Medicinal Chemistry, Tri-I TDI >4 years of experience in sales & marketing >30 years of experience in drug discovery research >33 publications, >24 patents https://axcelead-us. com/wp-content/uploads/2024/09/Takamatsu-297x300. png Satoshi Takamatsu, PhD Corporate Officer, CDMO Business Supervisor, Axcelead, Inc. / Representative Director, President and CEO, ARCALIS, Inc. >30 years of experience in life... --- ### Axcelead Drug Discovery Partners Enters into Master Service Agreement for Drug Discovery Projects with Acadia Pharmaceuticals - Published: 2024-09-10 - Modified: 2025-05-21 - URL: https://axcelead-us.com/news/axcelead-drug-discovery-partners-enters-into-master-service-agreement-for-drug-discovery-projects-with-acadia-pharmaceuticals/ - Categories: News, News Releases September 10, 2024 - Axcelead Drug Discovery Partners, Inc. (HQ: Fujisawa, Kanagawa, Japan; hereinafter referred to as “Axcelead DDP”) announces that it has entered into a Master Service Agreement with Acadia Pharmaceuticals Inc. (HQ: San Diego, CA, USA; hereinafter referred to as “Acadia”) to support their goal of discovering and developing innovative and novel medicines to help address unmet medical needs. Axcelead DDP has already been engaged in multiple drug discovery projects in the neuroscience area to identify candidate compounds since October 2022. Acadia and Axcelead DDP have entered into the Master Service Agreement so that Axcelead DDP can more efficiently and comprehensively support certain new drug discovery projects of Acadia. Axcelead DDP will provide drug discovery support to Acadia by leveraging its integrated drug discovery platform, deep knowledge and extensive experience in drug discovery research to potentially generate high-quality candidate compounds. A new drug discovery project under the executed MSA has been launched at the same time. Axcelead DDP will receive an upfront fee, research funding and milestone fees as in the previous projects. Details of the financial terms regarding the Master Service Agreement and the new project are not disclosed. “We are pleased to announce the start of the new drug discovery project and the signing of the Master Service Agreement to contribute to Acadia's drug discovery research efforts. Our strong progress to date has led to the execution of this Master Service Agreement,” said Kengo Okada, PhD. , Representative Director and CEO of Axcelead DDP. “We look... --- ### Axcelead DDP and Lilly Enter into A Research and Collaboration Agreement - Published: 2024-09-05 - Modified: 2025-05-21 - URL: https://axcelead-us.com/news/axcelead-ddp-and-lilly-enter-into-research-and-collaboration-agreement/ - Categories: News, News Releases September 5, 2024 – Axcelead Drug Discovery Partners, Inc. (HQ: Fujisawa, Kanagawa, Japan; “Axcelead DDP”) announced today that it has entered into a strategic research and collaboration agreement with Eli Lilly and Company (“Lilly”) for multiple drug discovery programs. Axcelead DDP generates drug candidates through its well-established drug discovery capabilities and innovative technologies, including AI. Leveraging its researchers' deep knowledge and extensive experience, Axcelead DDP is positioned to drive innovative advancements in drug discovery. “I am extraordinarily pleased to have entered into a strategic collaboration agreement with Lilly, a leading global pharmaceutical company. I firmly believe Lilly selected us as a drug discovery partner in recognition of our capabilities to generate new drug candidates and our wide-range novel drug discovery technologies,” said Kengo Okada, PhD. , Representative Director and CEO of Axcelead DDP. “We are dedicated to enhancing Lilly’s pipeline through our innovative drug discovery platform. Our goal is to deliver high-quality new drug candidates that have the potential to become the life-changing medicines of tomorrow, benefiting people worldwide. ” Under the terms of the agreement, Axcelead DDP will receive an upfront payment and is eligible to receive additional milestone payments based on the progress of each drug discovery program. About Axcelead DDP Axcelead DDP is Japan’s first drug discovery solution provider, established in July 2017 by inheriting the drug discovery platform from Takeda Pharmaceutical. Screening, medicinal chemistry, pharmacology/biology, DMPK, and safety research functions are integrated into one center with a state-of-the-art research base and original compound library. With the... --- ### Drug Discovery Services for Neuroscience - Published: 2024-08-23 - Modified: 2024-08-23 - URL: https://axcelead-us.com/brochures/drug-discovery-services-for-neuroscience/ - Categories: Brochures - Tags: Therapeutic Areas Download --- ### Neuroscience 2024 - Published: 2024-07-25 - Modified: 2025-05-16 - URL: https://axcelead-us.com/previous-conferences/neuroscience-2024/ - Categories: Previous Conferences Chicago, IL Conference Name: Neuroscience 2024 Time: October 5-9, 2024 Location: McCormick Place Convention Center in Chicago Axcelead will be attending Neuroscience 2024 in Chicago, Illinois. Visit us at Booth #138 to learn how we can empower your CNS drug discovery. Our team looks forward to meeting you there! https://axcelead-us. com/wp-content/uploads/2024/07/Neuroscience2024-1-1024x685. jpg Some of our flagship service in CNS. -Various Platforms for Validation Studies -iPS Cell Platform, In Vitro & Ex Vivo Assays -Brain Function: Functional Recovery, Translational Research -Tailor-Made In Vivo Assays -AI-powered Behavioral Analysis -IND-Enabling Projects --- ### Unique distribution of antisense oligonucleotidesin the brain by the intrathecal administration - Published: 2024-07-22 - Modified: 2024-07-22 - URL: https://axcelead-us.com/posters/unique-distribution-of-antisense-oligonucleotidesin-the-brain-by-the-intrathecal-administration/ - Categories: Posters - Tags: Biology The 9th Annual Meeting of the Nucleic Acid Therapeutics Society of Japan Download --- ### Axcelead Kinase Inhibitor Discovery Platform: Identification of Selective Inhibitors for 123 Kinases - Published: 2024-06-04 - Modified: 2024-06-05 - URL: https://axcelead-us.com/presentations/axcelead-kinase-inhibitor-discovery-platform-identification-of-selective-inhibitors-for-123-kinases/ - Categories: Presentations - Tags: Screening Discovery on Target 2023 Sponsored Presentation Download --- ### Immunology Capabilities - Published: 2024-06-02 - Modified: 2024-06-05 - URL: https://axcelead-us.com/brochures/immunology-capabilities/ - Categories: Brochures - Tags: Therapeutic Areas Download --- ### Cardiovascular/Metabolic Disease Capabilities - Published: 2024-06-02 - Modified: 2024-06-04 - URL: https://axcelead-us.com/brochures/cardiovascular-metabolic-disease-capabilities/ - Categories: Brochures - Tags: Therapeutic Areas Download --- ### Innovative RNA-targeting Small Molecules - Published: 2024-05-31 - Modified: 2025-01-06 - URL: https://axcelead-us.com/brochures/innovative-rna-targeting-small-molecules/ - Categories: Brochures - Tags: Therapeutic Modalities Download --- ### In-silico Technologies for Medicinal Chemistry - Published: 2024-05-31 - Modified: 2024-06-04 - URL: https://axcelead-us.com/brochures/in-silico-technologies-for-medicinal-chemistry/ - Categories: Brochures - Tags: Technology Platforms Download --- ### Axcelead DDP has become a certified provider of Single Cell Gene Expression Solution, from 10x Genomics - Published: 2024-05-29 - Modified: 2025-05-21 - URL: https://axcelead-us.com/news/axcelead-ddp-has-become-a-certified-provider-of-single-cell-gene-expression-solution-from-10x-genomics/ - Categories: News, Topics We’re delighted to announce that Axcelead Drug Discovery Partners, Inc. (“Axcelead DDP”) has received official certification from 10x Genomics as a Certified Service Provider (CSP) of single cell gene expression analysis services. The CSP status is awarded to providers who can deliver contract research service concerning single cell gene expression analysis at a quality level that meets or exceeds a certain standard. Axcelead DDP has previously received CSP certification for Visium, a spatial transcriptomics technology, and has now received CSP certification for its single cell gene expression analysis service as well. In single cell gene expression analysis, we can obtain gene expression profiles at a single cell level from hundreds of thousands of cells. This allows us to unveil the diversity of cell types and explore cell type-specific pathological mechanism and drug responsiveness. It is expected to be used in a variety of drug discovery research processes, including discovery of targets and biomarker molecules, verification of pharmacological effects of drugs, and analysis of toxicity mechanisms. We have been providing comprehensive contract research services covering from experiments to bioinformatics analysis in single cell gene expression analysis for many customers. Please get in touch to discuss how we can help overcome your drug discovery challenges through our services and drug discovery platforms. Related Papers H. Hiyoshi et al. , Identification and removal of unexpected proliferative off-target cells emerging after iPSC-derived pancreatic islet cell implantation. Proc Natl Acad Sci U S A 121, e2320883121 (2024). K. Sakuma et al. , CDK8/19 inhibition plays... --- ### Drug Discovery Services for Oncology - Published: 2024-05-28 - Modified: 2024-06-04 - URL: https://axcelead-us.com/brochures/drug-discovery-services-for-oncology/ - Categories: Brochures - Tags: Therapeutic Areas Download --- ### Achieved the First Milestone in Drug Discovery Support to Otsuka Pharmaceutical - Published: 2024-05-27 - Modified: 2025-05-21 - URL: https://axcelead-us.com/news/achieved-the-first-milestone-in-drug-discovery-support-to-otsuka-pharmaceutical/ - Categories: News, News Releases May 27, 2024 – Axcelead Drug Discovery Partners, Inc. (HQ: Fujisawa-city, Kanagawa; “Axcelead DDP”) announces that the first milestone has been achieved in the drug discovery project to support Otsuka Pharmaceutical Co. , Ltd. (HQ: Chiyoda-ku, Tokyo, President: Makoto Inoue; “Otsuka Pharmaceutical”) in the area of central nervous system diseases, which had been started in June 2020. Axcelead DDP provided promising lead compounds which were created through established evaluation platforms and in-depth modification of seed compounds derived from the IND-Enabling Projects* owned by Axcelead DDP, to Otsuka Pharmaceutical. Given further drug discovery research activities at Otsuka Pharmaceutical, a compound was discovered to meet the pre-determined criteria of pharmacological properties, resulting in the first milestone. With this achievement, Axcelead DDP will receive a milestone fee under the agreement. Otsuka Pharmaceutical will significantly accelerate its drug discovery by leveraging the IND-Enabling Projects. “We are pleased that the new drug candidate discovered from our unique asset, the IND-Enabling Projects, has met Otsuka Pharmaceutical's expectations. I believe that this milestone achievement demonstrates that the IND-Enabling Projects can make unique values for customers,” said Kengo Okada, PhD, Representative Director and CEO of Axcelead DDP. “We have gained confidence in the ability of the IND-Enabling Projects to deliver high-quality new drug candidate compounds in a short period of time, continuing to contribute to improving the efficiency of drug discovery research for those who take challenges around the world. ” *About IND-Enabling Projects The IND-Enabling Projects (Formerly named A-HiT projects) are an asset owned by Axcelead DDP,... --- ### BIO International Convention 2024 - Published: 2024-05-08 - Modified: 2025-05-16 - URL: https://axcelead-us.com/previous-conferences/bio-international-convention-2024/ - Categories: Previous Conferences San Diego, CA Conference Name: BIO International Convention 2024 Time: June 3-6, 2024 Location: San Diego Convention Center, California Axcelead will be attending BIO International Convention 2024 in San Diego Convention Center, San Diego, California. Visit us at Booth #2114 to learn how we can empower your drug discovery. Our team looks forward to meeting you there! https://axcelead-us. com/wp-content/uploads/2024/01/bio-yoshinori-3-297x300. jpg Yoshinori Ikeura, PhD CEO, Axcelead, Inc. / Chairperson, Axcelead Drug Discovery Partners, Inc. Former Head of Shonan research center, Takeda Pharmaceutical Company Former Chairman of Japan Pharmaceutical Manufacturers Association R&D committee Former Board member of Japan Bio industry Association RSC, Med. Chem. Comm. editorial board >30 years of experience in Drug discovery（>5 IND) >16 publication, >17 patent https://axcelead-us. com/wp-content/uploads/2024/02/ii-san-1-297x300. png Masayuki Ii, PhD CSO, Axcelead Drug Discovery Partners, Inc. Former Head of inflammation DDU, Takeda Pharmaceutical Company >29 years of experience in Drug discovery, lead of reserach in global development program >50 publicastions, patents https://axcelead-us. com/wp-content/uploads/2024/01/bio-aso-2-1-297x300. jpg Kazuyoshi Aso, PhD Head, Global Business Development, Axcelead Drug Discovery Partners, Inc. Former VP, Head of Chemistry, Axcelead DDP Former VP, Head of Medicinal Chemistry, Tri-I TDI >3 years of experience in sales & marketing >30 years of experience in drug discovery research >33 publications, >24 patents --- ### Identification and removal of unexpected proliferative off target cells emerging after iPSC derived pancreatic islet cell implantation - Published: 2024-04-10 - Modified: 2024-04-22 - URL: https://www.pnas.org/doi/10.1073/pnas.2320883121#new_tab - Categories: Publications Proceedings of the National Academy of Sciences --- ### Change of Representative Director - Published: 2024-04-01 - Modified: 2025-05-21 - URL: https://axcelead-us.com/news/change-of-representative-director/ - Categories: News, News Releases Kanagawa, Japan, April 1, 2024 --- Axcelead Drug Discovery Partners, Inc (hereafter Axcelead DDP) announced that the following change in its Representative Director at the Extraordinary General Meeting of Shareholders held on March 28 and the Extraordinary Board of Directors Meeting held today. Details of Changes in Positions (as of April 1, 2024) Name Current Position New Position Kengo Okada COO Representative Director, President and CEO, and concurrently serves as COO Reason for change This is due to the resignation of Nobuhiko Yamada, Representative Director, President and CEO, on March 31, 2024, from his position for personal reasons. Brief history of the new CEO Kengo Okada is currently, and has been since April 2024, the Representative Director, President and CEO at Axcelead DDP and Representative Director at Axcelead Tokyo West Partners, Inc. He joined Axcelead DDP in 2017, and had been taking on responsibilities for business plan development and overall business management. He previously worked at Takeda Pharmaceutical Company from 2004 as a Senior Research Scientist at the Pharmaceutical Research Division. Held various roles including a business assignment in San Diego, Global Project Leader, and eventually moved into management of the drug discovery platform division within the research organization. Worked as an assistant professor at the Nara Institute of Science and Technology after a position as a doctoral researcher in Sweden. Earned a PhD from the Graduate School of Science at Osaka City University in 1997. End of document Download --- ### AACR ANNUAL MEETING 2024 - Published: 2024-02-29 - Modified: 2025-05-16 - URL: https://axcelead-us.com/previous-conferences/aacr-annual-meeting-2024/ - Categories: Previous Conferences San Diego, CA Conference Name: AACR ANNUAL MEETING 2024 Time: April 5 - 10, 2024 Location: San Diego Convention Center, San Diego, California Axcelead will be attending AACR ANNUAL MEETING 2024 in San Diego Convention Center, San Diego, California. Visit us at Booth #4424 to learn how we can empower your cancer drug discovery. Our team looks forward to meeting you there! Axcelead offers an unparalleled portfolio of services, coupled with deep expertise and cutting-edge platforms, to bring reliable human extrapolation for your cancer drug discovery endeavors. Our commitment to excellence ensures timely and cost-effective delivery of results. https://axcelead-us. com/wp-content/uploads/2024/02/AACR-1024x685. png Some of our flagship service in oncology. -Fresh Human Tumor Samples -Full Range of Immuno-Profiling -Advanced Humanized Mouse Models -Orthotopic Tumor Models / In Vivo Imaging -Cell-Based Assays -Combination Partner Analysis https://axcelead-us. com/wp-content/uploads/2024/02/Neil_banner-1-1024x430. png --- ### Characterization of membrane protein using mass spectrometry-based technologies — affinity selection-mass spectrometry (AS-MS) - Published: 2024-02-16 - Modified: 2024-02-16 - URL: https://axcelead-us.com/posters/characterization-of-membrane-protein-using-mass-spectrometry-based-technologies-affinity-selection-mass-spectrometry-as-ms/ - Categories: Posters - Tags: Screening SLAS 2024 in Boston Download --- ### Global Life Science Partnering ＆Investor Conference - Published: 2024-02-14 - Modified: 2025-05-16 - URL: https://axcelead-us.com/previous-conferences/global-life-science-partnering-%ef%bc%86investor-conference/ - Categories: Previous Conferences San Diego, CA Conference Name: Global Life Science Partnering & Investor Conference Time: February 27 - 29, 2024 Location: THE LODGE AT TORREY PINES | LA JOLLA, CALIFORNIA Axcelead will be attending Global Life Science Partnering & Investor Conference presented by Biocom California. Our team will be available onsite to discuss how we can improve your drug discovery. We look forward to meeting you there! https://axcelead-us. com/wp-content/uploads/2024/01/bio-yoshinori-3-297x300. jpg Yoshinori Ikeura, PhD CEO, Axcelead, Inc. / Chairperson, Axcelead Drug Discovery Partners, Inc. Former Head of Shonan research center, Takeda Pharmaceutical Company Former Chairman of Japan Pharmaceutical Manufacturers Association R&D committee Former Board member of Japan Bio industry Association RSC, Med. Chem. Comm. editorial board >30 years of experience in Drug discovery（>5 IND) >16 publication, >17 patent https://axcelead-us. com/wp-content/uploads/2024/02/ii-san-1-297x300. png Masayuki Ii, PhD CSO, Axcelead Drug Discovery Partners, Inc. Former Head of inflammation DDU, Takeda Pharmaceutical Company >29 years of experience in Drug discovery, lead of reserach in global development program >50 publicastions, patents https://axcelead-us. com/wp-content/uploads/2024/01/bio-aso-2-1-297x300. jpg Kazuyoshi Aso, PhD Head, Global Business Development, Axcelead Drug Discovery Partners, Inc. Former VP, Head of Chemistry, Axcelead DDP Former VP, Head of Medicinal Chemistry, Tri-I TDI >3 years of experience in sales & marketing >30 years of experience in drug discovery research >33 publications, >24 patents --- ### Accelerate and achieve an optimal IND for your project～Smart-IND®～ - Published: 2024-01-11 - Modified: 2024-01-31 - URL: https://axcelead-us.com/previous-seminars/accelerate-and-achieve-an-optimall-ind-for-your-project/ - Categories: Previous Seminars A webinar co-hosted by Axcelead Drug Discovery Partners (ADDP), SEKISUI MEDICAL, and KRCC. The webinar is for Korean scientists. After the speech, the breakout meeting rooms are available, where our experts will answer your further and detailed questions. 16:00 – 17:00 (KST) A webinar co-hosted by Axcelead Drug Discovery Partners (ADDP), SEKISUI MEDICAL, and KRCC. The webinar is for Korean scientists. After the speech, the breakout meeting rooms are available, where our experts will answer your further and detailed questions. Webinar Overview:Are you interested in one-stop service that can support your IND-enabling studies from planning to implementation? There are many obstacles and individual issues to overcome when applying for an IND. To solve these problems, the integrated IND-enabling service, Smart-IND® is launched. The entire preclinical study process will be managed by Axcelead as a hub to significantly reduce your burden for IND. Programs for IND are considered and proposed based on the Target Product Profile by our well-experienced scientists. Also, the whole process of your individual studies from planning to report finalization, preparation of an investigative brochure, response about inquiries from regulatory authorities, will be supported promptly and fully. In this seminar, an overview of Smart-IND® and detailed examples of solutions will be introduced. After that, the breakout meeting rooms are also available, where our experts will answer your further and detailed questions. Presentation: Download Speaker https://axcelead. wpenginepowered. com/wp-content/uploads/2023/12/jinno_640_340. webp Fumihiro Jinno Axcelead Drug Discovery Partners Inc,Applied Regulatory Science Director 1993, School of Pharmaceutical Science of University of Shizuoka, JAPAN(Bachelor of Pharmaceutical Science) 1995, School of Pharmaceutical Science of University of Shizuoka, JAPAN(Master of Pharmaceutical Science) 2012, Graduate School of University of Shizuoka, JAPAN (Ph. D. in Pharmaceutical Science) 1995-, Takeda Pharmaceutical Company Limited, Animal Drug Research Office 1999-, Takeda Pharmaceutical Company... --- ### Axcelead DDP's English Version of Official Website Renewed - Published: 2024-01-05 - Modified: 2025-05-21 - URL: https://axcelead-us.com/news/axcelead-ddps-english-version-of-official-website-renewed/ - Categories: News, News Releases We are pleased to announce the renewal of Axcelead DDP's English version of the official website. The entire site has fully been redesigned to make accessing the latest and required information easier along with improving the navigation paths to individual pages. We will continually expand and enhance the contents to provide better user experience while visiting the website. Release date of the renewed version of the English website: January 5, 2024 --- ### Axcelead Drug Discovery Partners and Acadia Pharmaceuticals Launch 2nd Drug Discovery Project in Neuroscience - Published: 2023-12-25 - Modified: 2025-05-21 - URL: https://axcelead-us.com/news/axcelead-drug-discovery-partners-and-acadia-pharmaceuticals-launch-2nd-drug-discovery-project-in-neuroscience/ - Categories: News, News Releases December 25, 2023 – Axcelead Drug Discovery Partners, Inc. (HQ: Fujisawa, Kanagawa, Japan; hereinafter referred to as “Axcelead DDP”) announces the launch of a second drug discovery project with Acadia Pharmaceuticals Inc. (HQ: San Diego, CA, USA; hereinafter referred to as “Acadia”) to generate innovative medicines within the field of neuroscience. Acadia and Axcelead DDP initiated the second project following the first project that commenced in October 2022, the objective of which was to identify drug candidate compounds also in specific therapeutic indications within neuroscience. In the second project, the parties will proceed with research programs to discover and advance candidate compounds for clinical development. Axcelead DDP will lead research activities to generate high-quality, target-selective candidate compounds by leveraging its integrated drug discovery platform, deep knowledge and extensive experience in drug discovery research. Acadia will leverage its deep expertise in central nervous system disorders to execute on the clinical development and potential commercialization of successful compounds. Axcelead DDP will receive upfront fees, research funding and development milestone fees as with the first drug discovery project. “We are delighted to contribute to the second drug discovery project with Acadia. We believe that Acadia highly recognizes the progress of our first drug discovery project in the neuroscience area, which started in October 2022 as well as our drug discovery capabilities. This project successfully passed early milestones as planned and is expected to achieve drug candidate selection in the near future,” said Nobuhiko Yamada, chief executive officer of Axcelead DDP. “We will continue... --- ### Lineage tracing of T cell differentiation from T-iPSC by 2D feeder-free culture and 3D organoid culture - Published: 2023-12-15 - Modified: 2024-01-24 - URL: https://www.frontiersin.org/articles/10.3389/fimmu.2023.1303713/full#new_tab - Categories: Publications Frontiers in Immunology --- ### How to proceed GLP toxicity study without cynomolgus monkeys - Published: 2023-12-15 - Modified: 2024-01-24 - URL: https://axcelead-us.com/previous-seminars/how-to-proceed-glp-toxicity-study-without-cynomolgus-monkeys-2/ - Categories: Previous Seminars High-throughput screening (HTS) is the key methodology to identify hit and lead compouds for drug discovery. The innovative technologies for drugging undruggable targets and IPS cells have been shed new light on small molecule drug discovery. Webinar Overview: Since the end of last year, the price of monkeys has soared, import restrictions have made it difficult to conduct non-clinical safety studies using cynomolgus monkeys (cynos) , and many projects seem to have been canceled or suspended. Knock-in mice/rats may solve the problem of high prices and supply shortages in cynos. Speaker Introduction: https://axcelead. wpenginepowered. com/wp-content/uploads/2023/12/fukui_640_360. webp Hideo Fukui, PhD, DABT, DJSOT Applied Regulatory Science Senior Director/Senior Consultant I joined Takeda Pharmaceuticals in 1989 after finishing a MS degree in Nutritional Biochemistry at the Nagoya University Graduate School of Bio agricultural Sciences. In 1994 I completed a PhD in Pharmacology at the Kyoto University Graduate School of Pharmaceutical Sciences. In 2000 I was appointed postdoctoral researcher at the Department of Medicine at Columbia University in the U. S. I have professional toxicologist accreditation from the American Board of Toxicology (ABT) in the U. S. and the Japanese Society of Toxicology (JSOT). I worked at Global Takeda as the lead on non-clinical safety assessments, primarily for therapeutic drugs in the gastroenterology domain, where my duties involved addressing a range of toxicity issues, liaising with regulatory authorities, and conducting due diligence on candidate compounds. I also served as President of the 48th Annual Meeting of the Japanese Society of Toxicology in Kobe in 2021. https://axcelead. wpenginepowered. com/wp-content/uploads/2023/12/takeyama-1024x576. jpg Michiyasu Takeyama, PhD Integrated & Translational Research Director I joined Takeda Pharmaceuticals in 1991 after finishing a PhD in Engineering at the Osaka University Graduate School of Engineering. I have since... --- ### Rapid Discovery! Accelerate drug discovery from hit id to clinic - Published: 2023-12-15 - Modified: 2024-01-24 - URL: https://axcelead-us.com/previous-seminars/rapid-discovery-accelerate-drug-discovery-from-hit-id-to-clinic-2/ - Categories: Previous Seminars Mounting competitive pressure is forcing the biopharma industry to look at new ways to shorten the time scale for all aspects of drug discovery. Description： Mounting competitive pressure is forcing the biopharma industry to look at new ways to shorten the time scale for all aspects of drug discovery. While advances in computation, structural chemistry, and molecular modeling are facilitating rational design activities, high throughput screening (HTS) has emerged as a key enabler in accelerating drug discovery. This is due to its ability to test and identify a large number of compounds quickly and efficiently. However, effective integration of compound supply, assay operation, and data management are essential to achieve the necessary productivity. To discuss these considerations and more, Syngene, in association with Axcelead, brings you an interactive virtual webinar on ‘Rapid Discovery’ and how to accelerate drug discovery – hit identification to the clinic. Speaker Introduction: https://axcelead. wpenginepowered. com/wp-content/uploads/2023/12/Tomohiro-Kawamoto. jpg. webp Tomohiro Kawamoto, PhD Senior Director of Discovery Biology, Axcelead Drug Discovery Partners, Inc. Tomohiro holds a Ph. D. in Life and Environmental Sciences from Tsukuba University (Japan). He has about three decades of experience in the areas of drug discovery for small molecules. Prior to joining Axcelead, he was the Associate Director of Biomolecular Research Laboratories at Takeda Pharmaceutical Company, Limited, and had contributed to drug discovery research for more than twenty years on multiple drug targets and phenotypes, including enzymes, GPCRs, and transporters. At Axcelead, Tomohiro leads the Discovery Biology department and has strong track records in Hit Identification, and is trusted by global pharmaceutical companies and venture companies. https://axcelead. wpenginepowered. com/wp-content/uploads/2023/12/Takaharu-Hirayama. jpg. webp Takaharu Hirayama Ph. D. Senior Director of... --- ### Driving innovative drug discovery through integrated high-throughput screening platform - Published: 2023-12-15 - Modified: 2024-01-24 - URL: https://axcelead-us.com/previous-seminars/driving-innovative-drug-discovery-through-integrated-high-throughput-screening-platform-2/ - Categories: Previous Seminars High-throughput screening (HTS) is the key methodology to identify hit and lead compouds for drug discovery. The innovative technologies for drugging undruggable targets and IPS cells have been shed new light on small molecule drug discovery. DOWNLOAD： Presentation document Description： High-throughput screening (HTS) is the key methodology to identify hit and lead compouds for drug discovery. The innovative technologies for drugging undruggable targets and IPS cells have been shed new light on small molecule drug discovery. Axcelead has diverse and high-quality compound libraries and provides comprehensive hit/lead finding services including both target and phenotype based drug discovery. Dr. Kawamoto will demonstrate how Axcelead could successfully discover hit/lead compounds with our cutting edge technologies and multidisciplinary strategies. Moreover, you can learn about our capability on drugging undruggable targets such as RNA targeted drug discovery, Protein degraders and phenotypic screening using IPS cells. Axcelead accelerates your innovation. Speaker Introduction: https://axcelead. wpenginepowered. com/wp-content/uploads/2023/12/tomohiro-kawamoto. webp Tomohiro Kawamoto, PhD Senior Director of Discovery Biology, Axcelead Drug Discovery Partners, Inc. ＜Professional Experience＞ 2017-Present: Axcelead Drug Discovery Partners Inc. Senior Director, Discovery Biology, Discovery Science 1994-2017: Takeda Pharmaceutical Company, Limited 2012: Associate Director, Biomolecular Research Laboratories 2008: Associate Director, Discovery Research Laboratories ＜Education＞ 2015: Ph. D. Graduate School of Life and Environmental Sciences, Tsukuba University 1994: M. S. Graduate School of Engineering, Osaka University --- ### In-Vivo Science and Axcelead DDP Entered into Cooperative Agreement for Drug Discovery Services Using Disease Model Animals - Published: 2023-12-13 - Modified: 2025-05-21 - URL: https://axcelead-us.com/news/in-vivo-science-and-axcelead-ddp-entered-into-cooperative-agreement-for-drug-discovery-services-using-disease-model-animals/ - Categories: News, News Releases In-Vivo Science, Inc. (Headquarters: Meguro-ku, Tokyo; Branch Office: Kawasaki City, Kanagawa Prefecture; President: Koji Yoshimura; hereinafter “In-Vivo Science”) and Axcelead Drug Discovery Partners, Inc. (Headquarters: Fujisawa City, Kanagawa Prefecture; President & CEO: Nobuhiko Yamada; hereinafter “Axcelead DDP”) announce that we have now entered into a cooperative agreement for drug discovery services using disease model animals. In-Vivo Science globally supplies a wide range of disease model animals including NOG mice* and humanized mice, developed based on technology by the Central Institute for Experimental Animals (hereinafter, “CIEA”), and possesses know-how and information on experiments based on CIEA’s abundant experience and technology. Axcelead DDP employs more than 200 researchers experienced in drug discovery and provides drug discovery services pharmacological evaluation for various modalities and diseases to a variety of drug discovery players such as pharmaceutical companies, bio-ventures, and academia. Under this agreement, the cooperation between In-Vivo Science, with a wealth of information including know-how and practical knowledge on experiments using disease model animals, and Axcelead DDP, with outstanding technology regarding drug discovery using disease model animals, will be able to provide more robust in vivo evaluations that meet our customer needs more quickly. This agreement will also allow Axcelead DDP to gain expertise and technology concerning the characteristics and construction of humanized mouse models from In-Vivo Science and further enhance its capability for constructing disease model animals. Koji Yoshimura, President of In-Vivo Science, said “This cooperation will enable the abundant talents of Axcelead DDP, a drug discovery solution provider, and its technical excellence... --- ### SLAS2024 International Conference & Exhibition - Published: 2023-12-09 - Modified: 2025-05-16 - URL: https://axcelead-us.com/previous-conferences/name-of-conference-here/ - Categories: Previous Conferences Boston, MA Conference Name: SLAS2024 International Conference & Exhibition Time: February 3 - 7, 2024 Location: Boston, MA Axcelead will be exhibiting and showcasing our screening services at SLAS2024. Our scientists will be available onsite to discuss how to improve your drug discovery. Be sure to visit us at our booth 781 and do not forget to add our poster presentation to your schedule. Poster Presentation: Poster Title: Characterization of membrane protein using mass spectrometry-based technologies — affinity selection-mass spectrometry (AS-MS) Presenter: Hideyuki Oki Date & Time: 2:00 PM – 3:00 PM Monday February 5, 2024 Poster Assignment Number: 1029-B Session: Poster Session B Presentation: Download --- ### Axcelead Company Introduction - Published: 2023-12-05 - Modified: 2024-10-01 - URL: https://axcelead-us.com/brochures/axcelead-company-introduction/ - Categories: Brochures - Tags: Company Introduction Download --- ### Target-based Drug Discovery - Published: 2023-12-05 - Modified: 2024-06-05 - URL: https://axcelead-us.com/brochures/target-based-drug-discovery/ - Categories: Brochures - Tags: Integrated Drug Discovery Download --- ### Integrated Phenotypic Drug Discovery - Published: 2023-12-05 - Modified: 2024-06-05 - URL: https://axcelead-us.com/brochures/integrated-phenotypic-drug-discovery/ - Categories: Brochures - Tags: Integrated Drug Discovery, Technology Platforms Download --- ### HTS Overview - Published: 2023-12-05 - Modified: 2024-10-22 - URL: https://axcelead-us.com/brochures/hts-overview/ - Categories: Brochures - Tags: Integrated Drug Discovery, Technology Platforms Download --- ### High-Throughput Affinity Selection Mass Spectrometry - Published: 2023-12-05 - Modified: 2025-01-14 - URL: https://axcelead-us.com/brochures/ht-asms/ - Categories: Brochures - Tags: Technology Platforms Download --- ### Lead Generation and Optimization - Published: 2023-12-05 - Modified: 2024-06-05 - URL: https://axcelead-us.com/brochures/lead-generation-and-optimization/ - Categories: Brochures - Tags: Integrated Drug Discovery Download --- ### Targeted Protein Degrader Integrated Solutions - Published: 2023-12-05 - Modified: 2024-10-22 - URL: https://axcelead-us.com/brochures/targeted-protein-degrader-integrated-solutions/ - Categories: Brochures - Tags: Therapeutic Modalities Download --- ### Smart-IND--IND Enabling Package Service - Published: 2023-12-05 - Modified: 2024-06-05 - URL: https://axcelead-us.com/brochures/smart-ind-ind-enadling-package-service/ - Categories: Brochures - Tags: Integrated Drug Discovery Download --- ### Tumorigenicity Testing Services for Regenerative Medicine Products - Published: 2023-12-05 - Modified: 2024-06-05 - URL: https://axcelead-us.com/brochures/tumorigenicity-testing-services-for-regenerative-medicine-products/ - Categories: Brochures - Tags: Technology Platforms Download --- ### Cardiac QT Risk Assessment Using a Human iPS-cardiomyocytes - Published: 2023-12-05 - Modified: 2024-06-05 - URL: https://axcelead-us.com/brochures/cardiac-qt-risk-assessment-using-a-human-ips-cardiomyocytes/ - Categories: Brochures - Tags: Technology Platforms Download --- ### Compound Screening Service using iPSC-derived Cells - Published: 2023-12-05 - Modified: 2024-06-05 - URL: https://axcelead-us.com/brochures/compound-screening-service-using-ipsc-derived-cells/ - Categories: Brochures - Tags: Technology Platforms Download --- ### Mini Kinase Panel 46 - Published: 2023-12-05 - Modified: 2024-06-04 - URL: https://axcelead-us.com/brochures/mini-kinase-panel-46/ - Categories: Brochures - Tags: Technology Platforms Download --- ### Discovery On Target 2023 - Published: 2023-12-01 - Modified: 2025-05-16 - URL: https://axcelead-us.com/previous-conferences/discovery-on-target-2023/ - Categories: Previous Conferences Sheraton Boston Conference Name: Discovery On Target 2023 Time: September 25 - 28, 2023 Location: Sheraton Boston Axcelead will be exhibiting at upcoming Discovery On Target 2023 in Boston. Visit us at Booth #200 to learn how we can empower your drug discovery. Our team looks forward to meeting you there! Presentation in symposium: Axcelead will also be presenting at the Strategies for Targeting Kinases Symposium on 9/25! Presenter: Akito Hata Date: Monday, September 25　14:30 – 14:45 Title: Axcelead Kinase Inhibitor Discovery Platform: Identification of Selective Inhibitors for 123 Kinases Presenter: Akito Hata, Director, Discovery Biology, Axcelead Drug Discovery Partners, Inc. Abstract: Axcelead, a spin-off from a Japanese pharmaceutical company, is a CRO with comprehensive preclinical research capabilities. Our uniqueness stems from inherited 1. 5 million compound library and retaining access to legacy data prior to the company separation. Here, we present approaches that are used to discover potent and selective inhibitors for 123 protein kinases: internal protein kinase panel database, kinase-focused library for selective hit identification, and Mini Kinase Panel 46. Poster: In-Person Presenter will remain by our poster during refreshment breaks. Presenter: Akito Hata P006: Discovery of Selective Inhibitors for 123 Protein Kinases Utilizing Internal Kinase Panel Dataset Presenter: Akito Hata, Director, Discovery Biology, Axcelead Drug Discovery Partners, Inc. https://axcelead. wpenginepowered. com/wp-content/uploads/2023/09/posts-akito-hata. webp Akito Hata Director, Discovery Biology, Axcelead Drug Discovery Partners, Inc. --- ### Strategies to determine the target human metabolites using Radiolabeled compounds - Example from nonclinical to clinical - Published: 2023-12-01 - Modified: 2023-12-01 - URL: https://axcelead-us.com/presentations/strategies-to-determine-the-target-human-metabolites-using-radiolabeled-compounds-example-from-nonclinical-to-clinical/ - Categories: Presentations - Tags: DMPK The 34th Workshop of the Korean Society of Non-clinical study Download --- ### Case study: Human relevancy and mode of action of toxic findings observed in GLP toxicity studies - Published: 2023-12-01 - Modified: 2023-12-01 - URL: https://axcelead-us.com/presentations/case-study-human-relevancy-and-mode-of-action-of-toxic-findings-observed-in-glp-toxicity-studies/ - Categories: Presentations - Tags: Safety The 44th Annual Meeting of the Japanese Society of Toxicology Download --- ### New approach: Tailor-made immunosuppressed pig/monkey models for regenerative medicine - Published: 2023-12-01 - Modified: 2023-12-01 - URL: https://axcelead-us.com/presentations/new-approach-tailor-made-immunosuppressed-pig-monkey-models-for-regenerative-medicine/ - Categories: Presentations - Tags: Biology CiRA 2019 International Symposium Download --- ### Echocardiographic evaluation of cardiotoxicity in mice treated with doxorubicin, an anticancer drug - Published: 2023-12-01 - Modified: 2023-12-01 - URL: https://axcelead-us.com/presentations/echocardiographic-evaluation-of-cardiotoxicity-in-mice-treated-with-doxorubicin-an-anticancer-drug/ - Categories: Presentations - Tags: Biology The 48th Annual Meeting of the Japanese Society of Toxicology Download --- ### Rapid and efficient synthesis of deuterated cyclobutane derivatives using continuous photo flow chemistry - Published: 2023-12-01 - Modified: 2024-01-03 - URL: https://axcelead-us.com/posters/rapid-and-efficient-synthesis-of-deuterated-cyclobutane-derivatives-using-continuous-photo-flow-chemistry/ - Categories: Posters - Tags: Chemistry The 138th Annual Meeting of the Pharmaceutical Society of Japan Download --- ### Phenotypic screening with TREM2 knockout iCell® Microgria - Published: 2023-12-01 - Modified: 2023-12-01 - URL: https://axcelead-us.com/posters/phenotypic-screening-with-trem2-knockout-icell-microgria/ - Categories: Posters - Tags: Biology The 13th conference on biomolecular screenology Download --- ### Immunohistochemistry and in situ hybridization for Heat shock protein from mice treated with single administration of carbon tetrachloride - Published: 2023-12-01 - Modified: 2023-12-01 - URL: https://axcelead-us.com/posters/immunohistochemistry-and-in-situ-hybridization-for-heat-shock-protein-from-mice-treated-with-single-administration-of-carbon-tetrachloride/ - Categories: Posters - Tags: Safety The 39th Annual Meeting of the Japanese Society of Toxicologic Pathology Download --- ### Acetyl-CoA carboxylase 1 and 2 inhibition ameliorates hepatic fibrosis and steatosis in a murine model of nonalcoholic steatohepatitis - Published: 2023-12-01 - Modified: 2023-12-01 - URL: https://axcelead-us.com/posters/acetyl-coa-carboxylase-1-and-2-inhibition-ameliorates-hepatic-fibrosis-and-steatosis-in-a-murine-model-of-nonalcoholic-steatohepatitis/ - Categories: Posters - Tags: Biology The 92nd Annual Meeting of the Japanese Pharmacological Society Download --- ### Characterization of mesoridazine transport in human cerebral microvessel endothelial cells, hCMEC/D 3 - Published: 2023-12-01 - Modified: 2023-12-01 - URL: https://axcelead-us.com/posters/characterization-of-mesoridazine-transport-in-human-cerebral-microvessel-endothelial-cells-hcmec-d-3/ - Categories: Posters - Tags: DMPK 33rd JSSX Annual Meeting and 22nd MDO Download --- ### Characterization of metoclopramide transport in human cerebral microvessel endothelial cells, hCMEC/D 3 - Published: 2023-12-01 - Modified: 2023-12-01 - URL: https://axcelead-us.com/posters/characterization-of-metoclopramide-transport-in-human-cerebral-microvessel-endothelial-cells-hcmec-d-3/ - Categories: Posters - Tags: DMPK 34th JSSX Annual Meeting Download --- ### Comparison between administration routes in brain distribution and drug efficacy of ASO (ICV vs IT) - Published: 2023-12-01 - Modified: 2023-12-01 - URL: https://axcelead-us.com/posters/comparison-between-administration-routes-in-brain-distribution-and-drug-efficacy-of-aso-icv-vs-it/ - Categories: Posters - Tags: Biology The 8th Annual Meeting of the Nucleic Acid Therapeutics Society of Japan Download --- ### Discovery of Selective Inhibitors for 123 Protein Kinases Utilizing Internal Kinase Panel Dataset - Published: 2023-12-01 - Modified: 2023-12-01 - URL: https://axcelead-us.com/posters/discovery-of-selective-inhibitors-for-123-protein-kinases-utilizing-internal-kinase-panel-dataset/ - Categories: Posters - Tags: Screening Discovery On Target 2023 in Boston Download --- ### Establishment of intranasal administration method to conscious rats - Published: 2023-12-01 - Modified: 2023-12-01 - URL: https://axcelead-us.com/posters/establishment-of-intranasal-administration-method-to-conscious-rats/ - Categories: Posters - Tags: Biology 33rd Annual Meeting The Academy of Pharmaceutical Science and Technology Download --- ### Discovery of a B-Cell Lymphoma 6 Protein-Protein Interaction Inhibitor by a Biophysics-driven Fragment-based Approach - Published: 2023-12-01 - Modified: 2023-12-01 - URL: https://axcelead-us.com/posters/discovery-of-a-b-cell-lymphoma-6-protein-protein-interaction-inhibitor-by-a-biophysics-driven-fragment-based-approach/ - Categories: Posters - Tags: Screening Fragment-Based Drug Discovery Down Under Conference 2019 Download --- ### Effect of PassPort System on compounds with low transdermal absorption in hairless rats - Published: 2023-12-01 - Modified: 2023-12-01 - URL: https://axcelead-us.com/posters/effect-of-passport-system-on-compounds-with-low-transdermal-absorption-in-hairless-rats/ - Categories: Posters - Tags: DMPK The 35th Annual Meeting of The Academy of Pharmaceutical Science and Technology, Japan Download --- ### PXB-mice with new donor hepatocytes: Reproducible animal model for prediction of huma pharmacokinetic parameter - Published: 2023-12-01 - Modified: 2023-12-01 - URL: https://axcelead-us.com/posters/pxb-mice-with-new-donor-hepatocytes-reproducible-animal-model-for-prediction-of-huma-pharmacokinetic-parameter/ - Categories: Posters - Tags: DMPK 33rd JSSX Annual Meeting and 22nd MDO Download --- ### Evaluation of the extrapolation about the off-target effects of antisense oligonucleotides from in vitro to human - Published: 2023-12-01 - Modified: 2023-12-01 - URL: https://axcelead-us.com/posters/evaluation-of-the-extrapolation-about-the-off-target-effects-of-antisense-oligonucleotides-from-in-vitro-to-human/ - Categories: Posters - Tags: Biology The 6th Annual Meeting of the Nucleic Acids Therapeutics Society of Japan Download --- ### PK/PD evaluation of antisense oligonucleotides in tissues and cells - Published: 2023-12-01 - Modified: 2023-12-01 - URL: https://axcelead-us.com/posters/pk-pd-evaluation-of-antisense-oligonucleotides-in-tissues-and-cells/ - Categories: Posters - Tags: Biology The 8th Annual Meeting of the Nucleic Acid Therapeutics Society of Japan Download --- ### Results of joint research with the University of Tokyo published in the international scientific journal “Nature Communications” - Published: 2023-11-22 - Modified: 2025-05-21 - URL: https://axcelead-us.com/news/results-of-joint-research-with-the-university-of-tokyo-published-in-the-international-scientific-journal-nature-communications/ - Categories: News, News Releases Axcelead Drug Discovery Partners Inc. (Headquarters: Fujisawa City, Kanagawa Prefecture; President & CEO: Nobuhiko Yamada; hereinafter “Axcelead DDP”) announces that the research results on the discovery of absorption pathways for essential nutrient “Choline” through a joint research conducted with Associate Professor Hisamitsu Hayashi and his research team at Graduate School of Pharmaceutical Sciences of University of Tokyo have been published in the international scientific journal “Nature Communications” released on November 21, 2023. Associate Professor Hisamitsu Hayashi and his research team have been researching to overcome hepatic diseases in children. One of these diseases, progressive familial intrahepatic cholestasis type 1 (PFIC1), is a rare disease for which the causal gene has been found, but its pathogenic mechanism and fundamental treatment are unknown. To discover the mechanism, a metabolomic analysis involving lipid molecules was conducted at Axcelead DDP on samples from PFIC1 animal models and patients provided by the University of Tokyo. As a result, we found that PFIC1 could cause malabsorption of lysophosphatidylcholine, a precursor of the essential nutrient choline, in patients, followed by a deficiency of choline itself, leading to disease development. Furthermore, the University of Tokyo research team confirmed that oral choline supplementation in PFIC1 animal models eliminated liver symptoms. These results indicated that choline supplementation could be a treatmenteutic potential for PFIC1. Axcelead DDP is currently supporting the University of Tokyo research team to prepare for its clinical trial. Masayuki Ii, PhD, CSO of Axcelead DDP, said ”We are very pleased to have achieved results leading to the... --- ### Intestinal Atp8b1 dysfunction causes hepatic choline deficiency and steatohepatitis - Published: 2023-11-21 - Modified: 2023-12-05 - URL: https://www.nature.com/articles/s41467-023-42424-x#new_tab - Categories: Publications Nature Communications --- ### FRONTEO and Axcelead DDP Sign Master Collaboration Agreement for AI Drug Discovery Support Partnership - Published: 2023-11-10 - Modified: 2025-05-21 - URL: https://axcelead-us.com/news/fronteo-and-axcelead-ddp-sign-master-collaboration-agreement-for-ai-drug-discovery-support-partnership/ - Categories: News, News Releases FRONTEO Inc. (Headquarters: Minato-ku, Tokyo; President & CEO: Masahiro Morimoto; hereinafter “FRONTEO”) and Axcelead Drug Discovery Partners Inc. (Headquarters: Fujisawa City, Kanagawa Prefecture; President: Nobuhiko Yamada; hereinafter “Axcelead DDP”) have entered into a master collaboration agreement for AI drug discovery support. FRONTEO offers services that improve efficiency, accelerate drug discovery and increase the probability of success through its Drug Discovery AI Factory business, which uses proprietary AI specialized for hypothesis generation in the field of pharmaceutical R&D. Axcelead DDP has unique and comprehensive capabilities for drug discovery, which it leverages to support a diverse range of drug discovery players, including pharmaceutical companies, bioventures, academia and government-affiliated research institutions. Under this master collaboration agreement, FRONTEO’s hypothesis generation AI and Axcelead DDP’s drug discovery platform will be brought together to efficiently go through a cycle of hypothesis building by dry research (data analysis using computers and AI) and validation through wet research (biological experiments using cells, animals, etc. ). Hiroyoshi Toyoshiba, PhD, Executive Officer and CTO of FRONTEO, said “As our Drug Discovery AI Factory business continues to advance, we are encountering numerous client requests for outsourcing the validation of hypotheses that have emerged from dry research to the subsequent wet research phase. I’m happy that we have concluded this master collaboration agreement with Axcelead DDP to meet the needs of our customers and further contribute to the development of their drug discovery research and business, while raising the quality of healthcare. ” Masayuki Ii, PhD, CSO of Axcelead DDP, said “I... --- ### Identification of the first highly selective inhibitor of human lactate dehydrogenase B - Published: 2023-11-01 - Modified: 2023-12-01 - URL: https://doi.org/10.1038/s41598-021-00820-7#new_tab - Categories: Publications Scientific Reports --- ### Lobular distribution of enhanced expression levels of heat shock proteins using in-situ hybridization in the mouse liver treated with a single administration of CCl4 - Published: 2023-10-27 - Modified: 2023-12-01 - URL: https://www.jstage.jst.go.jp/article/tox/advpub/0/advpub_2023-0053/_article#new_tab - Categories: Publications Journal of Toxicologic Pathology --- ### BIO-Europe: Meet us in Munich, Germany - Published: 2023-10-03 - Modified: 2025-05-21 - URL: https://axcelead-us.com/news/bio-europe-meet-us-in-munich-germany/ - Categories: News, Topics Axcelead will be exhibiting at upcoming BIO-Europe in Munich, Germany. Visit us at Booth #10 to learn how we can empower your drug discovery. Our team looks forward to meeting you there! And also, we would like to discuss more details at the partneringONE meetings! Date: November 6–8, 2023 | Munich, Germany November 14–15, 2023 | Digital Partnering Venue: Munich, Germany https://axcelead. wpenginepowered. com/wp-content/uploads/2023/11/posts-yoshinori-keura. jpg Yoshinori Ikeura, PhD Board Chairperson https://axcelead. wpenginepowered. com/wp-content/uploads/2023/11/posts-masayuki-Ii. jpg YMasayuki Ii, Ph. D. CSO, Head of Applied Regulatory Science https://axcelead. wpenginepowered. com/wp-content/uploads/2023/11/posts-kazuyoshi-aso. jpg Kazuyoshi Aso, Ph. D. VP, Head of Customer Innovation Accelerator --- ### Discovery On Target 2023: Meet us in Boston - Published: 2023-09-12 - Modified: 2025-05-21 - URL: https://axcelead-us.com/news/discovery-on-target-2023-meet-us-in-boston/ - Categories: News, Topics Axcelead will be exhibiting at upcoming Discovery On Target 2023 in Boston. Visit us at Booth #200 to learn how we can empower your drug discovery. Our team looks forward to meeting you there! Date: September 25 – 28, 2023 Venue: Sheraton Boston Booth No. #200 ■ Presentation in symposium Axcelead will also be presenting at the Strategies for Targeting Kinases Symposium on 9/25! Date: Monday, September 25　14:30 – 14:45 Title: Axcelead Kinase Inhibitor Discovery Platform: Identification of Selective Inhibitors for 123 Kinases Presenter: Akito Hata, Director, Discovery Biology, Axcelead Drug Discovery Partners, Inc. Abstract: Axcelead, a spin-off from a Japanese pharmaceutical company, is a CRO with comprehensive preclinical research capabilities. Our uniqueness stems from inherited 1. 5 million compound library and retaining access to legacy data prior to the company separation. Here, we present approaches that are used to discover potent and selective inhibitors for 123 protein kinases: internal protein kinase panel database, kinase-focused library for selective hit identification, and Mini Kinase Panel 46. ■ Poster In-Person Presenter will remain by our poster during refreshment breaks. P006: Discovery of Selective Inhibitors for 123 Protein Kinases Utilizing Internal Kinase Panel Dataset Presenter: Akito Hata, Director, Discovery Biology, Axcelead Drug Discovery Partners, Inc. https://axcelead. wpenginepowered. com/wp-content/uploads/2023/09/posts-akito-hata. webp Akito Hata Director, Discovery Biology, Axcelead Drug Discovery Partners, Inc. --- ### Axcelead DDP’s Drug Discovery Support Business Honored with the 6th Japan Medical Research and Development Grand Prize - Published: 2023-08-23 - Modified: 2025-05-21 - URL: https://axcelead-us.com/news/axcelead-ddps-drug-discovery-support-business-honored-with-the-6th-japan-medical-research-and-development-grand-prize/ - Categories: News, News Releases Axcelead Drug Discovery Partners Inc. (“Axcelead DDP”) is pleased to announce that it has been honored with the Startup Encouragement Award at the 6th Japan Medical Research and Development Grand Prize Award Ceremony presented by the Japanese Cabinet Office. The Japan Medical Research and Development Grand Prize aims to recognize and celebrate remarkable achievements in the realm of medical research and development, including groundbreaking achievements and pioneering applications of advancements by universities, public research institutions and companies. This award program is expected to lead to the further advancement of medical research and development in Japan. In the 6th edition of the awards, a category of “Startup” was newly introduced to recognize promising startup companies in the field of medical research and development, thereby expanding the scope of companies that can apply for an award. Name of Award: Japan Medical Research and Development Grand Prize, Startup Encouragement Award Project Name: Contribution to Diverse Drug Discovery Projects Utilizing Innovative Technology Platforms Achievements: Serving as a platformer for drug discovery, Axcelead DDP has contributed to the advancement of drug discovery research, from fundamental studies to clinical applications, for a variety of entities in the drug discovery field. Since its inception, the company has worked with over 200 entities, including pharmaceutical companies, startups, academia and public research institutions. Notably, repeat business with pharmaceutical companies stands at approximately 90%, underscoring their trust and expectations. Moreover, Axcelead DDP’s participation in AMED’s drug discovery support initiatives have facilitated translational research for bridging between academia and pharmaceutical companies.... --- ### Discussions Begin on Collaborative Genomic Drug Discovery Support Using the IQVIA Genome Wide Study Platform - Published: 2023-07-06 - Modified: 2025-05-21 - URL: https://axcelead-us.com/news/discussions-begin-on-collaborative-genomic-drug-discovery-support-using-the-iqvia-genome-wide-study-platform/ - Categories: News, News Releases Axcelead Drug Discovery Partners Inc. (Headquarters: Fujisawa, Kanagawa; President and CEO: Nobuhiko Yamada; hereinafter, “Axcelead DDP”) and IQVIA Solutions Japan Co. , Ltd. (Headquarters: Minato-ku, Tokyo; President: Fumihiko Ugajin; hereinafter, “IQVIA”) have entered discussions regarding a collaboration on genomic drug discovery support utilizing IQVIA’s genetic database, the IQVIA Genome Wide Study Platform (hereinafter, “GWSP”). GWSP integrates multiple genetic databases in Japan and is currently capable of performing correlation analyses of genetic information and health-related information of up to 130,000 people. GWSP makes it possible to easily search genome-wide association study (GWAS) data by disease name, gene name and single nucleotide polymorphism (SNP) IDs. The platform’s distinctive feature is that it makes it possible to obtain data reflecting gender, regional and ethnic specificity. We plan to use GWSP to analyze genetic information and thereby search for novel drug targets, biomarkers and candidate diseases. If new candidates are discovered, we will verify the results using clinical samples while performing additional investigations via IQVIA to assess the potential of genomic drug discovery support services. Nobuhiko Yamada, President and CEO of Axcelead DDP, said “The identification of novel drug targets and biomarkers using genetic databases is crucial if we are to increase the success rate of drug discovery, and is the area that is drawing attention. Through this collaboration with IQVIA, which has the largest gene database in Japan, we will keep striving to provide high quality genome driven drug discovery services to companies aiming to develop innovative new drugs. ” About IQVIA IQVIA... --- ### BIO International Convention 2023: Meet us in Boston - Published: 2023-05-16 - Modified: 2025-05-21 - URL: https://axcelead-us.com/news/bio-international-convention-2023-meet-us-in-boston/ - Categories: News, News Releases Axcelead will be exhibiting at upcoming BIO International Convention 2023 in Boston. Visit us at Japan Pavilion Booth #1353 to learn how we can empower your drug discovery. Our team looks forward to meeting you there! Date: Monday, June 5, 2023 – Thursday, June 8, 2023 Venue: Boston Convention & Exhibition Center – Boston, MA Japan Innovation Night JETRO (Japan External Trade Organization) and CIC Boston will hold Japan Innovation Night during BIO International Convention 2023. At this event, there will be Pitch Session and Networking Session by Japanese biotech companies (related to drug discovery, regenerative medicine, etc. ) who aspire to achieve success alongside Boston’s ecosystem stakeholders. Axcelead will also participate in the Pitch Session. Don’t miss this opportunity to expand your professional network and explore potential collaborations! Date: 4:00pm – 8:00pm on Monday, June 8, 2023 *Pitch Session will be held from 5:20pm to 6:20pm Venue: Cambridge Innovation Center (1 Broadway, Cambridge, MA 02142) https://axcelead. wpenginepowered. com/wp-content/uploads/2023/11/伊井さん-768x908. jpg. jpg Masayuki Ii, Ph. D. CSO, Head of Applied Regulatory Science https://axcelead. wpenginepowered. com/wp-content/uploads/2023/11/麻生さん-768x908-1. jpg Kazuyoshi Aso, Ph. D. VP, Head of Customer Innovation Accelerator https://axcelead. wpenginepowered. com/wp-content/uploads/2023/11/DSC_4013-4-768x908. jpg. jpg Takahiro Tanaka Ph. D. Director of Sales --- ### Luncheon seminar at the 43rd Workshop of the Korean Society of Nonclinical Study - Published: 2023-05-12 - Modified: 2025-05-21 - URL: https://axcelead-us.com/news/luncheon-seminar-at-the-43rd-workshop-of-the-korean-society-of-nonclinical-study/ - Categories: News, News Releases Join us for our luncheon seminar and visit us at booth #8 during the 43rd Workshop of the Korean Society of Nonclinical Study in Suwon. Luncheon seminar #2 「Driving innovative drug discovery through Axcelead integrated platform」 Date: 12:10~12:30 on Friday, May 26th, 2023 Location: Convention Hall 3, Suwon Convention Center Speaker: Dr. Takahiro Tanaka (Director, Sales, Axcelead Drug Discovery Partners, Inc. ) Axcelead Drug Discovery Partners Inc. is an integrated solution provider in drug discovery, having carved from Takeda Pharmaceuticals. Our well-experienced team walk together with you to generate drug candidates from target discovery toward IND application, utilizing brand-new research platform, pharma library and legacy data of drug discovery inherited from Takeda Pharmaceuticals. In this seminar, we will introduce unique solutions to success in drug discovery with our core values and integrated platform. Let’s start innovative drug discovery with Axcelead! Takahiro Tanaka Ph. D. Director of Sales, Axcelead Drug Discovery Partners, Inc. Takahiro Tanaka is a results-driven sales leader and pharmaceutical expert, currently serving as the Sales Director at Axcelead, where he leads global sales activities and has achieved remarkable business deals. A graduate of Kyoto University, Takahiro’s extensive experience includes working at Takeda Pharmaceuticals as a GI pharmacology specialist, and a year-long stint at Pittsburgh University as a visiting scholar, where he focused on studying visceral pain. During his time at Takeda Pharmaceuticals, Takahiro successfully led and coordinated global projects, showcasing his exceptional leadership skills and industry acumen. With his proven track record of driving sales growth and strategic... --- ### Discovery of a Novel Series of Potent, Selective, Orally Available, and Brain-Penetrable C1s Inhibitors for Modulation of the Complement Pathway - Published: 2023-04-25 - Modified: 2023-12-01 - URL: https://pubs.acs.org/doi/10.1021/acs.jmedchem.3c00348#new_tab - Categories: Publications Journal of Medicinal Chemistry --- ### Interview with Ikeura, President and CEO of Axcelead, a holding company, was published in “PHARMA JAPAN”. 『Axcelead to Expand Overseas Biz, Shoots for 130 Billion Yen Sales and 5,000-Plus Researchers』 - Published: 2023-04-20 - Modified: 2025-05-21 - URL: https://axcelead-us.com/news/interview-with-ikeura-president-and-ceo-of-axcelead-a-holding-company-was-published-in-pharma-japan-%e3%80%8eaxcelead-to-expand-overseas-biz-shoots-for-130-billion-yen-sales-and/ - Categories: News, News Releases As a global CRDMO (Contract Research, Development and Manufacturing Organization), Axelead, a holding company, will be fully developing its overseas business in the future. Dr. Ikeura answers questions from the media. （April 13, 2023） Read full article PHARMA JAPAN Posted on April 13, 2023 Jiho Inc. permits the use of articles. --- ### Change of President & CEO - Published: 2023-04-13 - Modified: 2025-05-21 - URL: https://axcelead-us.com/news/change-of-president-ceo/ - Categories: News, News Releases Kanagawa, Japan, April 13, 2023 — We announced that it has decided to make the following changes to its President & CEO effective May 1, 2023. １．Details of Changes in Positions (as of May 1, 2023) Name Current Position New Position Yoshinori Ikeura President & CEO Chairperson, Member of the Board Nobuhiko Yamada COO President & CEO ２． Reason for change This is due to the appointment of Yoshinori Ikeura, President and CEO of Axcelead Drug Discovery Partners, Inc. (hereinafter “Axcelead DDP”), to the position of President and CEO of Axcelead, Inc. , the parent company of Axcelead DDP. Nobuhiko Yamada will continue to serve in his current position as COO after May 1 of this year. ３．Brief history of the new CEO Nobuhiko Yamada joined Takeda Pharmaceutical Company Limited in 1986 after graduating from university, where he was assigned to the domestic sales department and the company-wide business controller in the process of globalization for 10 years. He was in charge of Vice President of Sales Planning & Controlling Department, Pharmaceutical Sales Division from 2013, and he was engaged in the reorganization of the R&D department as Japan Head of the R&D Transformation Office from 2015. In 2017, he and Yoshinori Ikeura launched the predecessor of Axcelead DDP, and caused Drug Discovery Gateway Investment Limited Partnership, of which Whiz Partner is General Partner, to spin off Axcelead DDP. In December 2018, he was transferred to Axcelead DDP and assumed COO. Axcelead DDP is working to establish a solid management... --- ### Multi-laboratory evaluation of immunoaffinity LC-MS-based glucagon-like peptide-1 assay - Published: 2023-03-24 - Modified: 2023-12-01 - URL: https://pubmed.ncbi.nlm.nih.gov/36961372/#new_tab - Categories: Publications Bioanalysis --- ### Orizuru Therapeutics and Axcelead DDP Collaborate on Drug Discovery Support Services Regarding iPS Cells - Published: 2023-03-10 - Modified: 2025-05-21 - URL: https://axcelead-us.com/news/orizuru-therapeutics-and-axcelead-ddp-collaborate-on-drug-discovery-support-services-regarding-ips-cells/ - Categories: News, News Releases Kyoto and Kanagawa, Japan, March 10, 2023 — Orizuru Therapeutics Inc. (“OZTx”) and Axcelead Drug Discovery Partners, Inc (“Axcelead DDP”) have entered into a collaboration for drug discovery support services related to iPS cells. OZTx has a broad range of technology and expertise in the field of iPS cells, and has skilled researchers that are capable of inducing differentiation of undifferentiated human iPS cells into a wide variety of cell types. Axcelead DDP provides drug discovery support services such as phenotypic screening, drug efficacy and safety evaluation using differentiated iPS cells, and the collaboration between the two companies will facilitate drug discovery using human iPS cells that are expected to have clinical applications. Both companies are based in the Shonan Health Innovation Park, and researchers from OZTx will induce differentiation of iPS cells at Axcelead DDP’s research facility, enabling seamless drug discovery support from induction of differentiation of undifferentiated iPS cells to experiments using differentiated cells and data acquisition. The synergy of this collaboration will deliver highly convenient and rapid services, resulting in improved accuracy of their customers’ drug discovery research. Kenji Nonaka, President, Representative Director and CEO of OZTx, said, “We are very pleased to be able to collaborate with Axcelead DDP, a drug discovery solution provider with an outstanding track record. We expect that this collaboration will further accelerate our drug discovery research support business by bringing together our diverse iPS cell differentiation technologies with Axcelead DDP’s strengths in cell-based drug screening technology platforms. We will continue to... --- ### Teijin and Axcelead to Establish Drug Discovery Research JV - Published: 2023-02-20 - Modified: 2025-05-21 - URL: https://axcelead-us.com/news/teijin-and-axcelead-to-establish-drug-discovery-research-jv/ - Categories: News, News Releases Tokyo, Japan, February 20, 2023 — Teijin Limited and Axcelead, Inc. jointly announced today their basic agreement on a capital and business alliance to establish a joint venture company that will primarily utilize the drug discovery research capabilities of Teijin Pharma Limited, the Teijin Group’s core healthcare company. Teijin and Axcelead will now determine the name, ownership ratio and other details of the new company, aiming to conclude a final agreement within the fiscal year ending in March 2024 and then establish the company promptly thereafter. The new company will utilize Teijin’s drug discovery research technologies, facilities, equipment and personnel. Axcelead aims to create synergies based on its proven expertise in drug-discovery support. The new company will investigate and acquire candidate compounds for new drugs as well as support drug discovery research. It is expected to grow its drug discovery support services worldwide by leveraging the combined strengths of Teijin and Axcelead in drug-discovery know-how, knowledge, technology and assets. Through their alliance, Teijin and Teijin Pharma look forward to innovating and strengthening drug discovery research for the early launch of drugs with high medical needs. Teijin Pharma and Teijin are committed to addressing issues of patients, families and communities in need of more support. Axcelead provides non-clinical drug discovery research services that meet the needs of bio-ventures and other pharmaceutical companies worldwide, thereby helping to strengthen and expand the global drug discovery business. This basic agreement, which accords with Axcelead’s concept of co-creating drug discovery platforms, responds to the global... --- ### Axcelead DDP Selected as Project Partner for Harvard Business School Immersive Field Course - Published: 2023-02-03 - Modified: 2025-05-21 - URL: https://axcelead-us.com/news/axcelead-ddp-selected-as-project-partner-for-harvard-business-school-immersive-field-course/ - Categories: News, News Releases Axcelead Drug Discovery Partners Inc. (Head Office: Fujisawa, Kanagawa prefecture, CEO: Yoshinori Ikeura, “Axcelead DDP”) was selected as a Project Partner for Harvard Business School’s Immersive Field Course in last October and in this January, we hosted a team of 4 students from this course for approximately 1 week, offering them an experiential learning opportunity. The Immersive Field Course (“IFC”) from Harvard Business School (“HBS”) is a second-year MBA elective course in which teaching objectives are met through student-centered active learning opportunities including project work, site visits, speakers and participation in discussions with senior leadership. Second-year students who has enrolled in the Japan IFC gain the opportunity for experiential learning by actually visiting a company that they have chosen from among 9 Tokyo project partner companies. . Students on the IFC are typically in their late 20’s and have an average of 5 yearsexperience of work in a range of fields, including finance, real estate, consulting, healthcare, the military and technology etc. Students are divided into small, diverse teams, and collect and analyze market research and other information on the companies selected as Project Partners, and, through processes such as on-site exchanges of opinions, they make proposals for solving a current challenge for the company. Yoshinori Ikeura, President and CEO of Axcelead DDP, said, “We are pleased to be selected as a Project Partner for this course, and to be able to work with HBS to provide students with a real-world learning experience in Japanese society. Through interviews and discussions... --- ### Consideration for the Validation of Clinical Laboratory Method in Non-Clinical Fields - Published: 2023-01-19 - Modified: 2023-12-01 - URL: https://www.future-science.com/doi/10.4155/bio-2022-0178#new_tab - Categories: Publications Future Science --- ### Kaken Pharmaceutical and Axcelead DDP Begin Collaboration to Create Innovative New Drugs - Published: 2023-01-11 - Modified: 2025-05-21 - URL: https://axcelead-us.com/news/kaken-pharmaceutical-and-axcelead-ddp-begin-collaboration-to-create-innovative-new-drugs/ - Categories: News, News Releases Kaken Pharmaceutical Co. , Ltd. (“Kaken”, Head Office: Bunkyo-ku, Tokyo; President and Representative Director, Hiroyuki Horiuchi) and Axcelead Drug Discovery Partners, Inc. (“Axcelead DDP”, Head Office: Fujisawa, Kanagawa; President and CEO, Yoshinori Ikeura) announced that the companies have entered into an agreement to collaborate on creating innovative new drugs. As part of initiatives that will be taken to realize the R&D strategy outlined in the company’s “Long-Term Business Plan 20311)”, Kaken will collaborate with Axcelead DDP to strengthen its pipeline creation engine using the drug discovery technologies and resources of both companies to continuously create innovative new drugs. Axcelead DDP has the wide range of platform capabilities and extensive experience in drug discovery, and through this collaboration it will promote multiple drug discovery projects from the discovery of new drug targets to IND and the clinical stage in the shortest term, supporting Kaken’s initiatives to expand its pipeline. Hiroyuki Horiuchi, President and Representative Director of Kaken, said, “We are committed to transforming our drug discovery research process to be more data-driven, in order to shorten the R&D period and increase the success rate of new drug discovery. This collaboration with Axcelead DDP entails a new form of drug discovery research that leverages the technologies and resources of both companies. Going forward, we will transform our discovery research process even faster and work with Axcelead DDP as ONE TEAM to create breakthrough new drugs. ” Yoshinori Ikeura, President and CEO of Axcelead DDP, said, “This collaboration with Kaken is one of... --- ### CDK8/19 inhibition plays an important role in pancreatic β-cell induction from human iPSCs - Published: 2023-01-05 - Modified: 2023-12-01 - URL: https://stemcellres.biomedcentral.com/articles/10.1186/s13287-022-03220-4#new_tab - Categories: Publications Stem Cell Research & Therapy --- ### ThinkCyte and Axcelead DDP collaborate to advance novel phenotypic screening methods - Published: 2022-12-27 - Modified: 2025-05-21 - URL: https://axcelead-us.com/news/thinkcyte-and-axcelead-ddp-collaborate-to-advance-novel-phenotypic-screening-methods/ - Categories: News, News Releases Tokyo and Fujisawa, Japan. December 27, 2022: ThinkCyte and Axcelead Drug Discovery Partners (DDP) announced a research partnership focused on developing new approaches to screen candidate drugs for treating human diseases. The partnership will combine Ghost Cytometry1), ThinkCyte’s AI-driven cell characterization and sorting technology, with Axcelead DDP’s phenotypic screening techniques2) and its diverse compound library of over 1. 5 million candidate drugs to evaluate how these compounds change cellular phenotypes (their form and function) in a disease setting. Phenotypic drug discovery is a powerful method used in early therapeutic development and looks more broadly at how candidate drugs affect diseased cells compared to conventional target-based approaches. By combining Axcelead DDP’s world-class compound library and deep expertise in phenotypic screening with Ghost Cytometry as a new high-throughput way to identify phenotypic changes in living cells without any labels, the partnership aims to develop a novel phenotypic drug discovery platform that can identify hit compounds that may be missed by standard drug screening approaches with bias from cell staining. “We are very excited about the research partnership with Axcelead DDP, a leader in the field of drug discovery screening,” said Waichiro Katsuda, CEO at ThinkCyte. “By combining Axcelead DDP’s extensive drug discovery experience and infrastructure, including its compound library, with our novel cell-based phenotypic screening technology, we aim to further advance the field of phenotypic drug discovery and provide a unique technology solution that will help find new drugs faster. ” “Through this unique research partnership with ThinkCyte, we are able to... --- ### Axcelead Drug Discovery Partners, Inc. has become a certified provider of spatial transcriptomics technology, Visium, from 10x Genomics - Published: 2022-11-14 - Modified: 2025-05-21 - URL: https://axcelead-us.com/news/axcelead-drug-discovery-partners-inc-has-become-a-certified-provider-of-spatial-transcriptomics-technology-visium-from-10x-genomics/ - Categories: News, Topics We’re delighted to announce that we have received official certification from 10x Genomics as a Certified Service Provider (CSP) of Visium, a spatial transcriptomics technology. The CSP status is awarded to providers who are able to deliver Visium services at a quality level that meets or exceeds a certain standard. Spatial transcriptomics enables simultaneous and comprehensive analysis of gene expression and target proteins in tissues and cells, and provides information on the histopathological localization of gene expression. It is expected to be used in a variety of drug discovery research settings, including discovery of targets and biomarker molecules, analysis of the mechanisms of drug efficacy and toxicity, and research on intra-tissue distribution of new modalities. We began providing Visium-related services in 2020. Since then, we have been the only company in Japan to offer a comprehensive service covering from study design consultation to bioinformatics analysis of data obtained in various studies, and many of our customers has been using our one-stop service so far. Please get in touch to discuss how we can help overcome your drug discovery challenges through our services and drug discovery platforms. --- ### Axcelead DDP and Knowledge Palette Enter into a Collaborative Research Contract on Gene Expression Analysis Concerning Drug-Resistant Cancer - Published: 2022-11-02 - Modified: 2025-05-21 - URL: https://axcelead-us.com/news/axcelead-ddp-and-knowledge-palette-enter-into-a-collaborative-research-contract-on-gene-expression-analysis-concerning-drug-resistant-cancer/ - Categories: News, News Releases Axcelead Drug Discovery Partners Inc. (headquarters: Fujisawa, Kanagawa; CEO: Yoshinori Ikeura) and Knowledge Palette, Inc. (headquarters: Kawasaki, Kanagawa; Co-Founders and Representative Directors: Hiroki Danno and Masakazu Fukuda) have entered into a collaborative research contract on gene expression analysis for drug-resistant cancer. In this collaborative research project, the companies will collaborate to discover specific cell populations and gene clusters involved in the drug resistance in lung cancer, and to identify related biomarkers. Knowledge Palette will comprehensively profile gene expression in frozen clinical specimens obtained from biobanks using the company’s core single-cell gene expression analysis technology (Quartz-Seq2). Based on the results of these analyses, Axcelead DDP will identify and validate the candidates of new drug targets and biomarkers for the drug-resistant cancer utilizing its wealth of knowledge and expertise in drug discovery. This research collaboration is expected to unveil new target proteins and biomarkers that have eluded conventional analytical techniques and will contribute to elucidate the mechanisms of drug-resistance in cancers, discover new drug targets, and find biomarkers that will enhance the success rate of clinical studies. Yoshinori Ikeura, President and CEO of Axcelead DDP, said, “If we can identify new target proteins and biomarkers in drug-resistant cancer through this research collaboration with Knowledge Palette and their outstanding genetic analysis technology, we will be able to support research and development initiatives to develop new drugs and improve the success rate of clinical studies. Axcelead DDP is committed to being the most trusted companion to all who endeavor to bring highly innovative medicine... --- ### Dr. Hideo Fukui will chair the international symposium about new modalities at the American College of Toxicology 2022 annual meeting. - Published: 2022-10-20 - Modified: 2025-05-21 - URL: https://axcelead-us.com/news/dr-hideo-fukui-will-chair-the-international-symposium-about-new-modalities-at-the-american-college-of-toxicology-2022-annual-meeting/ - Categories: News, Topics The American College of Toxicology 2022 annual meeting will be held in Denver on November 13 to 16, and an international symposium between the US, EU and Japan will be held on Tuesday, November 15, 2022. Dr. Hideo Fukui, a Senior Director of Axcelead Drug Discovery Partners, Inc. will chair the session “Antibody-Drug Conjugates, Exosomes: Perspectives from Researchers and Regulatory Scientists on These New Modalities of Drug Delivery”. Dr. Fukui is the past president of the Japanese Society of Toxicology annual meeting in 2021. In this session, he will keep you updated about the latest information on new modalities from the US, EU and Japan. Learn more（ACT‘s Website）: 8. Symposium – International Symposium Antibody-Drug Conjugates, Exosomes: Perspectives from Researchers and Regulatory Scientists on These New Modalities of Drug Delivery Hideo Fukui Ph. D. DABT, DJSOT Senior Director / Senior Consultant Specialty: nonclinical safety, gastrointestinal pharmacology Career: In 1989, after graduating from the Department of Nutritional Biochemistry, School of Bio-agricultural Sciences, Graduate School of Nagoya University, he joined the Drug Safety Research Laboratories, Takeda Pharmaceutical Company Limited. In 1993, he got a Ph. D. of pharmacology from the Graduate School of Kyoto University. After studying at the School of Medicine, Colombia University in the US, he led a nonclinical safety evaluation of drugs for gastrointestinal medications at Global Takeda Pharmaceuticals, and had much experience with solving various challenges of toxicity, dealing with regulatory authorities, and engaging in due diligence on in-license candidates. Since July 2018, he has served as the director... --- ### Axcelead Drug Discovery Partners and Acadia Pharmaceuticals Launch Drug Discovery Collaboration in Neuroscience - Published: 2022-10-05 - Modified: 2025-05-21 - URL: https://axcelead-us.com/news/axcelead-drug-discovery-partners-and-acadia-pharmaceuticals-launch-drug-discovery-collaboration-in-neuroscience/ - Categories: News, News Releases October 5, 2022 – Axcelead Drug Discovery Partners Inc. (HQ: Fujisawa, Kanagawa, Japan; hereinafter referred to as “Axcelead DDP”) announces a drug discovery collaboration with Acadia Pharmaceuticals Inc. (HQ: San Diego, CA, USA; hereinafter referred to as “Acadia”) to generate innovative medicines in the neuroscience area. The parties will engage in research programs to discover and advance candidate compounds for clinical development. Axcelead DDP will lead research activities to generate high-quality candidate compounds by leveraging its integrated drug discovery platform, deep knowledge and extensive experience of drug discovery research. Acadia will leverage its deep expertise in central nervous system disorders to execute clinical development and potential commercialization of successful compounds. Axcelead DDP will receive upfront fees, research funding and development milestone fees. “Our mission is to contribute to the discovery of innovative drugs as the best partner for people engaged in drug discovery, based on the technology and know-how we have accumulated through our research in the pharmaceutical industry and the vast amount of drug discovery data we have collected,” said Yoshinori Ikeura Ph. D. , chief executive officer of Axcelead. “We are delighted to collaborate with Acadia to potentially expand their development pipeline with the goals of delivering therapeutic drugs to patients suffering from neuropsychiatric diseases. Axcelead DDP is Japan’s first drug discovery solution provider established in July 2017 by taking over the drug discovery platform from Takeda Pharmaceutical. Screening, Medicinal chemistry, Pharmacology / Biology, DMPK, and Safety research functions are integrated into one center with a state-of-the-art research... --- ### Epigeneron and Axcelead DDP singed a master collaboration agreement on drug discovery research for novel drug targets - Published: 2022-09-01 - Modified: 2025-05-21 - URL: https://axcelead-us.com/news/epigeneron-and-axcelead-ddp-singed-a-master-collaboration-agreement-on-drug-discovery-research-for-novel-drug-targets/ - Categories: News, News Releases Epigeneron Inc. , (Headquarters: Chuo-ku, Tokyo, President: Tetsuya Mishima, “Epigeneron”) and Axcelead Drug Discovery Partners, Inc. (Headquarters: Fujisawa City, Kanagawa Prefecture, President: Yoshinori Ikeura, “Axcelead DDP”) have entered into a master collaboration agreement on drug discovery research for novel drug targets. Epigeneron has a new and unique technology to identify novel drug targets that regulate the gene expression closely related to diseases, aiming to make un-druggable target to druggable in drug discovery. Axcelead DDP possesses all the platform functions required for drug discovery research, and has extensive knowledge and track record. Combination with Axcelead DDP’s chemical library of 1. 5 million compounds and versatile HTS (High Throughput Screening) technologies will expand the possibilities of the drug discovery for novel targets discovered by Epigeneron and be expected to lead to the creation of breakthrough new medicine against novel drug targets. Tetsuya Mishima, President and CEO of Epigeneron, said, “We have been in discussions with Axcelead DDP to accelerate the drug discovery research of first-in-class breakthrough medicine for intractable diseases. Our partnership with Axcelead DDP, the first integrated drug discovery solutions provider in Japan, will enable us to conduct seamless research activities by mutually complementing drug discovery capabilities that Epigeneron has not established. I hope to deliver new treatment options to patients as quickly as possible through the collaboration. ”Yoshinori Ikeura, President and CEO of Axcelead DDP, said, “The collaboration with Epigeneron will enables us to advance drug discovery research on undruggable targets that have not been developed to date. We will... --- ### Perseus Proteomics and Axcelead DDP launch a collaboration for an antibody drug discovery support service - Published: 2022-08-19 - Modified: 2025-05-21 - URL: https://axcelead-us.com/news/perseus-proteomics-and-axcelead-ddp-launch-a-collaboration-for-an-antibody-drug-discovery-support-service/ - Categories: News, News Releases Perseus Proteomics Inc. (Head office: Meguro, Tokyo; President & CEO: Takuya Yokokawa, “Perseus”) and Axcelead Drug Discovery Partners Inc. (Head office: Fujisawa, Kanagawa; President & CEO: Yoshinori Ikeura, “Axcelead DDP”) today announced a collaboration in the antibody drug discovery support service. Perseus is generating antibody-based transformative therapeutics. Perseus has the proprietary and unique screening platform, ICOS*, for phage display methods utilizing highly diversified human and camel antibody libraries, in addition to hybridoma methods. The unique multiple platforms enable discovery of highly potent and selective functional antibodies against challenging targets. The collaboration with Axcelead DDP, which has rich experience of in vitro/in vivo evaluation for various targets, will enable higher quality and customized support for antibody drug discovery according customer’s needs. This collaboration aims to provide customers with the seamlessly integrated one-stop support for antibody drug discovery. Perseus provides antibody generation such as screening, humanization, and improvement of physical properties with the innovative platforms, and Axcelead DDP, which has broad drug discovery platform capabilities, performs various nonclinical studies including in vitro/in vivo evaluation of efficacy, safety and distribution utilizing a broad range of drug discovery capabilities. Takuya Yokokawa, President & CEO of Perseus, said, “When we collaborate, as antibody professionals, with Axcelead DDP that provides all types of drug discovery solutions from advice for drug discovery research to outsourcing service, a high-quality antibody drug discovery support service can be provided in one-stop. We will further strive for better antibody technologies and contribute to promoting antibody drug discovery throughout the world. ”... --- ### ARCALIS and Axcelead DDP Announce Collaboration to Provide Integrated Drug Discovery Support Service for mRNA Therapeutics - Published: 2022-07-20 - Modified: 2025-05-21 - URL: https://axcelead-us.com/news/arcalis-and-axcelead-ddp-announce-collaboration-to-provide-integrated-drug-discovery-support-service-for-mrna-therapeutics/ - Categories: News, News Releases TOKYO, JAPAN, 20 JULY 2022: ARCALIS Inc. (Head office: Kashiwa, Chiba; President & CEO: Tomoyuki Fujisawa; “ARCALIS”) and Axcelead Drug Discovery Partners Inc. (Head office: Fujisawa, Kanagawa; President & CEO: Yoshinori Ikeura; “Axcelead DDP”), both are subsidiary of Axcelead Inc. (Head office: Minato-ku, Tokyo; President & CEO: Tomoyuki Fujisawa; “Axcelead”), today announced a collaboration to provide integrated drug discovery support service for mRNA vaccines and therapeutics. This service enables the fastest and successful discovery of mRNA vaccines and therapeutics from scratch. ARCALIS, a contract development and manufacturing organization (CDMO) for mRNA pharmaceuticals, is in charge of mRNA design, synthesis, and evaluation, and Axcelead DDP, which has drug discovery platform capabilities, conducts the preparation of the lipid nanoparticle (LNP) formulation for mRNA transfection and in vitro/in vivo evaluations. Through this collaboration, it will be possible to provide lead mRNA-LNP formulations with confirmed in vivo expression in three months at the earliest. Once a candidate mRNA has been identified, Axcelead DDP supports research strategy planning and conducts pharmacological studies, pharmacokinetic studies, and toxicity studies for IND in consideration of project characteristics such as target molecules and potential indications. ARCALIS supports customers from CMC (Chemistry, Manufacturing and Control) development to cGMP-qualified drug substance manufacturing for both clinical development and commercial purposes. Through this service, customers can instantly obtain the in vivo expression-proven mRNA-LNP and validate the concept (go/no-go decision) just by providing ARCALIS/Axcelead DDP with target information of interest. Tomoyuki Fujisawa, President and CEO of Axcelead states, “Academic institutes and pharmaceutical companies around... --- ### Construction and Functional Evaluation of a Three-Dimensional Blood–Brain Barrier Model Equipped With Human Induced Pluripotent Stem Cell-Derived Brain Microvascular Endothelial Cells - Published: 2022-04-11 - Modified: 2023-12-05 - URL: https://www.researchgate.net/publication/359885521_Construction_and_Functional_Evaluation_of_a_Three-Dimensional_Blood-Brain_Barrier_Model_Equipped_With_Human_Induced_Pluripotent_Stem_Cell-Derived_Brain_Microvascular_Endothelial_Cells#new_tab - Categories: Publications Pharmaceutical Research --- ### Axcelead DDP and Knowledge Palette Entered into a Collaborative Research Contract for Establishment of a New Evaluation Platform Using Axcelead DDP’s Compound Libraries and Large-Scale Transcriptome Analysis Technologies - Published: 2022-03-31 - Modified: 2025-05-21 - URL: https://axcelead-us.com/news/axcelead-ddp-and-knowledge-palette-entered-into-a-collaborative-research-contract-for-establishment-of-a-new-evaluation-platform-using-axcelead-ddps-compound-libraries-and-large-scale-transcr/ - Categories: News, News Releases Axcelead Drug Discovery Partners Inc. (headquarters: Fujisawa, Kanagawa; CEO: Yoshinori Ikeura; hereinafter referred to as “Axcelead DDP”) and Knowledge Palette, Inc. (headquarters: Kawasaki, Kanagawa; Co-founder, Representative Director: Hiroki Danno, Masakazu Fukuda; hereinafter referred to as “Knowledge Palette”) announce that both companies have entered into a collaborative research contract for establishment of a new evaluation platform using Axcelead DDP’s compound libraries and Knowledge Palette’s large-scale transcriptome analysis technologies. In this collaboration, whole gene expression data of cells treated with a wide variety of characteristic compounds, which are selected from the Axcelead DDP’s compound libraries, will be obtained using Knowledge Palette’s large-scale transcriptome analysis technologies. Both companies are aiming to analyze genes linked with various diseases or drug efficacy, safety, toxicity, etc. of the compounds and establish a new evaluation platform which can predict and reveal mechanisms of drug action, by combining the newly obtained data with metadata which Axceleadd DDP has stored. Through the collaborative research, we will build an unique perturbative gene expression database by gene expression profiling of the cells treated with characteristic compounds. By utilizing the database, we can increase the effectiveness of target deconvolution in phenotypic drug screening, drug repositioning, lead generation and optimization, and toxicity prediction. Yoshinori Ikeura, CEO of Axcelead DDP, says: “The collaborative research with Knowledge Palette allows us to establish a competitively advantageous, unique database from our compound libraries. By using the database, we will make more effective processes for drug discovery research and make a contribution as a hub for drug discovery... --- ### Characterization and reduction of non-endocrine cells accompanying islet-like endocrine cells differentiated from human iPSC - Published: 2022-03-18 - Modified: 2023-12-05 - URL: https://www.nature.com/articles/s41598-022-08753-5#new_tab - Categories: Publications Scientific Reports --- ### IP Generator, Axcelead, and Axcelead Drug Discovery Partners Signed a Comprehensive Business Alliance Agreement - Published: 2022-01-12 - Modified: 2025-05-21 - URL: https://axcelead-us.com/news/ip-generator-axcelead-and-axcelead-drug-discovery-partners-signed-a-comprehensive-business-alliance-agreement/ - Categories: News, News Releases To Establish a Platform for the Efficient and High-quality Drug Discovery Aiming to Resolve Social Issues by Reducing Medical CostsOn January 11th, IP Generator, Inc. (hereafter “IPG”), Axcelead, Inc. (hereafter “Axcelead”) and Axcelead Drug Discovery Partners, Inc. (hereafter “Axcelead DDP”) (those three companies are collectively called “Parties”) have signed a comprehensive business alliance agreement (hereafter “Agreement”). Under this Agreement, Parties aim to establish a healthcare platform for the efficient and high-quality drug discovery activities. IPG does not have any capital relationship with Axcelead and Axcelead DDP. The purpose of this Agreement is to strengthen and expand the business foundation of the Parties. IPG will effectively utilize business networks, management resources, and drug discovery assets of Axcelead and Axcelead DDP, in order to select and develop promising research programs and license out them to pharmaceutical companies. For details, please refer to the next page titled, “Each company’s role in this alliance”. In the pharmaceutical industry, it would be believed that the number of companies that promote business based on the concept of personalized medicine will increase in the future. As a result, the strategy of R&D aiming at providing patients with a small quantity of a wide variety of drugs to meet the individual medical needs would be mandatory. Thus, the value of the alliance among, IPG efficiently generating promising and innovative drug candidates, Axcelead enabling access to a variety of therapeutic modalities, and Axcelead DDP providing highest quality one-stop non-clinical drug discovery research services, would become higher and higher. By... --- ### Hitachi and Axcelead DDP Launch Manufacturing Process Development Support Service for Cell Therapy and Gene Therapy - Published: 2021-12-15 - Modified: 2025-05-21 - URL: https://axcelead-us.com/news/hitachi-and-axcelead-ddp-launch-manufacturing-process-development-support-service-for-cell-therapy-and-gene-therapy/ - Categories: News, News Releases Supporting optimization of product development and manufacturing with automation and quality assessment Tokyo, December 15, 2021 — Hitachi, Ltd. (TSE:6501, “Hitachi”) and Axcelead Drug Discovery Partners Inc. (“Axcelead DDP”) announced today that they launch a manufacturing process development support service for cell therapy and gene therapy from December 16. This service enables evaluation of cell quality such as stability and biological equivalence, and optimization of the automated cell culture process by combining Hitachi’s automated cell culture equipment for cell therapy and gene therapy, and Axcelead DDP’s wealth of experience in drug discovery research, offering to support the development of cell manufacturing processes for pharmaceutical companies and research institutes. Hitachi and Axcelead, Inc. , which has Axcelead DDP as the core company, have been working on joint development of solutions contributing to more efficient discovery of next-generation biopharmaceuticals*, and this service is from one of such joint projects. * News Release on April 7, 2021 “Hitachi and Axcelead have agreed to start joint development of solutions contributing on more efficient creation of next-generation biopharmaceuticals” https://www. axcelead-hd. com/? p=493 Clinical application of cell therapy and gene therapy is becoming a reality, and commercial manufacturing of the cells by pharmaceutical companies is beginning. It requires the scale-up and high efficiency through mechanization and automation using automated cell culture equipment, etc. There are, however, technical challenges to maintain cell quality after the automation and scale-up cell culture since the quality of the cells is easy to change depending on the raw materials and culture... --- ### Axcelead Drug Discovery Partners was rated as “Excellent” by Japan Agency for Medical Research and Development (AMED)* in a program for “Drug Discovery Seeds Development” - Published: 2021-11-25 - Modified: 2025-05-21 - URL: https://axcelead-us.com/news/axcelead-drug-discovery-partners-was-rated-as-excellent-by-japan-agency-for-medical-research-and-development-amed-in-a-program-for-drug-discovery-seeds-development/ - Categories: News, News Releases Axcelead Drug Discovery Partners, Inc. (Axcelead DDP) has supported 24 research projects aiming at new drug development in an infrastructure program for “Drug Discovery Seeds Development ” since 2017. This program is one of initiatives in AMED to incubate drug discovery seeds originated in academic research organizations. In this program, Axcelead DDP has worked as “Innovation Engine Unit” which supports academia-originated projects at all drug discovery stages and provides consultations for the drug discovery programs to enhance attractiveness to pharmaceutical companies. Axcelead DDP was rated as “Excellent” with the following comments: “Axcelead DDP has established sufficient drug discovery research platforms and support systems with drug discovery research experts. It is highly commendable that drug discovery support has been carried out with high quality and agility. Furthermore, their problem finding and solution provision made significant contributions to exploratory research and target validation studies in the early stages of drug discovery”. AMED gave an “Excellent” rating only to Axcelead DDP among 7 organizations participated in this project. Yoshinori Ikeura, President and CEO of Axcelead DDP, said, “This project was initiated shortly after the establishment of Axcelead DDP in 2017. Axcelead DDP presents a founding vision to become a hub of the drug discovery ecosystem that bridges basic research to clinical application research. I remember vividly that all our employees were delighted to participate in this project which realizes our vision. In addition, I am proud that our drug discovery researchers have not only received such a wonderful evaluation but also contributed to... --- ### xFOREST Therapeutics, Axcelead DDP and Kyowa Kirin Initiated an Collaboration in RNA Structures Targeted Drug Discovering - Published: 2021-11-21 - Modified: 2025-05-21 - URL: https://axcelead-us.com/news/xforest-therapeutics-axcelead-ddp-and-kyowa-kirin-initiated-an-collaboration-in-rna-structures-targeted-drug-discovering/ - Categories: News, News Releases Tokyo, Japan, October ##, 2021 — xFOREST Therapeutics Co. , Ltd. (Headquarter: Kamigyo-ku, Kyoto, Japan, President and CEO: Shunichi Kashida, “xFOREST”), Axcelead Drug Discovery Partners Inc. (Headquarter: Fujisawa, Kanagawa, President: Yoshinori Ikeura, “Axcelead DDP”), and Kyowa Kirin Co. , Ltd. (Headquarter: Chiyoda-ku, Tokyo, TSE:4151, President and CEO: Masashi Miyamoto, “Kyowa Kirin”) announce that the three companies have entered into a joint research agreement to discover multiple drugs that target RNA structures. Axcelead DDP and Kyowa Kirin originally started collaboration on the development of innovative small-molecule drugs based on a novel drug discovery technology platform in October 2020. Under the terms of the agreement among three companies announced here, xFOREST participates in the research being conducted by Axcelead DDP and Kyowa Kirin on the drug discovery targeting RNA structures. xFOREST will provide its proprietary FOREST technologies, a suite of large-scale parallel analysis platforms, to promote systematic small-molecule drug discovery research targeting RNA structures. xFOREST obtains rights to receive milestone payments and royalties on sales from Kyowa Kirin according to the progress and success of its R&D. Kyowa Kirin has exclusive rights to develop and commercialize RNA-targeted small-molecules discovered from the collaboration. Shunichi Kashida, Ph. D. , President and CEO of xFOREST commented, “xFOREST Therapeutics has been promoting the development of its proprietary FOREST technologies, aiming to realize highly effective systematic RNA-targeted drug discovery. We appreciate that we will initiate the brand-new challenge to research for discovering the RNA-targeted drug with Kyowa Kirin and Axcelead DDP and we will push forward this... --- ### Axcelead DDP participates in “MONSTAR-SCREEN-2” of the 4th-stage industry-academia collaborative Cancer Genome Screening Project for Individualized Medicine in Japan “SCRUM-Japan”, as a joint research institute - Published: 2021-10-25 - Modified: 2025-05-21 - URL: https://axcelead-us.com/news/axcelead-ddp-participates-in-monstar-screen-2-of-the-4th-stage-industry-academia-collaborative-cancer-genome-screening-project-for-individualized-medicine-in-japan-scrum-jap/ - Categories: News, News Releases We are pleased to announce that Axcelead Drug Discovery Partners Inc. , (Headquarters: Fujisawa, Kanagawa, JAPAN, CEO: Yoshinori Ikeura, hereinafter “Axcelead DDP”) will participate as a joint research institution to support “MONSTAR-SCREEN-2” of the 4th-stage industry-academia collaborative Cancer Genome Screening Project for Individualized Medicine in Japan “SCRUM-Japan” led by the National Cancer Center Hospital East (Location: Kashiwa, Chiba, JAPAN, Director: Atsushi Ohtsu, hereinafter “NCCHE)”. In MONSTAR-SCREEN-2, multi-omics assays such as whole exome sequencing and whole transcriptome sequencing are performed using DNA / RNA extracted from tumor tissue, and immunohistochemical staining (IHC) is performed in clinical specimens. By evaluating protein expression and localization, the project performs comprehensive analysis toward not only cancer cells but also tumor microenvironment which is including both various immune cells and candidate for biomarkers. In this research, Axcelead DDP will utilize its unique and proprietary drug discovery platform to perform high-quality fluorescent multiplex immunostaining and acquire stained image data using the multiplex IHC method. Axcelead DDP will contribute to a complex understanding with multi-omics analysis by histologically elucidating complex tumor tissues through this joint research. Dr. Takayuki Yoshino, Project representative of MONSTAR-SCREEN-2 / Chief of the Department of Gastrointestinal Oncology, NCCHE, said, “Axcelead DDP, a drug discovery solution provider based on excellent technical capabilities and abundant research experience, will play a part in elucidating cancer cells and the tumor immune microenvironment that surrounds them. I am confident that the solution provided by Axcelead DDP will greatly contribute to the acceleration of novel therapeutic drug development through this... --- ### Axcelead has entered into a comprehensive agreement including transfer of key drug discovery platforms with a major Japanese pharmaceutical company - Published: 2021-10-18 - Modified: 2025-05-21 - URL: https://axcelead-us.com/news/axcelead-has-entered-into-a-comprehensive-agreement-including-transfer-of-key-drug-discovery-platforms-with-a-major-japanese-pharmaceutical-company/ - Categories: News, News Releases Axcelead Drug Discovery Partners Co. , Ltd. (Headquarters: Fujisawa, Kanagawa, President,　CEO: Yoshinori Ikeura; Axcelead) announces that the company has strengthened the platforms including high-throughput screening (HTS), high-throughput ADME (metabolism & pharmacokinetics) and TOX (safety) studies (HT-ADMET), based on a comprehensive business transfer agreement with a major Japanese pharmaceutical company (hereinafter, referred to as “the pharmaceutical company”). In recent years, changes in the environment surrounding the pharmaceutical industry have been accelerating, and Japanese and global pharmaceutical companies are working on open innovation activities in various ways. Axcelead has entered into a comprehensive business transfer agreement with the pharmaceutical company to make effective use of the specific drug discovery platforms of the pharmaceutical company and Axcelead’s know-how and experiences in drug discovery research. This comprehensive agreement provides a unique business model as drug discovery role-sharing between a pharmaceutical company and a platform company. 　We call this unique model “Horizontal Specialization Model in Drug Discovery”. A series of enhancements of drug discovery platform in Axcelead would contribute to effective and satisfactorily pipeline construction of customers. The HTS platform by utilizing the 1. 5 million compound library offers attractive hit identification service. The HT-ADMET service effectively and quickly provides high-reliable data of various parameters related to physicochemistry, metabolism & pharmacokinetics, and safety. About Axcelead: Axcelead is the first comprehensive integrated drug discovery solutions provider in the pharmaceutical industry in Japan, having succeeded some portion of the drug discovery research department of Takeda Pharmaceutical Company Limited. and started its business in July 2017. Axcelead provides... --- ### Reliable identification of cardiac cunduction abnormalities in drug discovery using automated patch clamp II: Best practices for Nav1.5 peak current in a high throughput screening enviroment - Published: 2021-09-06 - Modified: 2023-12-01 - URL: https://linkinghub.elsevier.com/retrieve/pii/S1056871921001787#new_tab - Categories: Publications Journal of Pharmacological and Toxicological Methods --- ### Identification of novel inhibitors of Keap1/Nrf2 by a promising method combining protein–protein interaction‑oriented library and machine learning - Published: 2021-04-01 - Modified: 2023-12-05 - URL: https://www.nature.com/articles/s41598-021-86616-1#new_tab - Categories: Publications Scientific reports --- ### Cryo-EM structure of K+-bound hERG channel complexed with the blocker astemizole - Published: 2021-01-14 - Modified: 2023-12-01 - URL: https://doi.org/10.1016/j.str.2020.12.007#new_tab - Categories: Publications Structure --- ### Axcelead’s response to the COVID-19 emergency declaration in January 2021 - Published: 2021-01-08 - Modified: 2025-05-21 - URL: https://axcelead-us.com/news/axceleads-response-to-the-covid-19-emergency-declaration-in-january-2021/ - Categories: News, Topics On January 7, the Japanese government declared State of Emergency to prevent the spread of COVID-19 pandemic for the Tokyo metropolitan area including Kanagawa Prefecture. Based on the Guidelines for the State of Emergency from the government, under strict countermeasures against infectious of COVID-19 Axcelead continue to work on the projects. If you have any questions about contracted studies, projects or new requests, please contact “contact@ axcelead. com” or our representative for each project. We will inform you separately on the website about the response when a new policy is issued by the government. --- ### Evommune and Axcelead Drug Discovery Partners Launch A Collaboration On A PKCtheta Program To Kick-off Evommune’s Inflammation Pipeline - Published: 2020-12-10 - Modified: 2025-05-21 - URL: https://axcelead-us.com/news/evommune-and-axcelead-drug-discovery-partners-launch-a-collaboration-on-a-pkctheta-program-to-kick-off-evommunes-inflammation-pipeline/ - Categories: News, News Releases Inhibition of PKCtheta as a therapeutic target has the potential to treat multiple inflammatory diseases Los Altos, California, USA and Fujisawa, Kanagawa, Japan – Dec. 10, 2020 – Evommune, Inc. , a private R&D company and innovation engine in chronic inflammation, and Axcelead Drug Discovery Partners, Inc. (Axcelead), a Japanese solution provider in drug discovery research, today announced they have started an exclusive partnership for a late-stage discovery program. The goal of the program will be to identify a potent and highly specific PKCtheta inhibitor, which could have broad utility across a spectrum of inflammatory diseases. The PKCtheta program is originated from Axcelead’s Hit-identified Target (A-HiT) project. In this program, Evommune and Axcelead will continue to collaboratively carry out lead optimization research. “This program lays the foundation for our new pipeline and aligns with our goal of providing new treatment options for patients living with chronic inflammatory conditions,” said Luis Peña, president and chief executive officer of Evommune. “We are impressed with the progress Axcelead has made on this program which leaves Evommune poised to identify multiple molecules for clinical development. ” “Over-activation of effector T-cells and the failure of anti-inflammatory regulatory T-cells to control this response are at the crux of many chronic inflammatory diseases”, said Hans Hofland, senior vice president, research. “PKCtheta inhibition suppresses effector T-cells, while activating regulatory T-cells. This dual-acting role in T-cell biology makes PKCtheta a highly attractive target for the treatment of a broad range of inflammatory diseases. ” “Our mission is to contribute... --- ### Comprehensive Cardiac Safety Assessment using hiPS-cardiomyocytes (Consortium for Safety Assessment using Human iPS Cells: CSAHi) - Published: 2020-11-09 - Modified: 2023-12-01 - URL: https://www.eurekaselect.com/176144/article#new_tab - Categories: Publications Current Pharmaceutical Biotechnology --- ### Bidirectional, non-necrotizing glomerular crescents are the critical pathology in X-linked Alport syndrome mouse model harboring nonsense mutation of human COL4A5 - Published: 2020-11-03 - Modified: 2023-12-01 - URL: https://www.nature.com/articles/s41598-020-76068-4#new_tab - Categories: Publications Scientific Reports --- ### Axcelead and Kyowa Kirin Started an Innovative Collaboration in Small-Molecule Drug Development - Published: 2020-10-02 - Modified: 2025-05-21 - URL: https://axcelead-us.com/news/axcelead-and-kyowa-kirin-started-an-innovative-collaboration-in-small-molecule-drug-development/ - Categories: News, News Releases Tokyo, Japan, October 2, 2020 —Axcelead Drug Discovery Partners Inc. （Axcelead, President: Yoshinori Ikeura）and Kyowa Kirin Co. , Ltd. (Kyowa Kirin, TSE:4151, President and CEO: Masashi Miyamoto) announce that the companies have started collaboration on the development of innovative small-molecule drugs based on a novel drug discovery technology platform. By integrating Axcelead ‘s broad range of small-molecule drug discovery technologies and experience with Kyowa Kirin’s innovative drug discovery technologies, the companies will be able to build a novel small-molecule drug discovery technology platform. Utilizing this technology platform the companies aim to expand R&D pipeline of Kyowa Kirin through the discovery of multiple innovative drug candidates for diverse targets that were inaccessible so far. “Our mission is to contribute to the discovery of innovative drugs as the best partner for people engaged in drug discovery, based on the technology and know-how we have accumulated through our research in the pharmaceutical industry and the vast amount of drug discovery data we have collected,” said Yoshinori Ikeura, President of Axcelead. “We are delighted to be able to develop fundamental technologies that will open up a new era of small-molecule drugs and contribute to the discovery of drugs for a variety of previously inaccessible drug targets. ” “We are actively engaged in small-molecule drug discovery by rational drug design including our proprietary structural analysis technology of disease-associated biomolecules”, said Yoshifumi Torii, Ph. D. , Executive Officer, Vice President, Head of R&D Division of Kyowa Kirin. “I am delighted to collaborate with Axcelead through integration... --- ### Reliable identification of cardiac liability in drug discovery using automated patch clamp: Benchmarking best practices and calibration standards for improved proarrhythmic assessment - Published: 2020-06-18 - Modified: 2023-12-01 - URL: https://www.sciencedirect.com/science/article/abs/pii/S1056871920302136#new_tab - Categories: Publications Journal of Pharmacological and Toxicological Methods --- ### Otsuka Pharmaceutical and Axcelead Drug Discovery Partners announce joint research in ​​CNS indications - Published: 2020-06-17 - Modified: 2025-05-21 - URL: https://axcelead-us.com/news/otsuka-pharmaceutical-and-axcelead-drug-discovery-partners-announce-joint-research-in-cns-indications/ - Categories: News, News Releases June 29,2020- Otsuka Pharmaceutical Co. , Ltd. (Headquarters: Chiyoda-ku, Tokyo, President: Makoto Inoue; Otsuka Pharmaceutical) and Axcelead Drug Discovery Partners Co. , Ltd. (Headquarters: Fujisawa, Kanagawa, President: Yoshinori Ikeura; Axcelead) announce a collaborative drug discovery research using the Axcelead Hit-identified Target (A-HiT) project* in the area of central nervous system diseases. Axcelead is the first comprehensive integrated drug discovery solutions provider in the pharmaceutical industry in Japan, having succeeded some portion of the drug discovery research department of Takeda Pharmaceutical Company Limited. and started its business in July 2017. Axcelead provides advisory services for research planning and problem solving, as well as integrated research services utilizing the most advanced drug discovery research platform. The A-HiT project is an asset owned by Axcelead, which consists of hit or lead compounds to deliver drug candidate compounds and an optimized evaluation system for specific drug targets. By leveraging the A-HiT project, a significant reduction of the number of drug discovery steps can be expected. Otsuka Pharmaceutical is a total health care company that is committed to a holistic approach to health and well-being of people based on the corporate philosophy of “Otsuka-people creating new products for better health worldwide” to create innovative products that contribute to the health of people around the world. In the medical-related business, Otsuka Pharmaceutical is engaged in research and development with the central nervous system area, cardiovascular/renal area, and oncology area as the most important areas. The two companies will jointly conduct lead generation and lead optimization research... --- ### Acetyl-CoA carboxylase 1 and 2 inhibition ameliorates steatosis and hepatic fibrosis in a MC4R knockout murine model of nonalcoholic steatohepatitis - Published: 2020-01-28 - Modified: 2023-12-01 - URL: https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0228212#new_tab - Categories: Publications PLOS ONE --- ### PassPort Technologies and Axcelead Drug Discovery Partners - Published: 2019-10-01 - Modified: 2025-05-21 - URL: https://axcelead-us.com/news/passport-technologies-and-axcelead-drug-discovery-partners/ - Categories: News, News Releases Enter a comprehensive collaborative partnership in the field of drug discovery service using PassPort System, a new active transdermal drug delivery technologyContribute to maximizing R&D pipeline value though providing a new modalityPassPort Technologies, Inc. (President and CEO: Tomoyuki Fujisawa, California, USA) (PPTI) and Axcelead Drug Discovery Partners Co. , Ltd. (President: Yoshinori Ikeura, Fujisawa, Kanagawa) (Axcelead), here inform entering a comprehensive collaborative partnership in the field of drug discovery service using PassPort System, a new active transdermal drug delivery technology. PassPort System is a new transdermal drug delivery technology that combines micro-poration technology that creates micropores on the skin surface and patch formulation technology that controls a drug absorption via micropores. By using this technology, new possibility of transdermal administration is able to be expanded for drugs that have been limited to injections and infusions. Axcelead is a comprehensive non-clinical drug discovery research service provider, from discovery of drug discovery targets to optimization of drug candidate compounds, as well as a bridge process to clinical development. Currently, Axcelead is expanding its business by developing distinctive services such as an integrated drug discovery service that undertakes drug discovery research on a project basis. Through this comprehensive collaboration using PassPort System, it is possible to provide an alternative transdermal drug delivery not only for low molecular weight drugs but also for other modalities such as medium molecular weight drugs such as peptides and oligonucleotides, and macromolecular biopharmaceuticals such as proteins. In addition, this collaboration will expand its application of the PassPort System... --- ### Fujifilm and Axcelead Drug Discovery Partners begin collaborating to advance drug discovery solutions using iPSCs - Published: 2019-07-10 - Modified: 2025-05-21 - URL: https://axcelead-us.com/news/fujifilm-and-axcelead-drug-discovery-partners-begin-collaborating-to-advance-drug-discovery-solutions-using-ipscs/ - Categories: News, News Releases To enhance the Process of Research and Development of Drug Candidates Tokyo/Kanagawa, July 10, 2019 ―FUJIFILM Corporation (President: Kenji Sukeno; Fujifilm) and Axcelead Drug Discovery Partners Inc. (President: Yoshinori Ikeura; Axcelead) announced a collaboration to provide customers with a human induced pluripotent stem cell (iPSC)-based integrated platform for drug discovery solutions. By combining Fujifilm’s iPSC-derived products that its U. S. subsidiary FUJIFILM Cellular Dynamics Inc. (FCDI) offers and Axcelead’s compound evaluation and analytical services, the companies will work towards developing new drug efficacy evaluation methods and toxicity testing to meet specific needs of clients. FCDI, located in Madison, Wisconsin, is a leader in the development, manufacture and application of human iPSC and iPSC-derived cells. Fujifilm has been offered its clients ranging from pharmaceutical and biotech companies to academia throughout the world, a selection of 15 kinds of iPSC-derived differentiated cells such as cardiomyocytes, hepatocytes and microglia cells* for life science research purpose supporting drug discovery. FCDI’s expertise in stem cell technologies combined with Fujifilm’s know-how in production process technology across a range of life science businesses ensures the delivery of consistent high-quality iPSCs, iPSC-derived cells and applications. Axcelead is a comprehensive nonclinical drug discovery solution provider, and fully equipped to provide non-clinical customized services from exploratory research and optimization of candidate compounds to the process of bringing initiatives to clinical development for its customers. The company is unveiling unique services such as Integrated Drug Discovery service that undertakes drug discovery research in project units, and is working to expand its... --- ### Transfer of All Axcelead Shares to Whiz Partners DDG Fund Completed - Published: 2019-04-01 - Modified: 2025-05-21 - URL: https://axcelead-us.com/news/transfer-of-all-axcelead-shares-to-whiz-partners-ddg-fund-completed/ - Categories: News, News Releases April 1, 2019 – Whiz Partners Inc. (hereinafter, “Whiz”), headquartered in Minato Ward, Tokyo, announced that it has completed an investment-in-kind to the “Drug Discovery Gateway Investment Limited Partnership” (hereinafter, “DDG Fund”) of issued Axcelead Drug Discovery Partners Inc. (hereinafter, “Axcelead”) shares held by Takeda Pharmaceutical Co. , Ltd. (hereinafter, “Takeda”), headquartered in Chuo Ward, Osaka. As announced by Takeda on August 3, 2018, the DDG Fund is an investment fund that was created in October 2018 to promote a drug discovery ecosystem in Japan based on an agreement between Whiz and Takeda. Since the creation of the DDG Fund, there has been continual interest in participation and investment from many financial institutions, biopharmaceutical industries, and investors. The fund is scheduled to complete an initial round of capitalization in the first half of 2019. In the future, the fund will invest in venture firms and academia with promising R&D both in Japan and overseas; furthermore, further support will be given to portfolio companies in order to encourage successful commercialization. In addition to completing the investment-in-kind of all Takeda-issued shares to the DDG Fund, Axcelead will provide broad drug discovery services to pharmaceutical companies and venture firms as a core investor in the DDG Fund. Whiz Partners, Inc. (Tokyo, Japan) is an alternative asset management firm with Growth Equity and Global Macro Hedgefund offerings. Whiz has a strong track record in HealthCare investments, now on its fifth fund. Through its former brand, CSK Venture Capital, Whiz financed the Japanese Biotech industry... --- ### Axcelead Drug Discovery Partners and ERS Genomics Enter into CRISPR/Cas9 License Agreement - Published: 2018-10-17 - Modified: 2025-05-21 - URL: https://axcelead-us.com/news/axcelead-drug-discovery-partners-and-ers-genomics-enter-into-crispr-cas9-license-agreement/ - Categories: News, News Releases Fujisawa, Japan and Dublin, Ireland, October 4, 2018 – Axcelead Drug Discovery Partners, Inc. (hereinafter referred to as “Axcelead”) and ERS Genomics Limited (hereinafter referred to as “ERS Genomics”) announced today a non-exclusive license agreement to provide Axcelead with worldwide access to ERS Genomics’ CRISPR/Cas9 genome editing intellectual property to enhance their drug discovery service offering. ERS Genomics holds rights to the foundational CRISPR/Cas9 patent portfolio from Dr. Emmanuelle Charpentier, co-inventor of the breakthrough gene editing technology. Axcelead is the first comprehensive integrated drug discovery solutions provider in the pharmaceutical industry in Japan, having succeeded some portion of the drug discovery research department of Takeda Pharmaceutical Company Limited. Axcelead started its business in July of 2017 and offers a comprehensive list of drug discovery services in a broad range of therapeutic areas. “We look forward to being able to offer our customers an expanded service offering that includes use of this important gene editing technology,” said Yoshinori Ikeura, CEO of Axcelead. “We expect the addition of the CRISPR/Cas9 technology for creation of genetically modified animals or cells to complement our strong capability in non-clinical drug discovery research. These animals or cells are indispensable tools for reliable drug discovery studies including validation of target and proof of concept study. ” “We are pleased to include Axcelead among the rapidly growing list of licensees to this fundamental CRISPR/Cas9 patent portfolio,” commented Eric Rhodes, CEO of ERS Genomics. “This is our first license in Japan following the issuance of our patent in Japan... --- ### Announcement on starting preparation to become a company independent from Takeda - Published: 2018-08-03 - Modified: 2025-05-21 - URL: https://axcelead-us.com/news/announcement-on-starting-preparation-to-become-a-company-independent-from-takeda/ - Categories: News, News Releases We are pleased to announce that Axcelead Drug Discovery Partners Inc. (“Axcelead”) preparation to become a company independent from Takeda Pharmaceutical Company Limited (“Takeda”) as a core company of “Drug Discovery Gateway Investment Limited Partnership” (“DDG Fund”). Under the terms of the agreement between Takeda and Japan-based Alternative Asset Management Firm, Whiz Partners, Inc. (“Whiz”), DDG Fund will be established by Whiz, and will be launched in November 2018. Takeda will invest Axcelead, in kind into the DDG Fund at the timing of DDG Fund’s launch, and Axcelead will be affiliated with go under the umbrella of DDG Fund. Takeda News Release --- ### Announcement of Start of Business Partnership between Axcelead and LAP&P for Modeling and Simulation of Drug Discovery - Published: 2018-05-30 - Modified: 2025-05-21 - URL: https://axcelead-us.com/news/announcement-of-start-of-business-partnership-between-axcelead-and-lapp-for-modeling-and-simulation-of-drug-discovery/ - Categories: News, News Releases We are pleased to announce that Axcelead Drug Discovery Partners, Inc. (Yoshinori Ikeura, President; Headquarters: Fujisawa-shi, Kanagawa, Japan; hereinafter referred to as “Axcelead”) and Leiden Experts on Advanced Pharmacokinetics & Pharmacodynamics Consultants BV (Henk-Jan Drenth, Managing Director; Headquarters: Leiden, the Netherlands; hereinafter referred to as “LAP&P”) decided to develop a business partnership for services provided by Axcelead, in the field of pharmacokinetic and pharmacodynamic analyses (hereinafter referred to as “PK/PD analyses”) and modeling and simulation (hereinafter referred to as “M&S”). PK/PD analyses and M&S allow the modeling of a potentially large amount of research data, information and findings accumulated in the past, leading to drug candidate evaluation and selection and study design obtained from predictions based on analysis results. In various stages of pharmaceutical research and development, this method has been positioned as an essential technique mainly in Europe and the U. S. as it is thought to lead to an improvement of success rate as well as time and cost reductions due to this process optimization. Currently, the practical and effective introduction of this method in Japan is still in an early stage. With this in mind, Axcelead, in partnership with LAP&P, a leading M&S company that globally has clients among pharmaceutical and biotech companies, can contribute to a value increase of our clients’ projects by strengthening existing non-clinical M&S offerings and adding new services for clinical M&S and translational research. Specifically, this business partnership enables integrated PK/PD modeling, including consultation service on M&S, interpretation of pharmacokinetic, drug effect,... --- ---